0000021076-20-000021.txt : 20201102 0000021076-20-000021.hdr.sgml : 20201102 20201102161621 ACCESSION NUMBER: 0000021076-20-000021 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201102 DATE AS OF CHANGE: 20201102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CLOROX CO /DE/ CENTRAL INDEX KEY: 0000021076 STANDARD INDUSTRIAL CLASSIFICATION: SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842] IRS NUMBER: 310595760 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-07151 FILM NUMBER: 201280652 BUSINESS ADDRESS: STREET 1: THE CLOROX COMPANY STREET 2: 1221 BROADWAY CITY: OAKLAND STATE: CA ZIP: 94612-1888 BUSINESS PHONE: 5102717000 MAIL ADDRESS: STREET 1: P.O. BOX 24305 CITY: OAKLAND STATE: CA ZIP: 94612-1305 10-Q 1 clx-20200930.htm 10-Q clx-20200930
0000021076false--06-30Q1202100000210762020-07-012020-09-30xbrli:shares00000210762020-10-19iso4217:USD00000210762019-07-012019-09-30iso4217:USDxbrli:shares00000210762020-09-3000000210762020-06-3000000210762019-06-3000000210762019-09-30xbrli:pure0000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-090000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-0900000210762020-07-092020-07-090000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-090000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-092020-07-090000021076us-gaap:ContractualRightsMemberclx:JointVentureInKingdomOfSaudiArabiaMember2020-07-090000021076us-gaap:CustomerRelationshipsMemberclx:JointVentureInKingdomOfSaudiArabiaMember2020-07-090000021076clx:TotalCommodityPurchaseDerivativeContractsMember2020-07-012020-09-300000021076clx:TotalCommodityPurchaseDerivativeContractsMember2020-09-300000021076clx:SoybeanOilFuturesMember2020-09-300000021076clx:JetFuelSwapsMember2020-09-300000021076clx:TotalCommodityPurchaseDerivativeContractsMember2020-06-300000021076clx:SoybeanOilFuturesMember2020-06-300000021076clx:JetFuelSwapsMember2020-06-300000021076clx:PurchasesofInventoryMemberus-gaap:ForeignExchangeContractMember2020-09-300000021076clx:PurchasesofInventoryMemberus-gaap:ForeignExchangeContractMember2020-06-300000021076us-gaap:InterestRateContractMember2020-07-012020-09-300000021076us-gaap:InterestRateContractMember2020-09-300000021076us-gaap:InterestRateContractMember2020-06-300000021076us-gaap:CommodityContractMember2020-07-012020-09-300000021076us-gaap:CommodityContractMember2019-07-012019-09-300000021076us-gaap:ForeignExchangeContractMember2020-07-012020-09-300000021076us-gaap:ForeignExchangeContractMember2019-07-012019-09-300000021076us-gaap:InterestRateContractMember2019-07-012019-09-300000021076clx:SoybeanOilFuturesMemberus-gaap:CommodityContractMember2020-09-300000021076clx:SoybeanOilFuturesMemberus-gaap:CommodityContractMember2020-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommodityContractMember2020-09-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CommodityContractMember2020-09-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommodityContractMember2020-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CommodityContractMember2020-06-300000021076us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:InterestRateContractMember2020-09-300000021076us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:InterestRateContractMember2020-09-300000021076us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:InterestRateContractMember2020-06-300000021076us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:InterestRateContractMember2020-06-300000021076us-gaap:CarryingReportedAmountFairValueDisclosureMember2020-09-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMember2020-09-300000021076us-gaap:CarryingReportedAmountFairValueDisclosureMember2020-06-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMember2020-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommodityContractMember2020-09-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CommodityContractMember2020-09-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommodityContractMember2020-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CommodityContractMember2020-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommodityContractMember2020-09-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CommodityContractMember2020-09-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommodityContractMember2020-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CommodityContractMember2020-06-300000021076us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-09-300000021076us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-09-300000021076us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-06-300000021076us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-06-300000021076us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-09-300000021076us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2020-09-300000021076us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-06-300000021076us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2020-06-300000021076us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:BankTimeDepositsMember2020-09-300000021076us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:BankTimeDepositsMember2020-09-300000021076us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:BankTimeDepositsMember2020-06-300000021076us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:BankTimeDepositsMember2020-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMemberclx:TrustAssetsForNonqualifiedDeferredCompensationPlansMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-09-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberclx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember2020-09-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMemberclx:TrustAssetsForNonqualifiedDeferredCompensationPlansMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberclx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember2020-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:LongTermDebtMemberclx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-09-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:LongTermDebtMemberclx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember2020-09-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:LongTermDebtMemberclx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:LongTermDebtMemberclx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember2020-06-300000021076us-gaap:CommonStockMember2019-06-300000021076us-gaap:AdditionalPaidInCapitalMember2019-06-300000021076us-gaap:RetainedEarningsMember2019-06-300000021076us-gaap:TreasuryStockMember2019-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300000021076us-gaap:NoncontrollingInterestMember2019-06-300000021076srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-06-300000021076srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-06-300000021076us-gaap:RetainedEarningsMember2019-07-012019-09-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000021076us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300000021076us-gaap:TreasuryStockMember2019-07-012019-09-300000021076us-gaap:CommonStockMember2019-09-300000021076us-gaap:AdditionalPaidInCapitalMember2019-09-300000021076us-gaap:RetainedEarningsMember2019-09-300000021076us-gaap:TreasuryStockMember2019-09-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300000021076us-gaap:NoncontrollingInterestMember2019-09-300000021076us-gaap:CommonStockMember2020-06-300000021076us-gaap:AdditionalPaidInCapitalMember2020-06-300000021076us-gaap:RetainedEarningsMember2020-06-300000021076us-gaap:TreasuryStockMember2020-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000021076us-gaap:NoncontrollingInterestMember2020-06-300000021076us-gaap:RetainedEarningsMember2020-07-012020-09-300000021076us-gaap:NoncontrollingInterestMember2020-07-012020-09-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000021076us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000021076us-gaap:TreasuryStockMember2020-07-012020-09-300000021076us-gaap:CommonStockMember2020-09-300000021076us-gaap:AdditionalPaidInCapitalMember2020-09-300000021076us-gaap:RetainedEarningsMember2020-09-300000021076us-gaap:TreasuryStockMember2020-09-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000021076us-gaap:NoncontrollingInterestMember2020-09-30clx:repurchase_program0000021076clx:A2BillionOpenMarketPurchaseProgramMember2020-09-300000021076clx:EvergreenProgramMember2020-09-300000021076clx:A2BillionOpenMarketPurchaseProgramMember2020-07-012020-09-300000021076clx:A2BillionOpenMarketPurchaseProgramMember2019-07-012019-09-300000021076clx:EvergreenProgramMember2020-07-012020-09-300000021076clx:EvergreenProgramMember2019-07-012019-09-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2019-06-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2019-07-012019-09-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-07-012019-09-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-07-012019-09-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2019-09-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-09-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-09-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-07-012020-09-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-09-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300000021076clx:LongTermInterCompanyLoansMember2020-07-012020-09-300000021076clx:LongTermInterCompanyLoansMember2019-07-012019-09-300000021076clx:RetirementIncomeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000021076clx:RetirementIncomeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-07-012019-09-300000021076country:USclx:RetirementIncomeMember2020-07-012020-09-300000021076country:USclx:RetirementIncomeMember2019-07-012019-09-300000021076clx:AlamedaCountyCaliforniaMatterMember2020-06-300000021076clx:AlamedaCountyCaliforniaMatterMember2020-09-300000021076clx:AlamedaCountyCaliforniaMatterMember2020-07-012020-09-300000021076clx:AlamedaCountyCaliforniaMatterMember2017-06-300000021076clx:DickinsonCountyMichiganMatterMember2020-09-300000021076clx:DickinsonCountyMichiganMatterMember2020-06-300000021076clx:DickinsonCountyMichiganMatterMember2020-07-012020-09-30clx:reportable_segment0000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2020-07-012020-09-300000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2019-07-012019-09-300000021076clx:HouseholdMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000021076clx:HouseholdMemberus-gaap:OperatingSegmentsMember2019-07-012019-09-300000021076clx:LifestyleMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000021076clx:LifestyleMemberus-gaap:OperatingSegmentsMember2019-07-012019-09-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2020-07-012020-09-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2019-07-012019-09-300000021076us-gaap:CorporateNonSegmentMember2020-07-012020-09-300000021076us-gaap:CorporateNonSegmentMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:WalmartStoresIncMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:WalmartStoresIncMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:CleaningMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:CleaningMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:ProfessionalProductsMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:ProfessionalProductsMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:VitaminsMineralsAndSupplementsMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:VitaminsMineralsAndSupplementsMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:BagsWrapsAndContainersMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:BagsWrapsAndContainersMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:CatLitterMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:CatLitterMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:GrillingMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:GrillingMember2019-07-012019-09-300000021076clx:HouseholdMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2020-07-012020-09-300000021076clx:HouseholdMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2019-07-012019-09-300000021076clx:HouseholdMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:FoodProductsMember2020-07-012020-09-300000021076clx:HouseholdMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:FoodProductsMember2019-07-012019-09-300000021076clx:HouseholdMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:NaturalPersonalCareMember2020-07-012020-09-300000021076clx:HouseholdMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:NaturalPersonalCareMember2019-07-012019-09-300000021076clx:HouseholdMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:WaterFiltrationMember2020-07-012020-09-300000021076clx:HouseholdMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:WaterFiltrationMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberus-gaap:ProductConcentrationRiskMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberus-gaap:ProductConcentrationRiskMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:InternationalMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:InternationalMember2019-07-012019-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2019-07-012019-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020.
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                to
Commission File Number: 1-07151
_________________________
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter) 
Delaware31-0595760
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
1221 Broadway, Oakland, California, 94612-1888
(Address of principal executive offices) (Zip code)
(510) 271-7000
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
___________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock - $1.00 par valueCLXNew York Stock Exchange
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large accelerated filer☑Accelerated filer☐Non-accelerated filer☐Smaller Reporting Company☐Emerging Growth Company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
 
As of October 19, 2020, there were 126,049,929 shares outstanding of the registrant’s common stock ($1.00 par value).

1

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements
The Clorox Company
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)
(Dollars in millions, except per share data)
Three Months Ended
9/30/20209/30/2019
Net sales$1,916 $1,506 
Cost of products sold996 843 
Gross profit920 663 
Selling and administrative expenses238 211 
Advertising costs179 137 
Research and development costs32 30 
Interest expense25 25 
Other (income) expense, net(80)2 
Earnings before income taxes526 258 
Income taxes109 55 
Net earnings417 203 
Less: Net earnings attributable to noncontrolling interests2 — 
Net earnings attributable to Clorox$415 $203 
Net earnings per share attributable to Clorox
Basic net earnings per share$3.28 $1.61 
Diluted net earnings per share$3.22 $1.59 
Weighted average shares outstanding (in thousands)
Basic126,346 125,823 
Diluted128,729 127,465 
Comprehensive income$434 $190 
Less: Total comprehensive income attributable to noncontrolling interests2 — 
Total comprehensive income attributable to Clorox$432 $190 

See Notes to Condensed Consolidated Financial Statements (Unaudited)
2

The Clorox Company
Condensed Consolidated Balance Sheets
(Dollars in millions, except per share data)
9/30/20206/30/2020
(Unaudited)
ASSETS
Current assets
Cash and cash equivalents$860 $871 
Receivables, net685 648 
Inventories, net534 454 
Prepaid expenses and other current assets65 47 
Total current assets2,144 2,020 
Property, plant and equipment, net of accumulated depreciation and amortization
        of $2,270 and $2,224, respectively
1,176 1,103 
Operating lease right-of-use assets281 291 
Goodwill1,793 1,577 
Trademarks, net786 785 
Other intangible assets, net265 109 
Other assets332 328 
Total assets$6,777 $6,213 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Current operating lease liabilities$64 $64 
Accounts payable and accrued liabilities1,395 1,329 
Income taxes payable57 25 
Total current liabilities1,516 1,418 
Long-term debt2,781 2,780 
Long-term operating lease liabilities268 278 
Other liabilities797 767 
Deferred income taxes104 62 
Total liabilities5,466 5,305 
Commitments and contingencies
Stockholders’ equity
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none
issued or outstanding
— — 
Common stock: $1.00 par value; 750,000,000 shares authorized; 158,741,461 shares
issued as of September 30, 2020 and June 30, 2020; and 126,037,019 and 126,198,606 shares outstanding as of September 30, 2020 and June 30, 2020, respectively
159 159 
Additional paid-in capital1,146 1,137 
Retained earnings3,840 3,567 
Treasury shares, at cost: 32,704,442 and 32,542,855 shares as of September 30, 2020
        and June 30, 2020, respectively
(3,407)(3,315)
Accumulated other comprehensive net (loss) income(623)(640)
Total Clorox stockholders’ equity1,115 908 
Noncontrolling interests196 — 
Total stockholders’ equity1,311 908 
Total liabilities and stockholders’ equity$6,777 $6,213 
See Notes to Condensed Consolidated Financial Statements (Unaudited)
3

The Clorox Company
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
Three Months Ended
9/30/20209/30/2019
Operating activities:
Net earnings$417 $203 
Adjustments to reconcile net earnings to net cash provided by operations:
Depreciation and amortization51 44 
Stock-based compensation13 6 
Deferred income taxes20 7 
Other(71)19 
Changes in:
Receivables, net(8)73 
Inventories, net(70)6 
Prepaid expenses and other current assets(18)(10)
Accounts payable and accrued liabilities20 (82)
Operating lease right-of-use assets and liabilities, net(1)1 
Income taxes payable / prepaid30 4 
Net cash provided by operations383 271 
Investing activities:
Capital expenditures(69)(54)
Businesses acquired, net of cash acquired(85)— 
Other3 12 
Net cash used for investing activities(151)(42)
Financing activities:
Notes and loans payable, net— 51 
Treasury stock purchased(100)(110)
Cash dividends paid(140)(133)
Issuance of common stock for employee stock plans and other(7)9 
Net cash used for financing activities(247)(183)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash3 (2)
Net increase (decrease) in cash, cash equivalents, and restricted cash(12)44 
Cash, cash equivalents, and restricted cash:
Beginning of period879 113 
End of period$867 $157 


See Notes to Condensed Consolidated Financial Statements (Unaudited)
4

The Clorox Company
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share data)

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2020 and 2019, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2020, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

Recently Issued Accounting Standards

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which improves consistency in the application of accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and by clarifying and amending existing guidance. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The amendments that are related to changes in ownership of foreign equity method investments or foreign subsidiaries are to be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The amendments that are related to franchise taxes that are partially based on income are to be applied on either a retrospective basis for all periods presented or a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. All other amendments under this ASU are to be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

Recently Adopted Accounting Standards

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The Company adopted this guidance as of July 1, 2020 on a prospective basis, and the adoption did not have a material impact on the Company’s consolidated financial statements, as the Company had no goodwill impairments during the first quarter of fiscal year 2021. The future impact of this new standard will depend on the specific facts and circumstances of future impairments that may occur, if any.
5

NOTE 2. BUSINESS ACQUIRED

Saudi Joint Venture Acquisition

On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture). The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. The Company had previously accounted for its 30 percent investment of $27 as of June 30, 2020, under the equity method of accounting. Subsequent to the closing of this transaction, the Company’s total ownership interest in each of the entities increased to 51 percent. The Company has consolidated this joint venture into the Company's consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests.

The total purchase consideration of $111 consisted of $100 cash paid, which was sourced from operations, and $11 on the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date using generally accepted accounting principles for business combinations. The excess of the purchase price over the fair value of the net identifiable assets acquired has been allocated to goodwill in the International reportable segment in the amount of $212. The goodwill is primarily attributable to the synergies expected to arise after the acquisition and reflects the value of further growth anticipated in the Gulf region. None of the goodwill is deductible for tax purposes.

As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, non-cash gain recorded in Other (income) expense, net in the consolidated statement of earnings and adjusted in Other operating activities in the consolidated statement of cash flows for the first quarter of fiscal year 2021. The fair values of the noncontrolling interests and previously held equity interest were determined using a discounted cash flow (DCF) method under the income approach. Under this approach, the Company estimates future cash flows and discounts these cash flows at a rate of return that reflects the entities’ relative risk.
 
The following table summarizes the estimated fair value of the joint ventures’ assets acquired and liabilities assumed and the related deferred income taxes as of the acquisition date. Due to the timing of the acquisition, the fair values of the assets acquired and liabilities assumed were based on a preliminary valuation and the Company’s estimates and assumptions are subject to change within the measurement period. The primary areas of the purchase price that are not yet finalized are related to goodwill and income taxes. The definite-lived intangibles acquired primarily represent the Company reacquiring previously licensed trademarks and customer relationships. The weighted-average estimated useful life of intangible assets subject to amortization is 9 years.

Joint Venture
Goodwill$212 
Reacquired rights (included in Other intangible assets, net)138 
Property, plant and equipment46 
Customer relationships (included in Other intangible assets, net)10 
Working capital, net (includes cash acquired of $26)
31 
Noncurrent liabilities, net(5)
Deferred income taxes(20)
Total fair value of net assets412 
Less: Fair value of noncontrolling interests(198)
Less: Fair value of previously held equity interest(103)
Total purchase consideration$111 

Included in the Company’s results for the first quarter of fiscal year 2021 was $23 of net sales from the joint venture. Pro forma results reflecting this transaction were not presented because it is not significant to the Company's consolidated financial results.
6

NOTE 3. INVENTORIES, NET
Inventories, net, consisted of the following as of:
9/30/20206/30/2020
Finished goods$396 $340 
Raw materials and packaging161 140 
Work in process9 7 
LIFO allowances(32)(33)
Total$534 $454 


NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Financial Risk Management and Derivative Instruments

The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.

Commodity Price Risk Management

The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.

As of September 30, 2020, the notional amount of commodity derivatives was $22, of which $11 related to soybean oil futures used for the Food products business and $11 related to jet fuel swaps used for the Grilling business. As of June 30, 2020, the notional amount of commodity derivatives was $27, of which $14 related to soybean oil futures and $13 related to jet fuel swaps.

Foreign Currency Risk Management

The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.

The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $58 and $70, respectively, as of September 30, 2020 and June 30, 2020.

Interest Rate Risk Management

The Company may enter into over-the-counter interest rate forward or swap contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt or to manage the Company’s level of fixed and floating rate debt. These interest rate forward or swap contracts historically have had durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by U.S. government bond and interest rate derivative dealers.

The notional amounts of outstanding interest rate contracts used by the Company were $300 and $225, respectively, as of September 30, 2020 and June 30, 2020. These contracts represent forward starting interest rate swap contracts with a maturity date of September 2022 to manage the exposure to interest rate volatility associated with future interest payments on a forecasted debt issuance.
7
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Commodity, Foreign Exchange and Interest Rate Derivatives

The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate forward contracts for forecasted interest payments as cash flow hedges.

The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:

Gains (losses) recognized in Other comprehensive (loss) income
Three Months Ended
9/30/20209/30/2019
Commodity purchase derivative contracts$1 $— 
Foreign exchange derivative contracts(1)1 
Interest rate derivative contracts3 — 
Total$3 $1 

Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months Ended
9/30/20209/30/2019
Commodity purchase derivative contractsCost of products sold$(1)$— 
Foreign exchange derivative contractsCost of products sold— — 
Interest rate derivative contractsInterest expense(2)(2)
Total$(3)$(2)

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of September 30, 2020, that is expected to be reclassified into Net earnings within the next twelve months is $(10).

8
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Counterparty Risk Management and Derivative Contract Requirements

The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of September 30, 2020 and June 30, 2020, $2 and $3, respectively, contained such terms. As of September 30, 2020 and June 30, 2020, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.

Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both September 30, 2020 and June 30, 2020, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.

Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of September 30, 2020 and June 30, 2020, the Company maintained cash margin balances related to exchange-traded futures contracts of $1 and $2, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.

Trust Assets

The Company has held interests in mutual funds and cash equivalents as part of the trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which to invest their compensation deferrals in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.

Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of September 30, 2020 and June 30, 2020, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
9
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 9/30/20206/30/2020
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contractsOther current assets1$1 $1 $— $— 
Interest rate forward contractsOther assets24 4 1 1 
 $5 $5 $1 $1 
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$— $— $1 $1 
Commodity purchase swaps contractsAccounts payable and accrued liabilities23 3 3 3 
Foreign exchange forward contractAccounts payable and accrued liabilities21 1 1 1 
$4 $4 $5 $5 

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 9/30/20206/30/2020
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Investments, including money market funds
Cash and cash
equivalents (a)
1$379 $379 $584 $584 
Time deposits
Cash and cash
equivalents (a)
2318 318 165 165 
Trust assets for nonqualified deferred compensation plansOther assets1114 114 100 100 
 $811 $811 $849 $849 
Liabilities
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (b)
22,781 3,049 2,780 3,051 
$2,781 $3,049 $2,780 $3,051 

____________________

(a)Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(b)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.

10

NOTE 5. INCOME TAXES

In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 20.7% and 21.5% for the three months ended September 30, 2020 and 2019, respectively. The decrease in the effective tax rate on earnings for the current three-month period was primarily due to the non-taxability of a portion of the remeasurement gain recognized on the Company’s previously held investment in the Saudi joint venture, partially offset by a lower rate benefit from excess tax benefits.


NOTE 6. NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months Ended
9/30/20209/30/2019
Basic126,346125,823
Dilutive effect of stock options and other2,3831,642
Diluted128,729127,465
Antidilutive stock options and other441 — 

Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.


NOTE 7. COMPREHENSIVE INCOME
The following table provides a summary of Comprehensive income for the periods indicated:
Three Months Ended
9/30/20209/30/2019
Net earnings$417 $203 
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments10 (16)
Net unrealized gains (losses) on derivatives5 2 
Pension and postretirement benefit adjustments2 1 
Total other comprehensive (loss) income, net of tax17 (13)
Comprehensive income434 190 
Less: Total comprehensive income attributable to noncontrolling interests2 — 
Total comprehensive income attributable to Clorox$432 $190 


11

NOTE 8. STOCKHOLDERS’ EQUITY

Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended September 30
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income		Non-controlling interests
Total Stockholders’ Equity
AmountSharesAmountShares
Balance as of June 30, 2019$159 158,741 $1,046 $3,150 $(3,194)(33,055)$(602)$— $559 
Cumulative effect of accounting changes, net of tax (1)
22 22 
Net earnings203 203 
Other comprehensive (loss) income(13)(13)
Dividends to Clorox stockholders ($1.06 per share declared)
(134)(134)
Stock-based compensation6 6 
Other employee stock plan activities(9)— 20 472 11 
Treasury stock purchased(104)(663)(104)
Balance as of September 30, 2019$159 158,741 $1,043 $3,241 $(3,278)(33,246)$(615)$— $550 
Balance as of June 30, 2020$159 158,741 $1,137 $3,567 $(3,315)(32,543)$(640)$— $908 
Net earnings415 2 417 
Other comprehensive (loss) income17 17 
Dividends to Clorox stockholders ($1.11 per share declared)
(141)(141)
Dividends to noncontrolling interests(4)(4)
Business combinations including purchase accounting adjustments198 198 
Stock-based compensation13 13 
Other employee stock plan activities(4)(1)8 283 3 
Treasury stock purchased(100)(444)(100)
Balance as of September 30, 2020$159 158,741 $1,146 $3,840 $(3,407)(32,704)$(623)$196 $1,311 

(1) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings.

The Company has two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.

Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:
Three Months Ended
9/30/20209/30/2019
AmountShares
(in thousands)		AmountShares
(in thousands)
Open-market purchase program$— — $— — 
Evergreen Program100 444 104 663 
Total stock repurchases$100 444 $104 663 
12
NOTE 8. STOCKHOLDERS’ EQUITY (Continued)
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three Months Ended September 30
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of June 30, 2019$(414)$(23)$(165)$(602)
Other comprehensive (loss) income before reclassifications(15)1 — (14)
Amounts reclassified from Accumulated other comprehensive net (loss) income— 2 2 4 
Income tax benefit (expense)(1)(1)(1)(3)
Net current period other comprehensive (loss) income(16)2 1 (13)
Balance as of September 30, 2019$(430)$(21)$(164)$(615)
Balance as of June 30, 2020$(450)$(18)$(172)$(640)
Other comprehensive (loss) income before reclassifications9 3 — 12 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 3 2 5 
Income tax benefit (expense), and other1 (1)— — 
Net current period other comprehensive (loss) income10 5 2 17 
Balance as of September 30, 2020$(440)$(13)$(170)$(623)

Included in foreign currency translation adjustments are re-measurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.
13

NOTE 9. EMPLOYEE BENEFIT PLANS
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months Ended
9/30/20209/30/2019
Service cost$— $— 
Interest cost4 5 
Expected return on plan assets (1)
(4)(4)
Amortization of unrecognized items3 2 
Total$3 $3 
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2021 net periodic benefit cost is 3.1%.
The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended September 30, 2020 and 2019.
During the three months ended September 30, 2020 and 2019, the Company made $2 in contributions to its domestic retirement income plans.
Net periodic benefit costs are reflected in Other (income) expense, net.
14

NOTE 10. OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of September 30, 2020 and June 30, 2020, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $14 of the recorded liability as of September 30, 2020 and June 30, 2020, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30-year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $14, which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $28 over an estimated 30-year period, or require the Company to take other actions and incur costs not included in the study.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability, as of September 30, 2020 and June 30, 2020. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements, and the future availability of alternative clean-up technologies.
The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of September 30, 2020 and June 30, 2020.
As of September 30, 2020, the Company was party to a letter of credit of $11, related to one of its insurance carriers, of which $0 had been drawn upon.


15

NOTE 11. SEGMENT RESULTS
The Company operates through strategic business units (SBUs) that are aggregated into four reportable segments based on the economics and nature of the products sold: Health and Wellness, Household, Lifestyle and International. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months Ended
9/30/20209/30/2019
Health and Wellness$813 $633 
Household500 361 
Lifestyle318 271 
International285 241 
Corporate— — 
Total$1,916 $1,506 
Earnings (losses) before income taxes
Three Months Ended
9/30/20209/30/2019
Health and Wellness$251 $170 
Household109 32 
Lifestyle102 71 
International124 39 
Corporate(60)(54)
Total$526 $258 

All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 25% and 26% for the three months ended September 30, 2020 and 2019, respectively.
16
NOTE 11. SEGMENT RESULTS (Continued)
The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:
Net sales
Three Months Ended
9/30/20209/30/2019
Cleaning29 %32 %
Professional Products9 %6 %
Vitamins, Minerals and Supplements4 %4 %
Health and Wellness42 %42 %
Bags and Wraps11 %12 %
Cat Litter6 %8 %
Grilling9 %4 %
Household26 %24 %
Food Products9 %9 %
Natural Personal Care4 %5 %
Water Filtration4 %4 %
Lifestyle17 %18 %
International15 %16 %
Total100 %100 %



17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Clorox Company
(Dollars in millions, except per share data)
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. The following discussion of the Company’s financial condition and results of operations should be read in conjunction with MD&A and the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which was filed with the Securities and Exchange Commission (SEC) on August 13, 2020, and the unaudited condensed consolidated financial statements and related notes contained in this Quarterly Report on Form 10-Q (this Report). Unless otherwise noted, MD&A compares the three-month period ended September 30, 2020 (the current period) to the three-month period ended September 30, 2019 (the prior period), with percentage and basis point calculations based on rounded numbers, except for per share data and the effective tax rate.

EXECUTIVE OVERVIEW
Clorox is a leading multinational manufacturer and marketer of consumer and professional products with approximately 8,800 employees worldwide. Clorox sells its products primarily through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning products, Pine-Sol® cleaners; Liquid-Plumr® clog removers; Poett® home care products; Fresh Step® cat litter; Glad® bags and wraps; Kingsford® grilling products; Hidden Valley® dressings; Brita® water-filtration products; Burt’s Bees® natural personal care products; and RenewLife®, Rainbow Light®, Natural Vitality®, NeoCell® and Stop Aging Now® vitamins, minerals and supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro™ and the Clorox Healthcare® brand names. The Company has operations in more than 25 countries or territories and sells its products in more than 100 markets.
The Company primarily markets its leading brands in midsized categories considered to be financially attractive. Most of the Company’s products compete with other nationally advertised brands within each category and with “private label” brands.

The Company operates through strategic business units (SBUs) which are also the Company’s operating segments. These SBUs are then aggregated into four reportable segments. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020. The four reportable segments consist of the following:
•Health and Wellness consists of cleaning products, professional products, and vitamins, minerals and supplement products mainly marketed and sold in the U.S. Products within this segment include cleaning products such as laundry additives, including bleach products under the Clorox® brand and Clorox 2® stain fighter and color booster; home care products, primarily under the Clorox®, Clorox® Scentiva®, Formula 409®, Liquid-Plumr®, Pine-Sol® and Tilex® brands; professional cleaning and disinfecting products under the CloroxPro™, Clorox Healthcare®, and Clorox® Total 360® brands and professional food service products under the Hidden Valley® brand; and vitamins, minerals and supplement products under the RenewLife®, Rainbow Light®, Natural Vitality®, NeoCell® and Stop Aging Now® brands.
•Household consists of grilling products; bags and wraps; and cat litter products marketed and sold in the U.S. Products within this segment include grilling products under the Kingsford® and Kingsford® Match Light® brands; bags and wraps under the Glad® brand; and cat litter products under the Fresh Step®, Scoop Away® and Ever Clean® brands.
•Lifestyle consists of food products, water-filtration systems and filters, and natural personal care products marketed and sold in the U.S. Products within this segment include dressings and sauces, primarily under the Hidden Valley® brand; water-filtration systems and filters under the Brita® brand; and natural personal care products under the Burt’s Bees® brand.
18

•International consists of products sold outside the U.S. Products within this segment include laundry additives; home care products; water-filtration systems and filters; digestive health products; grilling products; cat litter products; food products; bags and wraps; natural personal care products; and professional cleaning and disinfecting products primarily under the Clorox®, Ayudin®, Clorinda®, Poett®, Pine-Sol®, Glad®, Brita®, RenewLife®, Ever Clean® and Burt’s Bees® brands.

RECENT EVENTS RELATED TO COVID-19

The novel coronavirus (COVID-19) pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties. As a result, we have taken an active role in addressing the ongoing pandemic’s impact on our employees, operations, customers, consumers, and communities, including taking precautionary measures, such as implementing contingency plans, making operational adjustments where necessary, and providing support to organizations that support front-line workers. The impact of COVID-19 and responses of governments, consumers, and others to the pandemic are affecting our business in many ways; however, we believe that the actions we are taking will help us emerge from this global pandemic operationally sound, and well positioned for continued long-term growth.
For our fiscal first quarter ended September 30, 2020, we continued to experience increased demand for many of our products, especially our disinfecting cleaning products, in response to COVID-19. The extent of COVID-19’s effect on our operational and financial performance in the future will depend on future developments, including the duration, spread and intensity of the pandemic, our continued ability to manufacture and distribute our products, as well as any future government actions affecting consumers and the economy generally, all of which are uncertain and difficult to predict considering the rapidly evolving landscape.
For additional information on the impacts and our response to the coronavirus pandemic, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

RESULTS OF OPERATIONS
CONSOLIDATED RESULTS
Three Months Ended
9/30/20209/30/2019% Change
Net sales$1,916 $1,506 27 %

Three Months Ended September 30, 2020
Percentage change versus the year-ago period
Reported (GAAP) Net Sales Growth / (Decrease)Reported VolumeAcquisitions & DivestituresForeign Exchange Impact
Price/Mix/Other (1)
Organic Sales Growth / (Decrease) (Non-GAAP) (2)
Organic Volume (3)
Health and Wellness28 %26 %— %— %2 %28 %26 %
Household39 25 — — 14 39 25 
Lifestyle17 17 — — — 17 17 
International18 17 9 (8)8 17 9 
Total27 %23 %1 %(1)%5 %27 %22 %

(1) This represents the net impact on net sales growth / (decrease) from pricing actions, mix and other factors.
(2) Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of any acquisitions and divestitures as well as changes in foreign exchange rates. See “Non-GAAP Financial Measures” below for reconciliation of organic sales growth / (decrease) to net sales growth, the most directly comparable GAAP financial measure.
(3) Organic volume represents volume excluding the effect of any acquisitions and divestitures. In the three months ended September 30, 2020, the volume impact of acquisitions was 8% and 1% for International and Total Company, respectively.

19

Net sales in the current period increased by 27%, reflecting higher shipments across all reportable segments, led by the Health and Wellness reportable segment, primarily driven by increased demand due to COVID-19 and people spending more time at home. Volume increased by 23% versus the prior period. The variance between volume growth and net sales growth was primarily due to the impact of favorable mix, partially offset by unfavorable foreign currency exchange rates.

Three Months Ended
9/30/20209/30/2019% Change
Gross profit$920 $663 39 %
Gross margin48.0 %44.0 %

Gross margin, defined as gross profit as a percentage of net sales, increased by 400 basis points in the current period from 44% to 48%. The increase was primarily driven by higher volume, cost savings and favorable mix, partially offset by higher manufacturing and logistics costs.

Three Months Ended
% of Net Sales
9/30/20209/30/2019% Change9/30/20209/30/2019
Selling and administrative expenses$238 $211 13 %12.4 %14.0 %
Advertising costs179 137 31 9.3 9.1
Research and development costs32 30 7 1.7 2.0

Selling and administrative expenses, as a percentage of net sales, decreased by 160 basis points in the current period. The dollar increase in selling and administrative expenses was primarily due to higher incentive compensation expenses, consistent with the Company’s performance-based compensation philosophy.

Advertising costs, as a percentage of net sales, increased by 20 basis points in the current period. The increase in advertising expenses reflected the Company’s continued support behind its brands. The Company’s U.S. retail advertising spend as a percentage of net sales was approximately 11% in the current period.

Research and development costs, as a percentage of net sales, decreased by 30 basis points in the current period, however were essentially flat in terms of dollars. The Company continues to focus on product innovation and cost savings.

Interest expense, Other (income) expense, net, and the effective tax rate on earnings
Three Months Ended
9/30/20209/30/2019
Interest expense$25 $25 
Other (income) expense, net(80)2 
Effective tax rate on earnings20.7 %21.5 %

Other (income) expense, net was ($80) and $2 in the current and prior periods, respectively. The variance was primarily due to an $85 one-time non-cash gain from the remeasurement of the Company’s previously held investment in its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture) (see Notes to Condensed Consolidated Financial Statements).

The effective tax rate on earnings was 20.7% and 21.5% in the current and prior periods, respectively. The lower effective tax rate in the current period was primarily due to the non-taxability of a portion of the remeasurement gain recognized on the Company’s previously held investment in the Saudi joint venture, partially offset by lower excess tax benefits.

Diluted net earnings per share
Three Months Ended
9/30/20209/30/2019% Change
Diluted net earnings per share$3.22 $1.59 103 %

20

Diluted net earnings per share (EPS) increased by $1.63, or 103%, in the current period, primarily due to net sales growth, gross margin expansion, and the remeasurement gain recognized on the previously held investment in the Saudi joint venture, partially offset by higher advertising investments and selling and administrative expenses.

SEGMENT RESULTS

The following presents the results of operations from the Company’s reportable segments and certain unallocated costs reflected in Corporate (see Notes to Condensed Consolidated Financial Statements for a reconciliation of segment results to consolidated results):

Health and Wellness
Three Months Ended
9/30/20209/30/2019% Change
Net sales$813 $633 28 %
Earnings before income taxes251 170 48 

Volume, sales and earnings before income taxes increased by 26%, 28% and 48%, respectively, during the current period. The volume and sales growth reflected higher shipments in all SBUs, primarily fueled by continued strong demand for disinfecting and cleaning products across the Cleaning and Professional Products portfolios used both in and out of the home. The increase in earnings before income taxes was primarily due to sales growth and gross margin expansion, partially offset by higher investments in advertising and in people to help meet anticipated demand.

Household
Three Months Ended
9/30/20209/30/2019% Change
Net sales$500 $361 39 %
Earnings before income taxes109 32 241 

Volume, net sales and earnings before income taxes increased by 25%, 39% and 241%, respectively, during the current period. The volume growth reflected higher shipments across all SBUs, mainly in Grilling and Bags and Wraps, both benefited from higher consumer demand. The variance between volume and net sales was primarily due to favorable mix. The increase in earnings before income taxes was mainly due to sales growth and gross margin expansion, partially offset by higher investments in advertising.

Lifestyle 
Three Months Ended
9/30/20209/30/2019% Change
Net sales$318 $271 17 %
Earnings before income taxes102 71 44 

Volume, net sales and earnings before income taxes increased by 17%, 17% and 44%, respectively, during the current period. Both volume growth and net sales growth were primarily driven by higher shipments of Food and Brita water filtration products, mainly due to higher consumer demand. The increase in earnings before income taxes was primarily due to sales growth, partially offset by higher manufacturing and logistics costs.


21

International
Three Months Ended
9/30/20209/30/2019% Change
Net sales$285 $241 18 %
Earnings before income taxes124 39 218 

Volume, net sales and earnings before income taxes increased by 17%, 18% and 218%, respectively, during the current period. The volume increase was primarily driven by strong ongoing demand for disinfecting as well as other household products across multiple regions. The variance between volume and net sales was mainly due to the benefit of price increases implemented to offset inflation, partially offset by the impact of unfavorable foreign currency exchange rates. The increase in earnings before income taxes was primarily due to the remeasurment gain recognized on the previously held investment in the Saudi joint venture.

Argentina

Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, and as a result the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina. Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities of Clorox Argentina are recognized in Other (income) expense, net in the consolidated statement of earnings. The business environment in Argentina continues to be challenging due to significant volatility in Argentina’s currency, high inflation, an economic recession and impacts of COVID-19 that include temporary strict price controls. As of September 30, 2020 and June 30, 2020, the net asset position, excluding goodwill, of Clorox Argentina was $44. Of these net assets, cash balances were approximately $15 and $19 as of September 30, 2020 and June 30, 2020, respectively. Net sales from Clorox Argentina represented approximately 2% of the Company’s consolidated net sales for the three months ended September 30, 2020 and the fiscal year ended June 30, 2020.

For additional information on the impacts and our response to the business environment in Argentina, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

Corporate

Corporate includes certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses.

Three Months Ended
9/30/20209/30/2019% Change
Losses before income taxes$(60)$(54)11 %

Losses before income taxes increased by $6 in the current period primarily due to higher employee and incentive compensation expenses.

22

FINANCIAL POSITION AND LIQUIDITY
The Company’s financial condition and liquidity remained strong as of September 30, 2020. The following table summarizes cash activities:
Three Months Ended
9/30/20209/30/2019
Net cash provided by operations$383 $271 
Net cash used for investing activities(151)(42)
Net cash used for financing activities(247)(183)

Operating Activities

Net cash provided by operations was $383 in the current period, compared with $271 in the year-ago period. The increase was primarily driven by the Company’s profitable sales growth, partially offset by higher employee incentive compensation payments in the current period related to fiscal year 2020 performance. These higher sales resulted in larger receivable balances and the need for more inventory, both of which reduced the Company’s operating cash flows, but were largely offset by higher Accounts payable and accrued liabilities balances mainly due to the timing of payments and additional spending in the current period.

Investing Activities

Net cash used for investing activities was $151 in the current period, compared with $42 in the year-ago period. The year-over-year increase was mainly due to the acquisition of an additional interest in the Company's Saudi joint venture.

Financing Activities

Net cash used for financing activities was $247 in the current period, compared with $183 in the year-ago period. The year-over-year increase was mainly due to net cash sourced from short-term borrowings in the prior period.

Capital Resources and Liquidity

Global financial markets have experienced a significant increase in volatility due to heightened uncertainty over the adverse economic impact caused by the COVID-19 outbreak. Notwithstanding these potential adverse market conditions, the Company believes it will have the funds necessary to support our short-term liquidity and operating needs based on our anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings, and current borrowing availability under the credit agreement.

Credit Arrangements

As of September 30, 2020, the Company maintained a $1,200 revolving credit agreement that matures in November 2024 (the Credit Agreement). There were no borrowings under the Credit Agreement as of September 30, 2020 and June 30, 2020, and the Company believes that borrowings under the Credit Agreement are and will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations. The primary restrictive covenant is a minimum ratio of 4.0 calculated as total earnings before interest, taxes, depreciation and amortization and non-cash asset impairment charges (Consolidated EBITDA) to total interest expense for the trailing four quarters (Interest Coverage ratio), as defined and described in the Credit Agreement.

23

The following table sets forth the calculation of the Interest Coverage ratio as of September 30, 2020, using Consolidated EBITDA for the trailing four quarters, as contractually defined in the Credit Agreement:
Twelve Months Ended
9/30/2020
Net earnings $1,153 
Add back:
Interest expense99 
Income tax expense300 
Depreciation and amortization187 
Non-cash asset impairment charges2 
Deduct:
Interest income(3)
Non-recurring, non-cash gain(1)
(85)
Consolidated EBITDA$1,653 
Interest expense$99 
Interest Coverage ratio16.7 
(1) Non-recurring, non-cash gain from the remeasurement of the Company’s previously held investment in its Saudi joint venture (see Notes to Condensed Consolidated Financial Statements).

The Company was in compliance with all restrictive covenants and limitations in the Credit Agreement as of September 30, 2020, and anticipates being in compliance with all restrictive covenants for the foreseeable future. The Company continues to monitor the financial markets and assess its ability to continue to draw on the Credit Agreement, and currently expects it will continue to have access to borrowings under the Credit Agreement.

As of September 30, 2020, the Company maintained $38 of foreign and other credit lines, of which $2 was outstanding.

Stock Repurchases and Dividend Payments

As of September 30, 2020, the Company had two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.

Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:
Three Months Ended
9/30/20209/30/2019
AmountShares
(in thousands)		AmountShares
(in thousands)
Open-market purchase program$— — $— — 
Evergreen Program100 444 104 663 
Total stock repurchases$100 444 $104 663 

Dividends per share declared and total dividends paid were as follows for the periods indicated:
Three Months Ended
9/30/20209/30/2019
Dividends per share declared$1.11 $1.06 
Total dividends paid140 133 

24

CONTINGENCIES
See Notes to Condensed Consolidated Financial Statements for information on the Company’s contingencies.

RECENTLY ISSUED ACCOUNTING STANDARDS
See Notes to Condensed Consolidated Financial Statements for a summary of recently issued accounting standards relevant to the Company.

NON-GAAP FINANCIAL MEASURES

The non-GAAP financial measures that may be included in this MD&A and the reasons management believes they are useful to investors are described below. These measures should be considered supplemental in nature and are not intended to be a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these measures may not be the same as similarly named measures presented by other companies.

The Company uses the term Consolidated EBITDA because it is a term used in the Credit Agreement. As defined in the Credit Agreement, Consolidated EBITDA represents earnings before interest, taxes, depreciation and amortization, non-cash asset impairment charges and other non-cash, non-recurring gains or losses. Interest Coverage ratio is the ratio of Consolidated EBITDA to interest expense. The Company’s management believes disclosure of Consolidated EBITDA provides useful information to investors because it is used in the primary restrictive covenant in the Credit Agreement. For additional discussion of the Interest Coverage ratio and a reconciliation of Consolidated EBITDA to net earnings, see “Financial Position and Liquidity - Financing Activities - Credit Arrangements” above.

Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions and divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the Company was operating throughout the relevant periods, and the impact of foreign exchange rate changes, which are out of the control of the Company and management.

The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:
Three Months Ended September 30, 2020
Percentage change versus the year-ago period
Health and WellnessHouseholdLifestyleInternationalTotal
Net sales growth / (decrease) (GAAP)28 %39 %17 %18 %27 %
Add: Foreign Exchange— — — 8 1 
Add/(Subtract): Divestitures/Acquisitions— — — (9)(1)
Organic sales growth / (decrease) (non-GAAP)28 %39 %17 %17 %27 %

25

Cautionary Statement
This Quarterly Report on Form 10-Q (this Report), including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of governments, consumers, customers, suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings attributable to the Company, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the Company’s ability to achieve its strategic goals, are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020 and in this Report, as updated from time to time in the Company’s Securities and Exchange Commission filings. These factors include, but are not limited to, the uncertainties relating to the continued impact of COVID-19 on the Company’s business, operations, employees, financial condition and results of operations, as well as:
•intense competition in the Company’s markets;
•the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences;
•the impact of COVID-19 on the availability of, and efficiency of the supply, manufacturing and distribution systems for, the Company’s products, including any significant disruption to such systems;
•long-term changes in consumer preference or demand for the Company’s products as a result of any shortages or lack of availability of any products in the near-term;
•risks related to supply chain issues and product shortages as a result of reliance on a limited base of suppliers and the significant increase in demand for disinfecting and other products due to the COVID-19 pandemic;
•dependence on key customers and risks related to customer consolidation and ordering patterns;
•risks related to the Company’s use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, or service interruptions, especially at a time when a large number of the Company’s employees are working remotely and accessing its technology infrastructure remotely;
•risks relating to acquisitions, including the recent acquisition of the majority interest in the Company’s Saudi joint venture, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets and goodwill; and the ability to complete announced transactions and, if completed, integration costs and potential contingent liabilities related to those transactions;
•unfavorable worldwide, regional and local economic and financial market conditions, including as a result of fear of exposure to or actual impacts of a widespread disease outbreak, such as COVID-19;
•the Company’s ability to maintain its business reputation and the reputation of its brands and products;
•lower revenue, increased costs or reputational harm resulting from government actions and regulations;
•the ability of the Company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity;
•the ability of the Company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix;
•volatility and increases in commodity costs such as resin, sodium hypochlorite and agricultural commodities, and increases in energy, transportation or other costs;
•risks related to international operations and international trade, including foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls, including periodic changes in such controls; changes in U.S. immigration or trade policies, including the imposition of new or additional tariffs; labor claims and labor unrest; inflationary pressures, particularly in Argentina; impact of the United Kingdom’s exit from, and the related on-going negotiations with, the European Union; government-imposed price controls or other regulations; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action;
26

•the facilities of the Company and its suppliers being subject to disruption by events beyond the Company’s control, including work stoppages, cyber-attacks, natural disasters, disease outbreaks or pandemics, such as COVID-19, and terrorism;
•the ability of the Company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries;
•the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls;
•the ability of the Company to implement and generate cost savings and efficiencies;
•the success of the Company’s business strategies;
•risks related to additional increases in the estimated fair value of The Procter & Gamble Company’s interest in the Glad business;
•the accuracy of the Company’s estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based;
•the Company’s ability to attract and retain key personnel;
•environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances;
•increased focus by governmental and non-governmental organizations, customers, consumers and investors on sustainability issues, including those related to climate change;
•the Company’s ability to effectively utilize, assert and defend its intellectual property rights;
•any infringement or claimed infringement by the Company of third-party intellectual property rights;
•the effect of the Company’s indebtedness and credit rating on its business operations and financial results;
•the Company’s ability to access capital markets and other funding sources, as well as continued or increased market volatility;
•the Company’s ability to pay and declare dividends or repurchase its stock in the future;
•uncertainties relating to tax positions, tax disputes and any changes in tax rates and regulations on the Company;
•the Company’s ability to maintain an effective system of internal controls;
•the impacts of potential stockholder activism; and
•risks related to the Company’s discontinuation of operations in Venezuela.
The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.
In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us,” and “our” refer to The Clorox Company and its subsidiaries.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have not been any material changes to the Company’s market risk since June 30, 2020. For additional information, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

Item 4. Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
No change in the Company’s internal control over financial reporting occurred during the first fiscal quarter of the fiscal year ending June 30, 2021, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
27

PART II – OTHER INFORMATION
Item 1.A. Risk Factors
For information regarding Risk Factors, please refer to Item 1.A. in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020 and the information in “Cautionary Statement” included in this Report.

28

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In May 2018, the Board of Directors authorized the Company to repurchase up to $2,000 million in shares of common stock on the open market (the 2018 Open-Market Program), which has no expiration date.

In August 1999, the Board of Directors authorized a stock repurchase program to reduce or eliminate dilution upon the issuance of common stock pursuant to the Company’s stock compensation plans (the Evergreen Program). In November 2005, the Board of Directors authorized the extension of the Evergreen Program to reduce or eliminate dilution in connection with issuances of common stock pursuant to the Company’s 2005 Stock Incentive Plan. The Evergreen Program has no expiration date and has no specified limit as to dollar amount and therefore is not included in column [d] below.

The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the first quarter of fiscal year 2021.
[a][b][c][d]
PeriodTotal Number of
Shares Purchased
(1)		Average Price Paid
per Share (2)		Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs		Maximum Number (or
Approximate Dollar
Value) of Shares that
May Yet Be Purchased
Under the Plans or
Programs
July 1 to 31, 2020— $— — $1,493 million
August 1 to 31, 2020443,848 225.30 443,848 $1,493 million
September 1 to 30, 2020— — — $1,493 million
Total443,848 $225.30 443,848 
____________________

(1)All of the shares purchased in August 2020 were acquired pursuant to the Company’s 2018 Evergreen Program.
(2)Average price paid per share in the period includes commission.
29

Item 6. Exhibits
See Exhibit Index below, which is incorporated by reference herein.
EXHIBIT INDEX
Exhibit No.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.
101.LABXBRL Taxonomy Extension Label Linkbase Document.
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).
30

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
THE CLOROX COMPANY
(Registrant)
DATE: November 2, 2020BY/s/ Jeffrey R. Baker
Jeffrey R. Baker
Vice President – Chief Accounting Officer and Corporate Controller

31
 EX-10.1 2 clxq1fy2110qexhibit1011.htm EX-10.1 Document

Exhibit 10.1
THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN

Effective as of November 16, 2005
First Amendment and Restatement as of November 14, 2012
Second Amendment and Restatement as of September 22, 2020

1. Establishment, Objectives and Duration.
     (a) Establishment of the Plan. The Clorox Company, a Delaware corporation (hereinafter referred to as the “Company”), hereby establishes an incentive compensation plan to be known as “The Clorox Company 2005 Stock Incentive Plan” (hereinafter referred to as the “Plan”). The Plan permits the granting of Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares, Performance Units and Other Stock-Based Awards. The Plan was originally adopted effective as of November 16, 2005 and was subsequently amended and restated effective as of November 14, 2012 (the “Effective Date”). The current amendment and restatement of the Plan is adopted effective as of September 22, 2020. Definitions of capitalized terms used in the Plan are contained in the attached Glossary, which is an integral part of the Plan.
     (b) Objectives of the Plan. The objectives of the Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Participants and to optimize the profitability and growth of the Company through incentives that are consistent with the Company’s goals and that link the personal interests of Participants to those of the Company’s stockholders. The Plan is further intended to provide flexibility to the Company in its ability to motivate, attract, and retain the services of Participants who make or are expected to make significant contributions to the Company’s success and to allow Participants to share in the success of the Company.
     (c) Duration of the Plan. No Award may be granted under the Plan after the day immediately preceding the tenth (10th) anniversary of the Effective Date, or such earlier date as the Board or the Committee shall determine. The Plan will remain in effect with respect to outstanding Awards until no Awards remain outstanding.
2. Administration of the Plan.
     (a) The Committee. The Plan shall be administered by the Management Development and Compensation Committee of the Board or such other committee (the “Committee”) as the Board shall select consisting of two or more members of the Board, each of whom is intended to be an “independent director” under New York Stock Exchange listing standards and also may be a “non-employee director” within the meaning of Rule 16b-3 (or any successor rule) of the Exchange Act and/or an “outside director” under regulations promulgated under Section 162(m) of the Code. The members of the Committee shall be appointed from time to time by, and shall serve at the discretion of, the Board.
     (b) Authority of the Committee. Subject to Applicable Laws and the provisions of the Plan (including any other powers given to the Committee hereunder), and except as otherwise provided by the Board, the Committee shall have full and final authority in its discretion to take all actions determined by the Committee to be necessary in the administration of the Plan, including, without limitation, discretion to:
     (i) select the Employees, Directors and Consultants to whom Awards may from time to time be granted hereunder;
     (ii) determine whether and to what extent Awards are granted hereunder;
     (iii) determine the size and types of Awards granted hereunder;
     (iv) approve forms of Award Agreement for use under the Plan;
     (v) determine the terms and conditions of any Award granted hereunder;
1


     (vi) establish performance goals for any Performance Period and determine whether such goals were satisfied;
     (vii) amend the terms of any outstanding Award granted under the Plan, whether in the event of a Participant’s termination of employment, in the event of a Change in Control or otherwise, provided that, except as otherwise provided in Section 18, no such amendment shall reduce the Exercise Price of an outstanding Option or the grant price of an outstanding SAR, and at any time when the Exercise Price of an outstanding Option or the grant price of an outstanding SAR is above the Fair Market Value of a share of Common Stock, no such amendment shall provide for the cancellation and re-grant or the exchange of any such outstanding Option or SAR for either cash or a new Award with a lower (or no) exercise price without the approval of the stockholders of the Company, and provided further, that any amendment that would materially adversely affect the Participant’s rights under an outstanding Award shall not be made without the Participant’s written consent;
     (viii) construe and interpret the terms of the Plan and any Award Agreement entered into under the Plan, and to decide all questions of fact arising in its application; and
     (ix) take such other action, not inconsistent with the terms of the Plan, as the Committee deems appropriate.
Except to the extent prohibited by Applicable Laws, the Committee may delegate its authority as identified herein, including the power and authority to make Awards to Participants who are not “insiders” subject to Section 16(b) of the Exchange Act, Awards intended to satisfy the Performance-Based Exception and/or Awards intended to satisfy the exception under Rule 16b-3(d)(1) promulgated under the Exchange Act, pursuant to such conditions and limitations as the Committee may establish. References to the Committee in this Plan shall refer to a delegate with respect to any action of such delegate within the scope of the authority delegated to such delegate by the Committee.
     (c) Effect of Committee’s Decision. All decisions, determinations and interpretations of the Committee shall be final, binding and conclusive on all persons, including the Company, its Subsidiaries, its stockholders, Employees, Directors, Consultants and their estates and beneficiaries.
3. Shares Subject to the Plan; Effect of Grants; Individual Limits.
     (a) Number of Shares Available for Grants. Subject to adjustment as provided in Section 18 hereof, the maximum number of Shares which may be issued pursuant to Awards under the Plan granted after June 30, 2012 shall be 7,100,000 Shares, plus the number of Shares deemed not issued under the Plan or the Prior Plans pursuant to paragraphs (i), (ii), (iii) or (iv) of this Section 3(a). For the avoidance of doubt, the Company shall be entitled to issue Shares under awards granted under the Plan or the Prior Plans that were outstanding on June 30, 2012 and such issuances shall not reduce the foregoing.
     (i) Shares that are potentially deliverable under an Award or a Prior Plan award that expires or is canceled, forfeited, settled in cash or otherwise settled without the delivery of Shares shall not be treated as having been issued under the Plan or a Prior Plan.
     (ii) Shares that are held back or tendered (either actually or constructively by attestation) to cover the exercise price or tax withholding obligations with respect to an Award or Prior Plan award shall not be treated as having been issued under the Plan or a Prior Plan.
     (iii) Shares that are issued pursuant to awards that are assumed, converted or substituted in connection with a merger, acquisition, reorganization or similar transaction shall not be treated as having been issued under the Plan.
     (iv) Shares that are repurchased in the open market with Option Proceeds from Awards or Prior Plan awards shall not be treated as having been issued under the Plan or a Prior Plan; provided, however, that the aggregate number of Shares deemed not issued pursuant to the repurchase of Shares with Option Proceeds shall not be greater than the amount of such proceeds divided by the Fair Market Value of a Share on the date of exercise of the Option or Prior Plan option giving rise to such proceeds.
Notwithstanding paragraphs (i) through (iv) above, for purposes of determining the number of Shares available for grant as Incentive Stock Options, only Shares that are subject to an Award or a Prior Plan award that expires or is cancelled, forfeited or settled in cash shall be treated as not having been issued under the Plan or a Prior Plan.

2


     The Shares to be issued pursuant to Awards may be authorized but unissued Shares or treasury Shares.
     (b) Individual Limits. Subject to adjustment as provided in Section 18 hereof, the following rules shall apply with respect to Awards:
     (i) Options and SARs: The maximum aggregate number of Shares with respect to which Options and SARs may be granted in any 36-month period to any one Participant shall be 2,000,000 Shares.
     (ii) Restricted Stock, Restricted Stock Units, Performance Shares and Other Stock-Based Awards: The maximum aggregate number of Shares of Restricted Stock and Shares with respect to which Restricted Stock Units, Performance Shares and Other Stock-Based Awards may be granted in any 36-month period to any one Participant shall be 800,000 Shares.
     (iii) Performance Units: The maximum aggregate compensation that can be paid pursuant to Performance Units awarded in any one fiscal year to any one Participant shall be $10,000,000 or a number of Shares having an aggregate Fair Market Value on the date of grant not in excess of such amount.
4. Eligibility and Participation.
     (a) Eligibility. Persons eligible to participate in the Plan include all Employees, Directors and Consultants.
     (b) Actual Participation. Subject to the provisions of the Plan, the Committee may, from time to time, select from all eligible Employees, Directors and Consultants, those to whom Awards shall be granted and shall determine the nature and amount of each Award. The Committee may establish additional terms, conditions, rules or procedures to accommodate the rules or laws of applicable foreign jurisdictions and to afford Participants favorable treatment under such laws; provided, however, that no Award shall be granted under any such additional terms, conditions, rules or procedures with terms or conditions which are inconsistent with the provisions of the Plan.
5. Types of Awards.
     (a) Type of Awards. Awards under the Plan may be in the form of Options (both Nonqualified Stock Options and/or Incentive Stock Options), SARs, Restricted Stock, Restricted Stock Units, Performance Shares, Performance Units and Other Stock-Based Awards.
     (b) Designation of Award. Each Award shall be designated in the Award Agreement.
6. Options.
     (a) Grant of Options. Subject to the terms and provisions of the Plan, Options may be granted to Participants in such number and upon such terms, and at any time and from time to time, as shall be determined by the Committee.
     (b) Award Agreement. Each Option grant shall be evidenced by an Award Agreement that shall specify the Exercise Price, the duration of the Option, the number of Shares to which the Option pertains, and such other provisions as the Committee shall determine including, but not limited to, the Option vesting schedule, repurchase provisions, rights of first refusal, forfeiture provisions, form of payment (cash, Shares, or other consideration) upon settlement of the Award, and payment contingencies. The Award Agreement also shall specify whether the Option is intended to be an Incentive Stock Option or a Nonqualified Stock Option. Options that are intended to be Incentive Stock Options shall be subject to the limitations set forth in Section 422 of the Code.
     (c) Exercise Price. Except for Options adjusted pursuant to Section 18 herein, and replacement Options granted in connection with a merger, acquisition, reorganization or similar transaction, the Exercise Price for each grant of an Option shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on the date the Option is granted. However, in the case of an Incentive Stock Option granted to a Participant who, at the time the Option is granted, owns stock representing more


3

than ten percent (10%) of the voting power of all classes of stock of the Company or any Subsidiary, the Exercise Price for each grant of an Option shall not be less than one hundred ten percent (110%) of the Fair Market Value of a Share on the date the Option is granted.
     (d) Term of Options. The term of an Option granted under the Plan shall be determined by the Committee, in its sole discretion; provided, however, that such term shall not exceed ten (10) years. However, in the case of an Incentive Stock Option granted to a Participant who, at the time the Option is granted, owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Subsidiary, the term of the Incentive Stock Option shall be five (5) years from the date of grant thereof or such shorter term as may be provided in the Award Agreement.
     (e) Exercise of Options. Options granted under this Section 6 shall be exercisable at such times and be subject to such restrictions and conditions as set forth in the Award Agreement and as the Committee shall in each instance approve, which need not be the same for each grant or for each Participant.
     (f) Payments. Options granted under this Section 6 shall be exercised by the delivery of a written notice to the Company, setting forth the number of Shares with respect to which the Option is to be exercised and specifying the method of the Exercise Price. The Exercise Price of an Option shall be payable to the Company: (i) in cash or its equivalent, (ii) by tendering (either actually or constructively by attestation or through authorization to withhold Shares otherwise issuable upon exercise of an Option) Shares having an aggregate Fair Market Value at the time of exercise equal to the Exercise Price, (iii) in any other manner then permitted by the Committee that is determined to provide a benefit to the Company, or (iv) by a combination of any of the permitted methods of payment. The Committee may limit any method of payment, other than that specified under (i), for administrative convenience, to comply with Applicable Laws or otherwise. Shares issued upon exercise shall be subject to such continuing restrictions as shall be provided in a Participant’s Award Agreement.
     (g) Restrictions on Share Transferability. The Committee may impose such restrictions on any Shares acquired pursuant to the exercise of an Option granted under this Section 6 as it may deem advisable, including, without limitation, restrictions under applicable federal securities laws, under the requirements of any stock exchange or market upon which such Shares are then listed and/or traded, and under any blue sky or state securities laws applicable to such Shares.
     (h) Termination of Employment or Service. Each Participant’s Option Award Agreement shall set forth the extent to which the Participant shall have the right to exercise the Option following termination of the Participant’s employment or, if the Participant is a Director or Consultant, service with the Company and its Subsidiaries. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Options, and may reflect distinctions based on the reasons for termination of employment or service.
     (i) No Repricing without Stockholder Approval. The Company shall not, without the approval of the stockholders of the Company, reduce the Exercise Price of an outstanding Option. And, at any time when the Exercise Price of an outstanding Option is above the Fair Market Value of a share of Common Stock, the Company shall not, without the approval of the stockholders of the Company, provide for the cancellation and re-grant or the exchange of such outstanding Option for either cash or a new Award with a lower (or no) exercise price.
7. Stock Appreciation Rights.
     (a) Grant of SARs. Subject to the terms and provisions of the Plan, SARs may be granted to Participants in such amounts and upon such terms, and at any time and from time to time, as shall be determined by the Committee. The Committee may grant Freestanding SARs, Tandem SARs, or any combination of these forms of SAR.
     (b) Award Agreement. Each SAR grant shall be evidenced by an Award Agreement that shall specify the grant price, the term of the SAR, and such other provisions as the Committee shall determine.
     (c) Grant Price. The grant price of a Freestanding SAR shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on the date of grant of the SAR, and the grant price of a Tandem SAR shall equal the Exercise Price of the related Option; provided, however, that these limitations shall not apply to Awards that are adjusted pursuant to Section 18 herein.


4

     (d) Term of SARs. The term of a SAR granted under the Plan shall be determined by the Committee, in its sole discretion; provided, however, that such term shall not exceed ten (10) years.
     (e) Exercise of Tandem SARs. A Tandem SAR may be exercised only with respect to the Shares for which its related Option is then exercisable. To the extent exercisable, Tandem SARs may be exercised for all or part of the Shares subject to the related Option. The exercise of all or part of a Tandem SAR shall result in the forfeiture of the right to purchase a number of Shares under the related Option equal to the number of Shares with respect to which the SAR is exercised. Conversely, upon exercise of all or part of an Option with respect to which a Tandem SAR has been granted, an equivalent portion of the Tandem SAR shall similarly be forfeited.
     Notwithstanding any other provision of the Plan to the contrary, with respect to a Tandem SAR granted in connection with an ISO: (i) the Tandem SAR will expire no later than the expiration of the underlying ISO; (ii) the value of the payout with respect to the Tandem SAR may be for no more than one hundred percent (100%) of the difference between the Exercise Price of the underlying ISO and the Fair Market Value of the Shares subject to the underlying ISO at the time the Tandem SAR is exercised; and (iii) the Tandem SAR may be exercised only when the Fair Market Value of the Shares subject to the ISO exceeds the Exercise Price of the ISO.
     (f) Exercise of Freestanding SARs. Freestanding SARs may be exercised upon whatever terms and conditions the Committee, in its sole discretion, imposes upon them and sets forth in the Award Agreement.
     (g) Payment of SAR Amount. Upon exercise of a SAR, a Participant shall be entitled to receive payment from the Company in an amount determined by multiplying:
     (i) the difference between the Fair Market Value of a Share on the date of exercise over the grant price; by
     (ii) the number of Shares with respect to which the SAR is exercised.
     At the discretion of the Committee, the payment upon SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. Shares issued upon SAR exercise shall be subject to such continuing restrictions as shall be provided in a Participant’s Award Agreement.
     (h) Termination of Employment or Service. Each SAR Award Agreement shall set forth the extent to which the Participant shall have the right to exercise the SAR following termination of the Participant’s employment or, if the Participant is a Director or Consultant, service with the Company and its Subsidiaries. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all SARs, and may reflect distinctions based on the reasons for termination of employment or service.
     (i) No Repricing without Stockholder Approval. The Company shall not, without the approval of the stockholders of the Company, reduce the grant price of an outstanding SAR. And at any time when the grant price of an outstanding SAR is above the Fair Market Value of a share of Common Stock, the Company shall not, without the approval of the stockholders of the Company, provide for the cancellation and re-grant or the exchange of such outstanding SAR for either cash or a new Award with a lower (or no) exercise price.
8. Restricted Stock.
     (a) Grant of Restricted Stock. Subject to the terms and provisions of the Plan, Restricted Stock may be granted to Participants in such amounts and upon such terms, and at any time and from time to time, as shall be determined by the Committee.
     (b) Award Agreement. Each Restricted Stock grant shall be evidenced by an Award Agreement that shall specify the applicable restrictions, the number of Shares of Restricted Stock granted and issued on the grant date, and such other provisions as the Committee shall determine.

5

     (c) Other Restrictions. The Committee shall impose such other conditions and/or restrictions on any Shares of Restricted Stock granted pursuant to the Plan as it may deem advisable including, without limitation, a requirement that Participants pay a stipulated purchase price for each Share of Restricted Stock, a requirement that the issuance of Shares of Restricted Stock be delayed, restrictions based upon the achievement of specific performance goals, time-based restrictions requiring a minimum period of service as a condition of vesting any or all Shares of Restricted Stock, and/or restrictions under Applicable Laws or under the requirements of any stock exchange or market upon which such Shares are listed or traded, or holding requirements or sale restrictions placed on the Shares by the Company upon vesting of such Restricted Stock. The Company may retain in its custody any certificate evidencing the Shares of Restricted Stock and place thereon a legend and institute stop-transfer orders on such Shares, and the Participant shall be obligated to sign any stock power requested by the Company relating to the Shares to give effect to the forfeiture provisions and any other restrictions of the Restricted Stock.
     (d) Removal of Restrictions. Subject to Applicable Laws, Restricted Stock shall become freely transferable by the Participant after the lapse of all of the restrictions applicable thereto.
     (e) Voting Rights. Unless otherwise determined by the Committee and set forth in a Participant’s Award Agreement, to the extent permitted or required by Applicable Laws, as determined by the Committee, Participants holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares.
     (f) Dividends and Other Distributions. Except as otherwise provided in a Participant’s Award Agreement, to the extent permitted or required under Applicable Laws, Participants holding Shares of Restricted Stock shall receive all regular cash Dividends paid with respect to all Shares while they are so held, and, except as otherwise determined by the Committee, to the extent permitted or required under Applicable Laws, all other distributions paid with respect to such Restricted Stock shall be credited to Participants subject to the same restrictions on transferability and forfeitability as the Restricted Stock with respect to which they were paid and shall be delivered to Participants in conjunction with the Shares of Restricted Stock with respect to which such distributions were made. Notwithstanding the foregoing, Dividends or other distributions that relate to performance-based Restricted Stock will be subject to the same performance conditions as the underlying Award.
     (g) Termination of Employment or Service. Each Award Agreement shall set forth the extent to which the Participant shall have the right to retain unvested Restricted Stock following termination of the Participant’s employment or, if the Participant is a Director or Consultant, service with the Company and its Subsidiaries. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Awards of Restricted Stock, and may reflect distinctions based on the reasons for termination of employment or service.
9. Restricted Stock Units.
     (a) Grant of Restricted Stock Units. Subject to the terms and provisions of the Plan, Restricted Stock Units may be granted to Participants in such amounts and upon such terms, and at any time and from time to time, as shall be determined by the Committee.
     (b) Award Agreement. Each grant of Restricted Stock Units shall be evidenced by an Award Agreement that shall specify the applicable restrictions, the number of Restricted Stock Units granted, and such other provisions as the Committee shall determine.
     (c) Value of Restricted Stock Units. The initial value of a Restricted Stock Unit shall equal the Fair Market Value of a Share on the date of grant; provided, however, that this restriction shall not apply to Awards that are adjusted pursuant to Section 18 herein.
     (d) Other Restrictions. The Committee shall impose such other conditions and/or restrictions on any Restricted Stock Units and/or the Shares issuable upon the settlement of Restricted Stock Units granted pursuant to the Plan as it may deem advisable including, without limitation, a requirement that Participants pay a stipulated purchase price for each Restricted Stock Unit, time-based restrictions requiring a minimum period of service as a condition of settlement of any or all Restricted Stock Units, and/or restrictions under Applicable Laws or under the requirements of any stock exchange or market, or holding requirements or sale restrictions placed on any Shares issued by the Company upon vesting and in settlement of such Restricted Stock Units.



6

     (e) Form and Timing of Payment. Except as otherwise provided in Section 19 herein or a Participant’s Award Agreement, payment of Restricted Stock Units shall be made at a specified settlement date that shall not be earlier than the last day that any time-based restrictions have lapsed. The Committee, in its sole discretion, may settle Restricted Stock Units by delivery of Shares or by payment in cash of an amount equal to the Fair Market Value of such Shares (or a combination thereof). The Committee may provide that settlement of Restricted Stock Units shall be deferred, either on a mandatory basis or at the election of the Participant. Shares issued at the settlement date shall be subject to such continuing restrictions as shall be provided in a Participant’s Award Agreement.
     (f) Voting Rights. A Participant shall have no voting rights with respect to any Restricted Stock Units granted hereunder.
     (g) Termination of Employment or Service. Each Award Agreement shall set forth the extent to which the Participant shall have the right to receive a payout respecting an Award of Restricted Stock Units following termination of the Participant’s employment or, if the Participant is a Director or Consultant, service with the Company and its Subsidiaries. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Restricted Stock Units, and may reflect distinctions based on the reasons for termination of employment or service.
     (h) Dividends and Other Distributions. Shares underlying Restricted Stock Units shall be entitled to Dividends or other distributions only to the extent provided by the Committee. In the event that the Committee decides to grant Restricted Stock Units that are entitled to Dividends or other distributions, Dividends or other distributions that relate to performance-based Restricted Stock Units shall be subject to the same performance conditions as the underlying Award.
10. Performance Shares.
     (a) Grant of Performance Shares. Subject to the terms and provisions of the Plan, Performance Shares may be granted to Participants in such amounts and upon such terms, and at any time and from time to time, as shall be determined by the Committee.
     (b) Award Agreement. Each grant of Performance Shares shall be evidenced by an Award Agreement that shall specify the applicable Performance Period(s) and Performance Measure(s), the number of Performance Shares granted and issued on the grant date, and such other provisions as the Committee shall determine.
     (c) Performance Period and Other Restrictions. The Committee shall impose such conditions and/or restrictions on any Performance Shares granted pursuant to the Plan as it may deem advisable including, without limitation, a requirement that Participants pay a stipulated purchase price for each Performance Share, time-based restrictions requiring a minimum period of service as a condition of vesting of any or all Performance Shares, and/or restrictions under Applicable Laws or under the requirements of any stock exchange or market upon which the Shares are listed or traded, or holding requirements or sale restrictions placed on the Shares by the Company upon vesting of such Performance Shares. The Company may retain in its custody any certificate evidencing the Shares and place thereon a legend and institute stop-transfer orders on such Shares, and the Participant shall be obligated to sign any stock power requested by the Company relating to the Shares to give effect to the forfeiture provisions and any other restrictions of the Performance Shares.
     (d) Removal of Restrictions. Subject to Applicable Laws, Performance Shares shall become freely transferable by the Participant after the lapse of all of the restrictions applicable thereto.
     (e) Voting Rights. Unless otherwise determined by the Committee and set forth in a Participant’s Award Agreement, to the extent permitted or required by Applicable Laws, as determined by the Committee, Participants holding Performance Shares granted hereunder may exercise full voting rights with respect to those Shares.
     (f) Dividends and Other Distributions. Except as otherwise provided in a Participant’s Award Agreement, to the extent permitted or required under Applicable Laws, Participants holding Performance Shares shall receive all regular cash Dividends paid with respect to all Shares while they are so held; provided, however, that all Dividends or other distributions shall be subject to the same performance conditions as the underlying Award.



7

     (g) Termination of Employment or Service. Each Award Agreement shall set forth the extent to which the Participant shall have the right to retain unvested Performance Shares following termination of the Participant’s employment or, if the Participant is a Consultant, service with the Company and its Subsidiaries. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Participants, and may reflect distinctions based on the reasons for termination of employment or service.
11. Performance Units.
     (a) Grant of Performance Units. Subject to the terms and conditions of the Plan, Performance Units may be granted to Participants in such amounts and upon such terms, and at any time and from time to time, as shall be determined by the Committee.
     (b) Award Agreement. Each grant of Performance Units shall be evidenced by an Award Agreement that shall specify the number of Performance Units granted, the Performance Period(s) and Performance Measure(s), the performance goals and such other provisions as the Committee shall determine.
     (c) Value of Performance Units. The Committee shall set performance goals in its discretion that, depending on the extent to which they are met, will determine the number and/or value of Performance Units that will be paid out to the Participants.
     (d) Form and Timing of Payment. Except as otherwise provided in Section 19 herein or a Participant’s Award Agreement, payment of Performance Units shall be made following the close of the applicable Performance Period on a settlement date selected by the Committee. The Committee, in its sole discretion, may settle Performance Units in cash or in Shares that have an aggregate Fair Market Value equal to the value of the Performance Units (or a combination thereof). The Committee may provide that settlement of Performance Units shall be deferred, either on a mandatory basis or at the election of the Participant. Shares issued at the settlement date shall be subject to such continuing restrictions as shall be provided in a Participant’s Award Agreement.
     (e) Voting Rights. A Participant shall have no voting rights with respect to any Performance Units granted hereunder.
     (f) Termination of Employment or Service. Each Award Agreement shall set forth the extent to which the Participant shall have the right to receive a payout respecting an Award of Performance Units following termination of the Participant’s employment or, if the Participant is a Consultant, service with the Company and its Subsidiaries. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Performance Units and may reflect distinctions based on reasons for termination of employment or service.
     (g) Dividends and Other Distributions. Shares underlying Performance Units shall be entitled to Dividends or other distributions only to the extent provided by the Committee. In the event that the Committee decides to grant Performance Units that are entitled to Dividends or other distributions, Dividends or other distributions shall be subject to the same performance conditions as the underlying Award.
12. Other Stock-Based Awards.
     (a) Grant. The Committee shall have the right to grant other Awards that may include, without limitation, the grant of Shares based on attainment of performance goals established by the Committee, the payment of Shares as a bonus or in lieu of cash based on attainment of performance goals established by the Committee, and the payment of Shares in lieu of cash under other Company incentive or bonus programs.
     (b) Restrictions. The Committee shall impose such conditions and/or restrictions on Other Stock-Based Awards granted pursuant to the Plan as it may deem advisable including, without limitation, a requirement that Participants pay a stipulated purchase price for each Share subject to the Award, time-based restrictions requiring a minimum period of service as a condition of vesting in any or all Shares subject to the Award, and/or restrictions under Applicable Laws or under the requirements of any stock exchange or market, or holding requirements or sale restrictions placed on any Shares issued by the Company upon vesting and in settlement of Other Stock-Based Awards.


8

     (c) Payment of Other Stock-Based Awards. Settlement of any such Awards shall be made in such manner and at such times as the Committee may determine. The Committee may provide that settlement of Other Stock-Based Awards shall be deferred, either on a mandatory basis or at the election of the Participant. Shares issued upon settlement shall be subject to such continuing restrictions as shall be provided in a Participant’s Award Agreement.
     (d) Termination of Employment or Service. The Committee shall determine the extent to which the Participant shall have the right to receive Other Stock-Based Awards following termination of the Participant’s employment or, if the Participant is a Director or Consultant, service with the Company and its Subsidiaries. Such provisions shall be determined in the sole discretion of the Committee, such provisions may be included in an agreement entered into with each Participant, but need not be uniform among all Other Stock-Based Awards, and may reflect distinctions based on the reasons for termination of employment or service.
13. Dividend Equivalents. At the discretion of the Committee, Awards granted pursuant to the Plan may provide Participants with the right to receive Dividend Equivalents, which may be paid currently or credited to an account for the Participants, and may be settled in cash and/or Shares, as determined by the Committee in its sole discretion, subject in each case to such terms and conditions as the Committee shall establish. Notwithstanding the foregoing, Dividend Equivalents that relate to performance-based Awards will either not be made at all or shall be subject to the same performance conditions as the underlying Award.
14. Performance-Based Exception.
     (a) The Committee may specify that the attainment of one or more of the Performance Measures set forth in this Section 14 shall determine the degree of granting, vesting and/or payout with respect to Awards that the Committee intends will qualify for the Performance-Based Exception. The performance goals to be used for such Awards shall be chosen from among the following performance measures (the “Performance Measures”): total shareholder return, stock price, net customer sales, volume, gross profit, gross margin, operating profit, operating margin, management profit, earnings from continuing operations before income taxes, earnings from continuing operations, earnings per share from continuing operations, earnings before interest and taxes (“EBIT”), earnings before interest, taxes, depreciation and amortization (“EBITDA”), net operating profit after tax, net earnings, net earnings per share, return on assets, return on investment, return on equity, return on invested capital, cost of capital, average capital employed, cash value added, economic value added, economic profit, cash flow, cash flow from operations, working capital, working capital as a percentage of net customer sales, asset growth, asset turnover, market share, customer satisfaction, and employee satisfaction. The targeted level or levels of performance with respect to such Performance Measures may be established at such levels and on such terms as the Committee may determine, in its discretion, on a corporate-wide basis or with respect to one or more business units, divisions, subsidiaries, business segments or functions, and in either absolute terms or relative to the current and/or historical performance of one or more companies or an index covering multiple companies. Performance measures that are financial metrics may or may not be calculated in accordance with generally accepted accounting principles, at the Committee’s discretion. Awards that are not intended to qualify for the Performance-Based Exception may be based on these or such other performance measures as the Committee may determine.
     (b) Unless otherwise determined by the Committee, measurement of performance goals with respect to the Performance Measures above shall exclude the impact of charges for restructurings, discontinued operations, extraordinary items, and other unusual or non-recurring items, including, for example, asset impairment charges and force majeure, as well as the cumulative effects of tax or accounting changes, each as determined in accordance with generally accepted accounting principles or identified in the Company’s financial statements, notes to the financial statements, management’s discussion and analysis or other filings with the SEC.
     (c) Performance goals may differ for Awards granted to any one Participant or to different Participants.
     (d) Achievement of performance goals in respect of Awards intended to qualify under the Performance-Based Exception shall be measured over a Performance Period specified in the Award Agreement, and the goals shall be established not later than 90 days after the beginning of the Performance Period or, if less than 90 days, the number of days which is equal to 25% of the relevant Performance Period applicable to the Award.






9

     (e) The Committee shall have the discretion to adjust the determinations of the degree of attainment of the pre-established performance goals; provided, however, that Awards that are designed to qualify for the Performance-Based Exception may not be adjusted upward (the Committee may, in its discretion, adjust such Awards downward).
     (f) The Committee shall certify the extent to which any Performance Measures have been satisfied, and the amount payable as a result thereof, prior to payment, settlement or vesting of any Award that is intended to satisfy the Performance-Based Exception. Shares issued upon full or partial achievement of the selected Performance Measure(s) shall be subject to such continuing restrictions as shall be provided in a Participant’s Award Agreement.
15. Transferability of Awards. Incentive Stock Options may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution, and shall be exercisable during a Participant’s lifetime only by such Participant. Other Awards shall be transferable to the extent provided in the Award Agreement, except that no Award may be transferred for consideration. Each Award may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated by a Participant other than by will or the laws of descent and distribution, and each Option or Stock Appreciation Right shall be exercisable only by the Participant during his or her lifetime. Notwithstanding the foregoing, to the extent permitted by the Committee, the person to whom an Award (other than an Incentive Stock Option) is initially granted (the “Grantee”) may transfer an Award to any “family member” of the Grantee (as such term is defined in Section 1(a)(5) of the General Instructions to Form S-8 under the Securities Act of 1933, as amended (“Form S-8”)); provided that, (i) as a condition thereof, the transferor and the transferee must execute a written agreement containing such terms as may be specified by the Committee, and (ii) the transfer is pursuant to a gift or a domestic relations order to the extent permitted under the General Instructions to Form S-8.
16. Taxes. The Company shall have the power and right, prior to the delivery of Shares pursuant to an Award, to deduct or withhold, or require a participant to remit to the Company (or a Subsidiary), an amount (in cash or Shares) sufficient to satisfy any applicable tax withholding requirements applicable to an Award. Whenever under the Plan payments are to be made in cash, such payments shall be net of an amount sufficient to satisfy any applicable tax withholding requirements. Subject to such restrictions as the Committee may prescribe, a Participant may satisfy all or a portion of any tax withholding requirements for an Award payable or settled in Shares by electing to have the Company withhold Shares having a Fair Market Value equal to the amount to be withheld up to the minimum statutory tax withholding rate (or such other rate that will not cause the Award to be accounted for under variable award account or otherwise result in a negative accounting impact).
17. Conditions Upon Issuance of Shares.
     (a) Shares shall not be issued pursuant to the exercise or settlement of an Award unless the exercise or settlement of such Award and the issuance and delivery of such Shares pursuant thereto shall comply with all Applicable Laws, and shall be further subject to the approval of counsel for the Company with respect to such compliance.
     (b) As a condition to the exercise or settlement of an Award, the Company may require the person exercising such Award or receiving such settlement to represent and warrant at the time of any such exercise or settlement that the Shares are being acquired only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any Applicable Laws. The Company may also require the person exercising such Award or receiving such settlement to acknowledge and affirm any restrictions applicable to the Shares issuable upon the exercise or settlement of an Award.
18. Adjustments Upon Changes in Capitalization. Notwithstanding any other provision of the Plan to the contrary, in the event of any merger, reorganization, consolidation, recapitalization, liquidation, stock dividend, split-up, spin-off, stock split, reverse stock split, share combination, share exchange, extraordinary dividend, or any change in the corporate structure affecting the Shares, such adjustment shall be made in the number and kind of Shares or other securities or property that may be delivered under the Plan, the individual limits set forth in Section 3(b), and, with respect to outstanding Awards, in the number and kind of Shares or other securities or property subject to outstanding Awards, the Exercise Price, grant price or other price, if any, of Shares subject to outstanding Awards, any performance conditions relating to Shares, the market price of Shares, or per-Share results, and other terms and conditions of outstanding Awards, as may be determined to be appropriate and equitable by the Committee,



10

in its sole discretion, to prevent dilution or enlargement of rights; provided, however, that, unless otherwise determined by the Committee, the number of Shares or other securities or property subject to any Award shall always be rounded down to a whole number. Adjustments made by the Committee pursuant to this Section 18 shall be final, binding, and conclusive.
19. Change in Control, Cash-Out and Termination of Underwater Options/SARs, and Subsidiary Disposition.
     (a) Change in Control. Except as otherwise provided in a Participant’s Award Agreement or pursuant to Section 19(b) hereof, upon the occurrence of a Change in Control, unless otherwise specifically prohibited under Applicable Laws, or by the rules and regulations of any governing governmental agencies or national securities exchanges:
     (i) any and all outstanding Options and SARs granted hereunder shall become immediately exercisable unless such Awards are assumed, converted, replaced or continued by the continuing entity; provided, however, that in the event of a Participant’s termination of employment without Cause within twenty-four (24) months following consummation of a Change in Control, any Awards so assumed, converted, replaced or continued will become immediately exercisable;
     (ii) any Period of Restriction or other restriction imposed on Restricted Stock, Restricted Stock Units, Performance Shares, Performance Units and Other Stock-Based Awards shall lapse unless such Awards are assumed, converted, replaced or continued by the continuing entity; provided, however, that in the event of a Participant’s termination of employment without Cause within twenty-four (24) months following consummation of a Change in Control, the Period of Restriction on any Awards so assumed, converted, replaced or continued shall lapse; and
     (iii) the portion of any and all Performance Shares, Performance Units and other Awards (if performance-based) that remain outstanding following the occurrence of a Change in Control shall be determined by applying actual performance from the beginning of the Performance Period through the date of the Change in Control using the formula set forth in the Award Agreement (“Performance Measure Formula”) to determine the amount of the payout or distribution rounded to the nearest whole Share. Notwithstanding the foregoing, if the Change in Control occurs prior to the end of a Performance Period for an Award, the Performance Measure Formula shall generally be adjusted to take into account the shorter period of time available to achieve the Performance Measures. If a quantitative Performance Measure Formula for the entire Performance Period has been determined by the Company by adding together one or more goals for Performance Measures (“Performance Measure Goals”) for multiple time periods within the Performance Period (each a “subperiod”), then the adjusted Performance Measure Formula for a given level of performance shall be equal to the sum of (1) the Performance Measure Goals for each completed subperiod for such level of performance and (2) a prorated Performance Measure Goal (determined by the number of days in such subperiod falling on or before the occurrence of the Change in Control divided by the total number of days in such subperiod) for such level of performance for each subperiod not completed on or before the occurrence of the Change in Control. If there are no subperiods, then the quantitative Performance Measure Formula shall be prorated by taking the Performance Measure Goal for each specified level of performance for the entire Performance Period and multiplying it by a fraction, the numerator of which is the number of days in the Performance Period falling on or before the occurrence of the Change in Control and the denominator of which is the total number of days in the Performance Period. Qualitative Performance Measures shall not be adjusted. In the unlikely event that the Company is unable to substantially adjust the target Performance Measure(s) for an Award as set forth above, then the portion of such Award that shall remain outstanding shall be based on the assumption that the target level of performance for each Performance Measure for the entire Performance Period has been achieved.
The portion of the Award that remains outstanding following the occurrence of a Change in Control as determined in the preceding paragraph shall vest in full at the end of the Performance Period set forth in such Award so long as the Participant’s employment (or if the Participant is a Director or Consultant, service) with the Company or a Subsidiary does not terminate until the end of the Performance Period. Notwithstanding the foregoing, such portion shall vest in full upon the earliest to occur of the following events: (1) the termination of the Participant by the Company without Cause, (2) the refusal of the continuing entity to assume, convert, replace or continue the Award, or (3) if applicable, the resignation of the Participant for a “good reason”, as described further in the following paragraph.





11

With respect to paragraphs (i), (ii) and (iii) of Section 19(a) above, the Award Agreement may provide that any replacement awards will become immediately exercisable or any Period of Restriction shall lapse in the event of a termination of employment by the Participant for “good reason” if and as such term is defined in the Award Agreement or any employment agreement, severance agreement or other agreement or policy applicable to such Participant.
     (b) Cash-Out and Termination of Underwater Options/SARs. The Committee may, in its sole discretion, provide that (i) all outstanding Options and SARs shall be terminated upon the occurrence of a Change in Control and that each Participant shall receive, with respect to each Share subject to such Options or SARs, an amount in cash and/or Shares equal to the excess of the Fair Market Value of a Share immediately prior to the occurrence of the Change in Control over the Option Exercise Price or the SAR grant price; and (ii) Options and SARs outstanding as of the date of the Change in Control may be cancelled and terminated without payment therefore if the Fair Market Value of a Share as of the date of the Change in Control is less than the Option Exercise Price or the SAR grant price.
     (c) Subsidiary Disposition. The Committee shall have the authority, exercisable either in advance of any actual or anticipated Subsidiary Disposition or at the time of an actual Subsidiary Disposition and either at the time of the grant of an Award or at any time while an Award remains outstanding, to provide for the automatic full vesting and exercisability of one or more outstanding unvested Awards under the Plan and the termination of restrictions on transfer and repurchase or forfeiture rights on such Awards, in connection with a Subsidiary Disposition, but only with respect to those Participants who are at the time engaged primarily in Continuous Service with the Subsidiary involved in such Subsidiary Disposition. The Committee also shall have the authority to condition any such vesting and exercisability or release from the limitations of an Award upon the continuation or subsequent termination of the affected Participant’s Continuous Service with that Subsidiary within a specified period following the effective date of the Subsidiary Disposition. The Committee may provide that any Awards so vested or released from such limitations in connection with a Subsidiary Disposition, shall remain fully exercisable until the expiration or earlier termination of the Award.
20. Amendment, Suspension or Termination of the Plan.
     (a) Amendment, Modification and Termination. The Board or the Committee may at any time and from time to time, alter, amend, suspend or terminate the Plan in whole or in part; provided, however, that no amendment that requires stockholder approval in order for the Plan to continue to comply with the New York Stock Exchange listing standards or any rule promulgated by the SEC or any securities exchange on which Shares are listed or any other Applicable Laws shall be effective unless such amendment shall be approved by the requisite vote of stockholders of the Company entitled to vote thereon within the time period required under such applicable listing standard or rule. Unless the Board or the Committee adopt resolutions providing for an earlier date, the Plan shall automatically terminate on November 14, 2022. For purposes of Section 422 of the Code and also relevant provisions of Applicable Laws, the adoption of the Plan as approved by the stockholders on November 14, 2012 shall be deemed to be the adoption of a new plan.
     (b) Adjustment of Awards Upon the Occurrence of Certain Unusual or Nonrecurring Events. The Committee may make adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of unusual or nonrecurring events (including, without limitation, the events described in Section 18 hereof) affecting the Company or the financial statements of the Company or of changes in Applicable Laws, regulations, or accounting principles, whenever the Committee determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan. With respect to any Awards intended to comply with the Performance-Based Exception, unless otherwise determined by the Committee, any such exception shall be specified at such times and in such manner as will not cause such Awards to fail to qualify under the Performance-Based Exception.
     (c) Awards Previously Granted. No termination, amendment or modification of the Plan or of any Award shall adversely affect in any material way any Award previously granted under the Plan without the written consent of the participant holding such Award, unless such termination, modification or amendment is required by Applicable Laws and except as otherwise provided herein.







12




     (d) No Repricing. The Company shall not, without the approval of the stockholders of the Company, reduce the Exercise Price of an outstanding Option or the grant price of an outstanding SAR. And, at any time when the Exercise Price of an outstanding Option or the grant price of an outstanding SAR is above the Fair Market Value of a share of Common Stock, no amendment shall provide that any such outstanding Option or outstanding SAR be cancelled and re-granted or exchanged for either cash or a new Award with a lower (or no) exercise price, without the approval of the stockholders of the Company.
     (e) Compliance with the Performance-Based Exception. If it is intended that an Award comply with the requirements of the Performance-Based Exception, the Committee may apply any restrictions it deems appropriate such that the Awards maintain eligibility for the Performance-Based Exception. If changes are made to Code Section 162(m) or regulations promulgated thereunder, the Committee may, subject to the other provisions of this Section 20, make any adjustments to the Plan and/or Award Agreements it deems appropriate that does not prevent the Plan or any outstanding Awards intended to comply with the Performance-Based Exception from complying with Section 162(m) of the Code.
21. Reservation of Shares.
     (a) The Company, during the term of the Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan.
     (b) The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained.
22. Rights of Participants.
     (a) Continued Service. The Plan shall not confer upon any Participant any right with respect to continuation of employment or consulting relationship with the Company, nor shall it interfere in any way with his or her right or the Company’s right to terminate his or her employment or consulting relationship at any time, with or without cause.
     (b) Participant. No Employee, Director or Consultant shall have the right to be selected to receive an Award under the Plan, or, having been so selected, to be selected to receive future Awards.
23. Successors. All obligations of the Company under the Plan and with respect to Awards shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or other event, or a sale or disposition of all or substantially all of the business and/or assets of the Company and references to the “Company” herein and in any Award Agreements shall be deemed to refer to such successors.
24. Legal Construction.
     (a) Gender, Number and References. Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine, the plural shall include the singular and the singular shall include the plural. Any reference in the Plan to a Section of the Plan either in the Plan or any Award Agreement or to an act or code or to any section thereof or rule or regulation thereunder shall be deemed to refer to such Section of the Plan, act, code, section, rule or regulation, as may be amended from time to time, or to any successor Section of the Plan, act, code, section, rule or regulation.
     (b) Severability. In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provision had not been included.
     (c) Requirements of Law. The granting of Awards and the issuance of Shares or cash under the Plan shall be subject to all Applicable Laws and to such approvals by any governmental agencies or national securities exchanges as may be required.

13




     (d) Governing Law. To the extent not preempted by federal law, the Plan, and all agreements hereunder, shall be construed in accordance with and governed by the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Plan to the substantive law of another jurisdiction.
     (e) Non-Exclusive Plan. Neither the adoption of the Plan by the Board nor its submission to the stockholders of the Company for approval shall be construed as creating any limitations on the power of the Board or a committee thereof to adopt such other incentive arrangements as it may deem desirable.
     (f) Code Section 409A Compliance. To the extent applicable, it is intended that this Plan and any Awards granted hereunder either be exempt from the requirements of, or else comply with the requirements of, Section 409A of the Code and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision that would cause any Award granted hereunder to incur additional taxes under Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

14

GLOSSARY OF DEFINED TERMS
1. Definitions. As used in the Plan, the following definitions shall apply:
     “Applicable Laws” means the legal requirements relating to the administration of stock incentive plans, if any, under applicable provisions of federal securities laws, state corporate and securities laws, the Code, and the rules of any applicable stock exchange or national market system.
     “Award” means, individually or collectively, Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares, Performance Units and Other Stock-Based Awards granted under the Plan.
     “Award Agreement” means an agreement entered into by the Company and a Participant setting forth the terms and provisions applicable to an Award.
     “Board” means the Board of Directors of the Company.
     “Cause” means (i) the willful and continued failure of the Participant substantially to perform the Participant’s duties with the Company (other than any such failure resulting from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to the Participant by the Chief Executive Officer of the Company, a member of the Committee, or another authorized officer of the Company, which specifically identifies the manner in which the sender believes that the Participant has not substantially performed the Participant’s duties; or (ii) the willful engaging by the Participant in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company.
No act or failure to act on the part of the Participant shall be considered to be “willful” unless it is done, or omitted to be done, by the Participant in bad faith or without reasonable belief that the Participant’s action or omission was in the best interests of the Company. Any act or failure to act based upon authority given pursuant to a resolution duly adopted by the Board or upon the instructions of the Chief Executive Officer of the Company or the Committee or another authorized officer of the Company or based upon the advice of counsel for the Company shall be conclusively presumed to be done or omitted to be done by the Participant in good faith and in the best interests of the Company. The cessation of employment of the Participant shall not be deemed to be for Cause unless and until the Chief Executive Officer, Vice President of Human Resources and General Counsel unanimously agree that, in their good faith opinion, the Participant is guilty of the conduct described in subsections (i) or (ii) above, and so notify the Participant specifying the particulars thereof in detail.
     “Change in Control” means
      (a)      The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act ) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 30% of either the total fair market value of the then outstanding equity securities of the Company (the “Outstanding Company Common Stock”) or the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition directly from the Company, (ii) any acquisition by the Company, including any acquisition which, by reducing the number of shares outstanding, is the sole cause for increasing the percentage of shares beneficially owned by any such Person to more than the applicable percentage set forth above, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company or (iv) any acquisition by any corporation pursuant to a transaction which complies with clauses (i), (ii) and (iii) of subsection (c) of this definition; or
  
(b)Individuals who, as of the date hereof, constitute the Board (the “Incumbent Board”) cease for any reason within any period of 12 months to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by the Company’s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board, shall be considered as
            though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or
15

 
(c)Consummation by the Company of (i) a reorganization, merger, consolidation or similar transaction involving another business, (ii) a sale or other disposition of all or substantially all of the assets of the Company, or (iii) the acquisition of the securities or assets of another business (a “Business Combination”), in each case, unless, following such Business Combination, (A) more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the controlling parent entity resulting from such Business Combination (including without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) is represented by Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which such Outstanding Company Common Stock and Outstanding Company Voting Securities were converted pursuant to such Business Combination) and such ownership of common stock and voting power among the holders thereof is in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 30% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination and (iii) at least a majority of the members of the board of directors (or similar governing body) of the controlling parent entity resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination.
Notwithstanding any other provision in this definition, to the extent required in order to avoid additional income taxation under Section 409A, any transaction defined in subsections (a) through (c) of this definition that does not constitute a "change in the ownership or effective control" of the Company, or "change in the ownership of a substantial portion of the assets" of the Company within the meaning of Treasury Regulations Sections 1.409A-3(a)(5) and 1.409A-3(i)(5) shall not be treated as a Change in Control.
     “Code” means the Internal Revenue Code of 1986, as amended.
     “Committee” means the Committee, as specified in Section 2(a), appointed by the Board to administer the Plan.
     “Company” means The Clorox Company and any successor thereto as provided in Section 23 herein.
     “Consultant” means any consultant or advisor to the Company or a Subsidiary.
     “Continuous Service” means that the provision of services to the Company or any Subsidiary in any capacity of Employee, Director or Consultant is not interrupted or terminated. Continuous Service shall not be considered interrupted in the case of (i) any leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, any Subsidiary, or any successor. A leave of absence approved by the Company shall include sick leave, military leave, or any other personal leave approved by an authorized representative of the Company. For purposes of Incentive Stock Options, no such leave may exceed ninety (90) days, unless reemployment upon expiration of such leave is guaranteed by statute or contract.
     “Director” means any individual who is a member of the Board of Directors of the Company or a Subsidiary who is not an Employee.
     “Dividend” means the dividends declared and paid on Shares subject to an Award.
     “Dividend Equivalent” means, with respect to Shares subject to an Award, a right to be paid an amount equal to the Dividends declared and paid on an equal number of outstanding Shares prior to the issuance of Shares.
     “Employee” means any employee of the Company or a Subsidiary.
     “Exchange Act” means the Securities Exchange Act of 1934, as amended.
     “Exercise Price” means the price at which a Share may be purchased by a Participant pursuant to an Option.
16

     “Fair Market Value” means, as of any date, the value of a Share determined as follows:
      (a)      Where there exists a public market for the Share, the Fair Market Value shall be (A) the closing sales price for a Share on the date of the determination (or, if no sales were reported on that date, on the last trading date on which sales were reported) on the New York Stock Exchange, the NASDAQ Global Market or the principal securities exchange on which the Share is listed for trading, whichever is applicable, or (B) if the Share is not traded on any such exchange or national market system, the average of the closing bid and asked prices of a Share on the NASDAQ Capital Market, in each case, as reported in The Wall Street Journal or such other source as the Committee deems reliable; or
 
(b)In the absence of an established market of the type described above, for the Share, the Fair Market Value thereof shall be determined by the Committee in good faith, and such determination shall be conclusive and binding on all persons.
     “Freestanding SAR” means a SAR that is granted independently of any Options, as described in Section 7 herein.
     “Incentive Stock Option” or “ISO” means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code.
     “Nonqualified Stock Option” means an Option that is not intended to meet the requirement of Section 422 of the Code.
     “Option” means an Incentive Stock Option or a Nonqualified Stock Option granted under the Plan, as described in Section 6 herein.
     “Option Proceeds” means the cash received by the Company as payment of the Exercise Price upon exercise of an Option or a Prior Plan option plus the federal tax benefit that could be realized by the Company as a result of the Option of Prior Plan option exercise, which shall be determined by multiplying the amount that is deductible as a result of the Option or Prior Plan option exercise (currently equal to the amount upon which the Participant’s withholding tax obligation is calculated) by the maximum federal corporate income tax rate for the year of exercise. To the extent that a Participant pays the Exercise Price and/or withholding taxes with Shares, Option Proceeds shall not be calculated with respect to the amount paid in such manner.
     “Other Stock-Based Award” means a Share-based or Share-related Award granted pursuant to Section 12 herein.
     “Participant” means a current or former Employee, Director or Consultant who has rights relating to an outstanding Award.
     “Performance-Based Exception” means the performance-based exception from the tax deductibility limitations of Code Section 162(m).
     “Performance Measures” shall have the meaning set forth in Section 14(a).
     “Performance Period” means the period during which a performance measure must be met.
     “Performance Share” means an Award granted to a Participant, as described in Section 10 herein.
     “Performance Unit” means an Award granted to a Participant, as described in Section 11 herein.
     “Period of Restriction” means the period Restricted Stock, Restricted Stock Units or Other Stock-Based Awards are subject to a substantial risk of forfeiture and are not transferable.
     “Plan” means The Clorox Company 2005 Stock Incentive Plan.
     “Prior Plans” means The Clorox Company 1996 Stock Incentive Plan, The Clorox Company 1987 Long Term Compensation Program, The Clorox Company Independent Directors’ Stock-Based Compensation Plan, and the 1993 Directors’ Stock Option Plan.
     “Restricted Stock” means an Award granted to a Participant, as described in Section 8 herein.
     “Restricted Stock Units” means an Award granted to a Participant, as described in Section 9 herein.
17

     “SEC” means the United States Securities and Exchange Commission.
     “Share” means a share of common stock of the Company, par value $1.00 per share, subject to adjustment pursuant to Section 18 herein.
     “Stock Appreciation Right” or “SAR” means an Award granted to a Participant, either alone or in connection with a related Option, as described in Section 7 herein.
     “Subsidiary” means any corporation in which the Company owns, directly or indirectly, at least fifty percent (50%) of the total combined voting power of all classes of stock, or any other entity (including, but not limited to, partnerships and joint ventures) in which the Company owns, directly or indirectly, at least fifty percent (50%) of the equity securities thereof. Notwithstanding the foregoing, for purposes of determining whether any individual may be a Participant for purposes of any grant of Incentive Stock Options, the term “Subsidiary” shall have the meaning ascribed to such term in Code Section 424(f).
     “Subsidiary Disposition” means (i) the disposition by the Company of some or all of its equity holdings in any Subsidiary effected by a merger, consolidation or a similar transaction involving that Subsidiary, (ii) the Company’s sale or distribution of substantially all of the outstanding capital stock of such Subsidiary, in either case such that the Subsidiary is not longer a Subsidiary following such transaction, or (iii) the sale of all or substantially all of the assets of that Subsidiary.
     “Tandem SAR” means a SAR that is granted in connection with a related Option, as described in Section 7 herein.
     “Voting Securities” means voting securities of the Company entitled to vote generally in the election of Directors.

18
 EX-10.2 3 clxq1fy2110qexhibit1021.htm EX-10.2 Document


Exhibit 10.2
THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
(US Employees)

SUMMARY OF RESTRICTED STOCK UNIT AWARD
The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the following number of Restricted Stock Units (the “Units”), on the terms set forth below:

GRANTEE<<Participant ID>>
TOTAL RESTRICTED UNITS AWARDED<<Units Granted>>
DATE OF AWARD<<Grant Date>>
PERIOD OF RESTRICTION
25% vests on each of the first four anniversaries of the date of award; provided that [the Committee][a committee consisting of the Chief Executive Officer and the Chief People Officer] may provide in its sole discretion for the vesting of additional Units in an amount sufficient to satisfy any applicable tax withholding amounts arising due to Grantee’s eligibility under this Agreement to terminate employment or services due to “Retirement”.1,2

TERMS OF AGREEMENT

1.Grant of Units. The Company hereby grants to the Grantee the Units set forth above, subject to the terms, definitions and provisions of the Plan and this Agreement. All terms, provisions, and conditions applicable to the Units set forth in the Plan and not set forth herein are incorporated by reference. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. All capitalized terms that are used in this Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Plan.

2.Nature and Settlement of Award. The Units represent an unfunded, unsecured promise by the Company to issue Shares. Units will become vested and be settled in Shares on a one Share for one Unit basis, rounded to the nearest whole Share, less any Shares withheld in accordance with the provisions of Section 4 of this Agreement. Settlement shall occur as soon as practicable after the Period of Restriction lapses as provided in the Summary of Restricted Stock Unit Award above, but in any event, within the period ending on the later to occur of the date that is 2 ½ months from the end of (1) the Grantee’s tax year that includes the date of the lapse of the Period of Restriction, or (2) the Company’s tax year that includes the date of the lapse of the Period of Restriction (which payment schedule is intended to comply with the “short-term deferral” exemption from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)) (the “Settlement Date”). Notwithstanding the foregoing, if the Grantee elects to receive any
    1    To be included in agreements for individuals who are members of the Clorox Executive Committee and/or required to file disclosure statements under Section 16(a) of the Securities Exchange Act.
    2    To be included in agreements for individuals who are neither members of the Clorox Executive Committee nor required to file disclosure statements under Section 16(a) of the Securities Exchange Act.
    - 1 -

Shares on a Deferred Settlement Date established pursuant to Section 6 of this Agreement, the Units to which such election applies shall be settled on the Deferred Settlement Date. Although the Units shall be vested within the meaning of Section 83 of the Internal Revenue Code since no substantial risk of forfeiture exists after the Period of Restriction lapses, the Units will not be earned until the Grantee has fulfilled all of the conditions precedent set forth in this Agreement, including, but not limited to, the obligations set forth in Section 10(b), 10(c), 10(d), 10(e) and Section 11, and the Grantee shall have no right to retain the Shares or the value thereof upon vesting or settlement of the Units until all such conditions precedent have been satisfied.

3.Dividend Equivalents. No Dividend Equivalents shall be paid to the Grantee prior to the lapse of the Period of Restriction. Rather, such Dividend Equivalent payments will accrue and be notionally credited to the Grantee’s RSU account and paid out in the form of additional Shares, rounded down to the nearest whole Share, after the lapse of the Period of Restriction, within the time period described in Section 2 above.

4.Taxes. Pursuant to Section 16 of the Plan, the Committee shall have the power and the right to deduct or withhold, or require the Grantee to remit to the Company, an amount sufficient to satisfy any applicable tax withholding requirements applicable to this Award. The Committee may condition the issuance of Shares in settlement of Units upon the Grantee’s satisfaction of such withholding obligations. The Grantee may elect to satisfy all or part of such withholding requirement by tendering previously-owned Shares or by having the Company withhold Shares having a Fair Market Value equal to the minimum statutory tax withholding rate that could be imposed on the transaction (or such other rate that will not result in a negative accounting impact) or in such other manner as is acceptable to the Company. Such election shall be irrevocable, made in writing, signed by the Grantee, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

5.Termination of Employment or Service.

a.If the Grantee’s employment or service with the Company and its Subsidiaries is terminated for any reason, any Units (the “Unvested Units”) for which the Period of Restriction has not lapsed before such termination of employment or service and/or any Dividend Equivalents related thereto shall be forfeited. Notwithstanding the above, if the Grantee’s termination of employment or service is due to (i) Retirement and is more than 6 months from the date of award set forth in this Agreement, then the restrictions on the Units and all Dividend Equivalents related thereto shall continue to lapse in accordance with the Period of Restriction provided in the Summary of Restricted Stock Unit Award above, provided that the “Settlement Date” for such Units and Dividend Equivalents shall occur no later than December 31 of the calendar year in which the applicable Period of Restriction lapses or (ii) death or Disability, the Units shall become 100% vested and the Period of Restriction on the Units shall lapse and all Dividend Equivalents related thereto shall become immediately vested and payable as of such termination date.

b.Definition of “Disability.” For purposes of this Agreement, the Grantee’s employment shall be deemed to have terminated due to the Grantee’s Disability if the Grantee is entitled to long-term disability benefits under the Company’s long-term disability plan or policy, as in effect on the date of termination of the Grantee’s employment.

c.Definition of “Retirement.” For purposes of this Agreement, the Grantee’s employment or service shall be deemed to have terminated due to “Retirement” if the Grantee terminates employment or service as an Employee for any reason, including Disability (but other than for Cause) after (1) twenty (20) or more years of “vesting service,” which solely for purposes of this Agreement, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Grantee with respect to the 401(k) Plan (“Vesting Service”), or (2) attaining age fifty-five (55) with ten (10) or more years of Vesting Service.
    
6.Election to Defer Settlement. Within the first four (4) months following the Date of Award set forth above, the Grantee may elect to defer the settlement of the date on which the Period of Restriction lapses until a date at
    - 2 -


least two years following such date, or until the Grantee’s later termination of employment or service. Such date shall be referred to as the “Deferred Settlement Date”. If the Grantee makes such an election, it will become irrevocable on the date of such election. If the Grantee makes such an election, any Dividend Equivalents awarded with respect to such deferred Shares shall also be deferred under the same terms. If the Grantee makes such an election, but a transaction occurs that subjects the Grantee’s Shares to Section 19 of the Plan prior to the Deferred Settlement Date, the Grantee’s deferral election will terminate and the Grantee’s Shares and Dividend Equivalents will be settled as of the date of that transaction. The Company may terminate any deferral hereunder if a change in law requires such termination.

7.Authorization to Return Forfeited Units. The Grantee authorizes the Company or its designee to return to the Company all Units and related Dividend Equivalents and Shares subject thereto which are forfeited along with any cash or other property held with respect to or in substitution of such Units, related Dividend Equivalents and/or Shares. Any such action shall comply with all applicable provisions of this Agreement or the Plan.

8.Transferability of Units. Unless otherwise determined by the Committee, Units shall not be transferable by the Grantee other than by will or by the laws of descent or distribution. For avoidance of doubt, Shares issued to the Grantee in settlement of Units pursuant to Section 2 of this Agreement shall not be subject to any of the foregoing transferability restrictions.

9.Change in Control. Upon the occurrence of a Change in Control, unless otherwise specifically prohibited under Applicable Laws or by the rules and regulations of any governing governmental agencies or national securities exchanges, any Unvested Units and related Dividend Equivalents shall become 100% vested and the Period of Restriction for the Units and related Dividend Equivalents shall lapse, unless the Units are assumed, converted or replaced by the continuing entity; provided, however, that in the event the Grantee’s employment is terminated without Cause or by the Grantee for Good Reason upon or within twenty-four (24) months following consummation of a Change in Control, the Period of Restriction on any replacement awards shall lapse and all Dividend Equivalents related thereto shall become immediately payable.

For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following with respect to the Grantee:

(a) the assignment to the Grantee of any duties inconsistent in any material respect with the Grantee’s position (including offices and reporting requirements), authority, duties or responsibilities, as in effect immediately prior to the occurrence of the Change in Control or the date of the Grantee’s termination of employment, whichever is greater, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(b) any failure by the Company to substantially comply with, or any reduction by the Company in, any of the material provisions of the Grantee’s compensation plans, programs, agreements or arrangements as in effect immediately prior to the Change in Control, including, without limitation, any material reduction in base salary, cash incentive compensation target bonus opportunity, equity compensation opportunity in the aggregate, or employee benefits and perquisites in the aggregate, other than an isolated, insubstantial and inadvertent failure or reduction not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(c) the Company’s requiring the Grantee to be based at any office or location other than that in effect immediately prior to the Change in Control or any office or location not requiring the Grantee’s commute to increase by more than 35 miles from his or her commute immediately prior to the Change in Control;

(d) any purported termination by the Company of the Grantee’s employment other than (A) due to the death or Disability of the Grantee or (B) a termination of the Grantee’s employment by the Company for Cause; or

    - 3 -


(e) any material failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume the obligations of the Company under this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.

Any termination by the Grantee for Good Reason shall be communicated by a written notice to the Company within a period not to exceed ninety (90) days of such Grantee’s knowledge of the condition. Such written notice (1) must indicate the specific termination provision in the Good Reason definition relied upon, (2) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Grantee’s employment under the provision so indicated and (3) the Grantee's intended date of termination if the Company does not cure the issue (which date shall be not less than thirty (30) days after the giving of such notice). After receipt by the Company of such written notice, the Company shall have thirty (30) days during which it may remedy the condition and thereby cure the event or circumstance constituting “Good Reason”.

10.Protection of Trade Secrets and Limitations on Retention.

a.Definitions.

i.“Affiliated Company” means any organization controlling, controlled by or under common control with the Company.

ii.“Confidential Information” means the Company’s technical or business or personnel information not readily available to the public or generally known in the trade, including inventions, developments, trade secrets and other confidential information, knowledge, data and know-how of the Company or any Affiliated Company, whether or not they originated with the Grantee, or information which the Company or any Affiliated Company received from third parties under an obligation of confidentiality.

iii.“Conflicting Product” means any product, process, machine, or service of any person or organization, other than the Company or any Affiliated Company, in existence or under development that (1) resembles or competes with a product, process, machine, or service upon or with which the Grantee shall have worked during the two years prior to the Grantee’s termination of employment with the Company or any Affiliated Company or (2) with respect to which during that period of time the Grantee, as a result of his/her job performance and duties, shall have acquired knowledge of Confidential Information, and whose use or marketability could be enhanced by application to it of Confidential Information. For purposes of this section, it shall be conclusively presumed that the Grantee has knowledge of information to which s/he has been directly exposed through actual receipt or review of memorandum or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed.

iv.“Conflicting Organization” means any person or organization that is engaged in or about to become engaged in research on or development, production, marketing or selling of a Conflicting Product.

b.Right to Retain Units/Shares Contingent on Protection of Confidential Information. In partial consideration for the award of these Units, the Grantee agrees that at all times, both during and after the term of the Grantee’s employment with the Company or any Affiliated Company, to hold in the strictest confidence, and not to use (except for the benefit of the Company at the Company’s direction) or disclose (except for the benefit of the Company at the Company’s direction), regardless of when disclosed to the Grantee, any and all Confidential Information of the Company or any Affiliated Company. The Grantee understands that for purposes of this Section 9(b), Confidential Information further includes, but is not limited to, information pertaining to any aspect of the business of the Company or any Affiliated Company which is either information not known (or known as a result of a wrongful act of the Grantee or of others who were under confidentiality obligations as to the item or items involved) by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company. If, prior to the
    - 4 -


expiration of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee discloses or uses, or threatens to disclose or use, any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the Units, whether vested or not, will be immediately forfeited and cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares.

c.No Interference with Customers or Suppliers. In partial consideration for the award of these Units, in order to forestall the disclosure or use of Confidential Information as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from using Confidential Information to (1) divert or attempt to divert from the Company (or any Affiliated Company) any business of any kind in which it is engaged, or (2) intentionally solicit its customers with which it has a contractual relationship as to Conflicting Products, or interfere with the contractual relationship with any of its suppliers or customers (collectively, “Interfere”). If, during the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Interfere, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. For avoidance of doubt, the term “Interfere” shall not include any advertisement of Conflicting Products through the use of media intended to reach a broad public audience (such as television, cable or radio broadcasts, generalized online marketing, or newspapers or magazines) or the broad distribution of coupons through the use of direct mail or through independent retail outlets. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS “NO INTERFERENCE WITH CUSTOMERS OR SUPPLIERS” PROVISION DURING THE PERIOD OF RESTRICTION OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

d.No Solicitation of Employees. In partial consideration for the award of these Units, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from soliciting for employment any person employed by the Company, or by any Affiliated Company, during the period of the solicited person’s employment and for a period of one (1) year after the termination of the solicited person’s employment with the Company or any Affiliated Company (collectively “Solicit”). If, during the term of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Solicit, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS NON-SOLICITATION OF EMPLOYEES PROVISION DURING THE PERIOD OF RESTRICTION OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

    - 5 -


e.Injunctive and Other Available Relief. By acceptance of these Units and any Shares issued in settlement thereof, the Grantee acknowledges that, if the Grantee were to breach or threaten to breach his/her obligation hereunder not to Interfere or Solicit or not to disclose or use any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the harm caused to the Company by such breach or threatened breach would be, by its nature, irreparable because, among other things, damages would be significant and the monetary harm that would ensue would not be able to be readily proven, and that the Company would be entitled to injunctive and other appropriate relief to prevent threatened or continued breach and to such other remedies as may be available at law or in equity. To the extent not prohibited by law, any cancellation of the Units pursuant to any of Sections 10(b) through 10(d) above shall not restrict, abridge or otherwise limit in any fashion the types and scope of injunctive and other available relief to the Company. Notwithstanding any provision of this Agreement to the contrary, nothing under this Agreement shall limit, abridge, modify or otherwise restrict the Company (or any Affiliated Company) from pursuing any or all legal, equitable or other appropriate remedies to which the Company may be entitled under any other agreement with the Grantee, any other plan, program, policy or arrangement of the Company (or any Affiliated Company) under which the Grantee is covered or participates, or any applicable law, all to the fullest extent not prohibited under applicable law.

f.Permitted Reporting and Disclosure. Notwithstanding any language in this Agreement to the contrary, nothing in this Agreement prohibits Grantee from reporting possible violations of federal law or regulation to any governmental agency or governmental entity, or making other disclosures that are protected under federal law or regulation; provided, that, in each case such communications and disclosures are consistent with applicable law. Notwithstanding the foregoing, under no circumstance is Grantee authorized to disclose any information covered by the Company’s attorney-client privilege or attorney work product or the Company’s trade secrets without prior written consent of the Company’s General Counsel. Any reporting or disclosure permitted under this Section 10(f) shall not result in the cancellation of Shares. Grantee is entitled to certain immunities from liability under state and federal law for disclosing trade secrets if the disclosure was made to report or investigate an alleged violation of law, subject to certain conditions. Please see the Company’s Confidential Information Policy for further details.

11.Right to Retain Units/Shares Contingent on Continuing Non-Conflicting Employment. In partial consideration for the award of these Units in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, from rendering services, directly or indirectly, as director, officer, employee, agent, consultant or otherwise, to any Conflicting Organization except a Conflicting Organization whose business is diversified and that, as to that part of its business to which the Grantee renders services, is not a Conflicting Organization, provided that the Company shall receive separate written assurances satisfactory to the Company from the Grantee and the Conflicting Organization that the Grantee shall not render services during such period with respect to a Conflicting Product. If, prior to the expiration of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee shall render services to any Conflicting Organization other than as expressly permitted herein, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE GRANTEE FROM RENDERING SERVICES TO A CONFLICTING ORGANIZATION, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO RENDER SUCH SERVICES DURING THE PERIOD OF RESTRICTION OR WITHIN ONE YEAR AFTER THE SETTLEMENT DATE.

    - 6 -


12.Repayment Obligation. In the event that (1) the Company issues a restatement of financial results to correct a material error and (2) the Committee determines, in good faith, that the Grantee’s fraud or willful misconduct was a significant contributing factor to the need to issue such restatement and (3) some or all of the Units that were granted and/or vested prior to such restatement would not have been granted and/or vested, as applicable, based upon the restated financial results, the Grantee shall immediately return to the Company any Units or any Shares or the pre-tax income derived from any disposition of any Shares previously received in settlement of the Units that would not have been granted and/or vested based upon the restated financial results (the “Repayment Obligation”). The Company shall be able to enforce the Repayment Obligation by all legal means available, including, without limitation, by withholding such amount from other sums owed by the Company to the Grantee.

13.Miscellaneous Provisions.

a.Rights as a Stockholder. Neither the Grantee nor the Grantee’s transferee or representative shall have any rights as a stockholder with respect to any Shares subject to this Award until the Units have been settled and Share certificates have been issued to the Grantee, transferee or representative, as the case may be.

b.Choice of Law, Exclusive Jurisdiction and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of the State of Delaware shall have exclusive jurisdiction over any disputes or other proceedings relating to this Agreement, and venue shall reside with the courts in New Castle County, Delaware, including if jurisdiction shall so permit, the U.S. District Court for the District of Delaware. Accordingly, the Grantee agrees that any claim of any type relating to this Agreement must be brought and maintained in the appropriate court located in New Castle County, Delaware, including if jurisdiction will so permit, in the U.S. District Court for the State of Delaware. The Grantee hereby consents to the jurisdiction over the Grantee of any such courts and waives all objections based on venue or inconvenient forum.

c.Modification or Amendment. This Agreement may be modified or amended by the Board or the Committee at any time; provided, however, no modification or amendment to this Agreement shall be made which would materially and adversely affect the rights of the Grantee, without such Grantee’s written consent.

d.Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of this Agreement, and this Agreement shall be construed and enforced to reflect the intent of the parties to the fullest extent not prohibited by law, and in the event that such provision is not able to be so construed and enforced, then this Agreement shall be construed and enforced as if such illegal or invalid provision had not been included. In amplification of the preceding sentence, in the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall have the power to reduce the time period or scope to the maximum time period or scope permitted by law.

e.References to Plan. All references to the Plan shall be deemed references to the Plan as may be amended.

f.Headings. The captions used in this Agreement are inserted for convenience and shall not be deemed a part of this Agreement for construction or interpretation.

g.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or by the Company forthwith to the Board or the Committee, which shall review such dispute at its next regular meeting. The resolution of such dispute by the Board or the Committee shall be final and binding on all persons. It is the intention of the Company and the Grantee to make the promises contained in this Agreement reasonable and binding only to the extent that it may be lawfully done under existing applicable laws. This Agreement and the Plan constitute the entire and exclusive agreement between the
    - 7 -


Grantee and the Company, and it supersedes all prior agreements or understandings, whether written or oral, with respect to the grant of Units set forth in this Agreement.

h.Section 409A Compliance. To the extent applicable, it is intended that the Plan and this Agreement comply with the requirements of Section 409A of the Code, and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision of the Plan or this Agreement that would cause this Award to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

Notwithstanding any provision of the Plan to the contrary, if the Grantee is a “specified employee” (as defined in Section 1.409A-1(i) of the Treasury Department Regulations) at the time of the Grantee’s “separation from service” (as defined in Section 1.409A-1(h) of the Treasury Department Regulations and including a termination of employment or service on account of Disability that does not satisfy the definition of “disability” under Section 409A-3(i)(4) of the Treasury Department Regulations), and payments to the Grantee hereunder are not exempt from Section 409A as a short-term deferral or otherwise, these payments, to the extent otherwise payable within six (6) months after the Grantee’s separation from service shall be delayed until the earlier of the date which is six (6) months after the date of the Grantee’s separation from service or the date of death of the Grantee. Any payments that were scheduled to be paid during the six (6) month period following the Grantee’s separation from service, but which were delayed pursuant to this Section 13(h), shall be paid without interest on, or as soon as administratively practicable after, the first day following the six (6) month anniversary of the Grantee’s separation from service (or, if earlier, the date of the Grantee’s death). Any payments that were originally scheduled to be paid following the six (6) months after the Grantee’s separation from service shall continue to be paid in accordance with their predetermined schedule.

i.Agreement with Terms. Receipt of any benefits under this Agreement by the Grantee shall constitute the Grantee’s acceptance of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Agreement, and the Company shall administer this Agreement accordingly.

THE CLOROX COMPANY
                                
                        By:

    Its: Chief Executive Officer


THE GRANTEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT IS A UNILATERAL CONTRACT AND THAT THE GRANTEE’S RIGHT TO THE SHARES PURSUANT TO THIS AGREEMENT IS ACCEPTED AND EARNED ONLY BY CONTINUING EMPLOYMENT (FOR PURPOSES OF THIS PARAGRAPH, IGNORING ANY ELECTION TO DEFER SETTLEMENT PURSUANT TO SECTION 6) AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OR ACQUIRING SHARES HEREUNDER) AND BY COMPLIANCE WITH THE GRANTEE’S VARIOUS OBLIGATIONS UNDER THIS AGREEMENT. THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE GRANTEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT ADVANCE NOTICE EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW.

The Grantee acknowledges that a copy of the Plan and Plan Information are available for viewing on the Company’s internal HR website at https://clxweb.clorox.com/hr/Pages/HRatClorox/HRContentPages/StockIncentiveProgram.aspx, and the Company’s Annual Report and Proxy Statement (the “Prospectus Information”) are available for viewing on the Company’s Clorox web site at http://CLOROXWEB/hr/stock. The
    - 8 -


Grantee hereby consents to receive the Prospectus Information electronically, or, in the alternative, to contact the HR Service Center at 1-800-709-7095 to request a paper copy of the Prospectus Information. The Grantee represents that s/he is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Grantee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of this Agreement. The Grantee acknowledges and hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement. The Grantee further agrees to notify the Company upon any change in the residence address indicated below.


Dated:______________________________ Signed:___________________________________
                            Grantee

                Residence Address:

                ___________________________________

                ___________________________________
    - 9 -

 EX-10.3 4 clxq1fy2110qexhibit1031.htm EX-10.3 Document

Exhibit 10.3
THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
(US Employees)

SUMMARY OF RESTRICTED STOCK UNIT AWARD
The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the following number of Restricted Stock Units (the “Units”), on the terms set forth below:

GRANTEE<<Participant ID>>
TOTAL RESTRICTED UNITS AWARDED<<Units Granted>>
DATE OF AWARD<<Grant Date>>
PERIOD OF RESTRICTION100% vests 36 months from the date of award

TERMS OF AGREEMENT

1.Grant of Units. The Company hereby grants to the Grantee the Units set forth above, subject to the terms, definitions and provisions of the Plan and this Agreement. All terms, provisions, and conditions applicable to the Units set forth in the Plan and not set forth herein are incorporated by reference. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. All capitalized terms that are used in this Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Plan.

2.Nature and Settlement of Award. The Units represent an unfunded, unsecured promise by the Company to issue Shares. Units will become vested and be settled in Shares on a one Share for one Unit basis, rounded to the nearest whole Share, less any Shares withheld in accordance with the provisions of Section 4 of this Agreement. Settlement shall occur as soon as practicable after the Period of Restriction lapses as provided in the Summary of Restricted Stock Unit Award above, but in any event, within the period ending on the later to occur of the date that is 2 ½ months from the end of (1) the Grantee’s tax year that includes the date of the lapse of the Period of Restriction, or (2) the Company’s tax year that includes the date of the lapse of the Period of Restriction (which payment schedule is intended to comply with the “short-term deferral” exemption from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)) (the “Settlement Date”). Notwithstanding the foregoing, if the Grantee elects to receive any Shares on a Deferred Settlement Date established pursuant to Section 6 of this Agreement, the Units to which such election applies shall be settled on the Deferred Settlement Date. Although the Units shall be vested within the meaning of Section 83 of the Internal Revenue Code since no substantial risk of forfeiture exists after the Period of Restriction lapses, the Units will not be earned until the Grantee has fulfilled all of the conditions precedent set forth in this Agreement, including, but not limited to, the obligations set forth in Section 10(b), 10(c), 10(d), 10(e) and Section 11, and the Grantee shall have no right to retain the Shares or the value thereof upon vesting or settlement of the Units until all such conditions precedent have been satisfied.

3.Dividend Equivalents. No Dividend Equivalents shall be paid to the Grantee prior to the lapse of the Period of Restriction. Rather, such Dividend Equivalent payments will accrue and be notionally credited to the Grantee’s RSU account and paid out in the form of additional Shares, rounded down to the nearest whole Share, after the lapse of the Period of Restriction, within the time period described in Section 2 above.

4.Taxes. Pursuant to Section 16 of the Plan, the Committee shall have the power and the right to deduct or withhold, or require the Grantee to remit to the Company, an amount sufficient to satisfy any applicable tax
    - 1 -

withholding requirements applicable to this Award. The Committee may condition the issuance of Shares in settlement of Units upon the Grantee’s satisfaction of such withholding obligations. The Grantee may elect to satisfy all or part of such withholding requirement by tendering previously-owned Shares or by having the Company withhold Shares having a Fair Market Value equal to the minimum statutory tax withholding rate that could be imposed on the transaction (or such other rate that will not result in a negative accounting impact) or in such other manner as is acceptable to the Company. Such election shall be irrevocable, made in writing, signed by the Grantee, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

5.Termination of Employment or Service.

a.If the Grantee’s employment or service with the Company and its Subsidiaries is terminated for any reason, any Units (the “Unvested Units”) for which the Period of Restriction has not lapsed before such termination of employment or service and/or any Dividend Equivalents related thereto shall be forfeited. Notwithstanding the above, if the Grantee’s termination of employment or service is due to death or Disability, the Units shall become 100% vested and the Period of Restriction on the Units shall lapse and all Dividend Equivalents related thereto shall become immediately vested and payable as of such termination date.

b.Definition of “Disability.” For purposes of this Agreement, the Grantee’s employment shall be deemed to have terminated due to the Grantee’s Disability if the Grantee is entitled to long-term disability benefits under the Company’s long-term disability plan or policy, as in effect on the date of termination of the Grantee’s employment.
    
6.Election to Defer Settlement. Within the first four (4) months following the Date of Award set forth above, the Grantee may elect to defer the settlement of the date on which the Period of Restriction lapses until a date at least two years following such date, or until the Grantee’s later termination of employment or service. Such date shall be referred to as the “Deferred Settlement Date”. If the Grantee makes such an election, it will become irrevocable on the date of such election. If the Grantee makes such an election, any Dividend Equivalents awarded with respect to such deferred Shares shall also be deferred under the same terms. If the Grantee makes such an election, but a transaction occurs that subjects the Grantee’s Shares to Section 19 of the Plan prior to the Deferred Settlement Date, the Grantee’s deferral election will terminate and the Grantee’s Shares and Dividend Equivalents will be settled as of the date of that transaction. The Company may terminate any deferral hereunder if a change in law requires such termination.

7.Authorization to Return Forfeited Units. The Grantee authorizes the Company or its designee to return to the Company all Units and related Dividend Equivalents and Shares subject thereto which are forfeited along with any cash or other property held with respect to or in substitution of such Units, related Dividend Equivalents and/or Shares. Any such action shall comply with all applicable provisions of this Agreement or the Plan.

8.Transferability of Units. Unless otherwise determined by the Committee, Units shall not be transferable by the Grantee other than by will or by the laws of descent or distribution. For avoidance of doubt, Shares issued to the Grantee in settlement of Units pursuant to Section 2 of this Agreement shall not be subject to any of the foregoing transferability restrictions.

9.Change in Control. Upon the occurrence of a Change in Control, unless otherwise specifically prohibited under Applicable Laws or by the rules and regulations of any governing governmental agencies or national securities exchanges, any Unvested Units and related Dividend Equivalents shall become 100% vested and the Period of Restriction for the Units and related Dividend Equivalents shall lapse, unless the Units are assumed, converted or replaced by the continuing entity; provided, however, that in the event the Grantee’s employment is terminated without Cause or by the Grantee for Good Reason upon or within twenty-four (24) months following consummation of a Change in Control, the Period of Restriction on any replacement awards shall lapse and all Dividend Equivalents related thereto shall become immediately payable.

    - 2 -


For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following with respect to the Grantee:

(a) the assignment to the Grantee of any duties inconsistent in any material respect with the Grantee’s position (including offices and reporting requirements), authority, duties or responsibilities, as in effect immediately prior to the occurrence of the Change in Control or the date of the Grantee’s termination of employment, whichever is greater, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(b) any failure by the Company to substantially comply with, or any reduction by the Company in, any of the material provisions of the Grantee’s compensation plans, programs, agreements or arrangements as in effect immediately prior to the Change in Control, including, without limitation, any material reduction in base salary, cash incentive compensation target bonus opportunity, equity compensation opportunity in the aggregate, or employee benefits and perquisites in the aggregate, other than an isolated, insubstantial and inadvertent failure or reduction not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(c) the Company’s requiring the Grantee to be based at any office or location other than that in effect immediately prior to the Change in Control or any office or location not requiring the Grantee’s commute to increase by more than 35 miles from his or her commute immediately prior to the Change in Control;

(d) any purported termination by the Company of the Grantee’s employment other than (A) due to the death or Disability of the Grantee or (B) a termination of the Grantee’s employment by the Company for Cause; or

(e) any material failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume the obligations of the Company under this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.

Any termination by the Grantee for Good Reason shall be communicated by a written notice to the Company within a period not to exceed ninety (90) days of such Grantee’s knowledge of the condition. Such written notice (1) must indicate the specific termination provision in the Good Reason definition relied upon, (2) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Grantee’s employment under the provision so indicated and (3) the Grantee's intended date of termination if the Company does not cure the issue (which date shall be not less than thirty (30) days after the giving of such notice). After receipt by the Company of such written notice, the Company shall have thirty (30) days during which it may remedy the condition and thereby cure the event or circumstance constituting “Good Reason”.

10.Protection of Trade Secrets and Limitations on Retention.

a.Definitions.

i.“Affiliated Company” means any organization controlling, controlled by or under common control with the Company.

ii.“Confidential Information” means the Company’s technical or business or personnel information not readily available to the public or generally known in the trade, including inventions, developments, trade secrets and other confidential information, knowledge, data and know-how of the Company or any Affiliated Company, whether or not they originated with the Grantee, or information which the Company or any Affiliated Company received from third parties under an obligation of confidentiality.

    - 3 -


iii.“Conflicting Product” means any product, process, machine, or service of any person or organization, other than the Company or any Affiliated Company, in existence or under development that (1) resembles or competes with a product, process, machine, or service upon or with which the Grantee shall have worked during the two years prior to the Grantee’s termination of employment with the Company or any Affiliated Company or (2) with respect to which during that period of time the Grantee, as a result of his/her job performance and duties, shall have acquired knowledge of Confidential Information, and whose use or marketability could be enhanced by application to it of Confidential Information. For purposes of this section, it shall be conclusively presumed that the Grantee has knowledge of information to which s/he has been directly exposed through actual receipt or review of memorandum or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed.

iv.“Conflicting Organization” means any person or organization that is engaged in or about to become engaged in research on or development, production, marketing or selling of a Conflicting Product.

b.Right to Retain Units/Shares Contingent on Protection of Confidential Information. In partial consideration for the award of these Units, the Grantee agrees that at all times, both during and after the term of the Grantee’s employment with the Company or any Affiliated Company, to hold in the strictest confidence, and not to use (except for the benefit of the Company at the Company’s direction) or disclose (except for the benefit of the Company at the Company’s direction), regardless of when disclosed to the Grantee, any and all Confidential Information of the Company or any Affiliated Company. The Grantee understands that for purposes of this Section 9(b), Confidential Information further includes, but is not limited to, information pertaining to any aspect of the business of the Company or any Affiliated Company which is either information not known (or known as a result of a wrongful act of the Grantee or of others who were under confidentiality obligations as to the item or items involved) by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company. If, prior to the expiration of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee discloses or uses, or threatens to disclose or use, any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the Units, whether vested or not, will be immediately forfeited and cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares.

c.No Interference with Customers or Suppliers. In partial consideration for the award of these Units, in order to forestall the disclosure or use of Confidential Information as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from using Confidential Information to (1) divert or attempt to divert from the Company (or any Affiliated Company) any business of any kind in which it is engaged, or (2) intentionally solicit its customers with which it has a contractual relationship as to Conflicting Products, or interfere with the contractual relationship with any of its suppliers or customers (collectively, “Interfere”). If, during the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Interfere, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. For avoidance of doubt, the term “Interfere” shall not include any advertisement of Conflicting Products through the use of media intended to reach a broad public audience (such as television, cable or radio broadcasts, generalized online marketing, or newspapers or magazines) or the broad distribution of coupons through the use of direct mail or through independent retail outlets. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS
    - 4 -


TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS “NO INTERFERENCE WITH CUSTOMERS OR SUPPLIERS” PROVISION DURING THE PERIOD OF RESTRICTION OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

d.No Solicitation of Employees. In partial consideration for the award of these Units, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from soliciting for employment any person employed by the Company, or by any Affiliated Company, during the period of the solicited person’s employment and for a period of one (1) year after the termination of the solicited person’s employment with the Company or any Affiliated Company (collectively “Solicit”). If, during the term of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Solicit, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS NON-SOLICITATION OF EMPLOYEES PROVISION DURING THE PERIOD OF RESTRICTION OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

e.Injunctive and Other Available Relief. By acceptance of these Units and any Shares issued in settlement thereof, the Grantee acknowledges that, if the Grantee were to breach or threaten to breach his/her obligation hereunder not to Interfere or Solicit or not to disclose or use any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the harm caused to the Company by such breach or threatened breach would be, by its nature, irreparable because, among other things, damages would be significant and the monetary harm that would ensue would not be able to be readily proven, and that the Company would be entitled to injunctive and other appropriate relief to prevent threatened or continued breach and to such other remedies as may be available at law or in equity. To the extent not prohibited by law, any cancellation of the Units pursuant to any of Sections 10(b) through 10(d) above shall not restrict, abridge or otherwise limit in any fashion the types and scope of injunctive and other available relief to the Company. Notwithstanding any provision of this Agreement to the contrary, nothing under this Agreement shall limit, abridge, modify or otherwise restrict the Company (or any Affiliated Company) from pursuing any or all legal, equitable or other appropriate remedies to which the Company may be entitled under any other agreement with the Grantee, any other plan, program, policy or arrangement of the Company (or any Affiliated Company) under which the Grantee is covered or participates, or any applicable law, all to the fullest extent not prohibited under applicable law.

f.Permitted Reporting and Disclosure. Notwithstanding any language in this Agreement to the contrary, nothing in this Agreement prohibits Grantee from reporting possible violations of federal law or regulation to any governmental agency or governmental entity, or making other disclosures that are protected under federal law or regulation; provided, that, in each case such communications and disclosures are consistent with applicable law. Notwithstanding the foregoing, under no circumstance is Grantee authorized to disclose any information covered by the Company’s attorney-client privilege or attorney work product or the Company’s trade secrets without prior written consent of the Company’s General Counsel. Any reporting or disclosure permitted under this Section 10(f) shall not result in the cancellation of Shares. Grantee is entitled to certain immunities from liability under state and federal law for disclosing trade secrets if the disclosure was made to report or investigate an alleged violation of law, subject to certain conditions. Please see the Company’s Confidential Information Policy for further details.
    - 5 -



11.Right to Retain Units/Shares Contingent on Continuing Non-Conflicting Employment. In partial consideration for the award of these Units in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, from rendering services, directly or indirectly, as director, officer, employee, agent, consultant or otherwise, to any Conflicting Organization except a Conflicting Organization whose business is diversified and that, as to that part of its business to which the Grantee renders services, is not a Conflicting Organization, provided that the Company shall receive separate written assurances satisfactory to the Company from the Grantee and the Conflicting Organization that the Grantee shall not render services during such period with respect to a Conflicting Product. If, prior to the expiration of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee shall render services to any Conflicting Organization other than as expressly permitted herein, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE GRANTEE FROM RENDERING SERVICES TO A CONFLICTING ORGANIZATION, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO RENDER SUCH SERVICES DURING THE PERIOD OF RESTRICTION OR WITHIN ONE YEAR AFTER THE SETTLEMENT DATE.

12.Repayment Obligation. In the event that (1) the Company issues a restatement of financial results to correct a material error and (2) the Committee determines, in good faith, that the Grantee’s fraud or willful misconduct was a significant contributing factor to the need to issue such restatement and (3) some or all of the Units that were granted and/or vested prior to such restatement would not have been granted and/or vested, as applicable, based upon the restated financial results, the Grantee shall immediately return to the Company any Units or any Shares or the pre-tax income derived from any disposition of any Shares previously received in settlement of the Units that would not have been granted and/or vested based upon the restated financial results (the “Repayment Obligation”). The Company shall be able to enforce the Repayment Obligation by all legal means available, including, without limitation, by withholding such amount from other sums owed by the Company to the Grantee.

13.Miscellaneous Provisions.

a.Rights as a Stockholder. Neither the Grantee nor the Grantee’s transferee or representative shall have any rights as a stockholder with respect to any Shares subject to this Award until the Units have been settled and Share certificates have been issued to the Grantee, transferee or representative, as the case may be.

b.Choice of Law, Exclusive Jurisdiction and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of the State of Delaware shall have exclusive jurisdiction over any disputes or other proceedings relating to this Agreement, and venue shall reside with the courts in New Castle County, Delaware, including if jurisdiction shall so permit, the U.S. District Court for the District of Delaware. Accordingly, the Grantee agrees that any claim of any type relating to this Agreement must be brought and maintained in the appropriate court located in New Castle County, Delaware, including if jurisdiction will so permit, in the U.S. District Court for the State of Delaware. The Grantee hereby consents to the jurisdiction over the Grantee of any such courts and waives all objections based on venue or inconvenient forum.

    - 6 -


c.Modification or Amendment. This Agreement may be modified or amended by the Board or the Committee at any time; provided, however, no modification or amendment to this Agreement shall be made which would materially and adversely affect the rights of the Grantee, without such Grantee’s written consent.

d.Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of this Agreement, and this Agreement shall be construed and enforced to reflect the intent of the parties to the fullest extent not prohibited by law, and in the event that such provision is not able to be so construed and enforced, then this Agreement shall be construed and enforced as if such illegal or invalid provision had not been included. In amplification of the preceding sentence, in the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall have the power to reduce the time period or scope to the maximum time period or scope permitted by law.

e.References to Plan. All references to the Plan shall be deemed references to the Plan as may be amended.

f.Headings. The captions used in this Agreement are inserted for convenience and shall not be deemed a part of this Agreement for construction or interpretation.

g.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or by the Company forthwith to the Board or the Committee, which shall review such dispute at its next regular meeting. The resolution of such dispute by the Board or the Committee shall be final and binding on all persons. It is the intention of the Company and the Grantee to make the promises contained in this Agreement reasonable and binding only to the extent that it may be lawfully done under existing applicable laws. This Agreement and the Plan constitute the entire and exclusive agreement between the Grantee and the Company, and it supersedes all prior agreements or understandings, whether written or oral, with respect to the grant of Units set forth in this Agreement.

h.Section 409A Compliance. To the extent applicable, it is intended that the Plan and this Agreement comply with the requirements of Section 409A of the Code, and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision of the Plan or this Agreement that would cause this Award to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

Notwithstanding any provision of the Plan to the contrary, if the Grantee is a “specified employee” (as defined in Section 1.409A-1(i) of the Treasury Department Regulations) at the time of the Grantee’s “separation from service” (as defined in Section 1.409A-1(h) of the Treasury Department Regulations and including a termination of employment or service on account of Disability that does not satisfy the definition of “disability” under Section 409A-3(i)(4) of the Treasury Department Regulations), and payments to the Grantee hereunder are not exempt from Section 409A as a short-term deferral or otherwise, these payments, to the extent otherwise payable within six (6) months after the Grantee’s separation from service shall be delayed until the earlier of the date which is six (6) months after the date of the Grantee’s separation from service or the date of death of the Grantee. Any payments that were scheduled to be paid during the six (6) month period following the Grantee’s separation from service, but which were delayed pursuant to this Section 13(h), shall be paid without interest on, or as soon as administratively practicable after, the first day following the six (6) month anniversary of the Grantee’s separation from service (or, if earlier, the date of the Grantee’s death). Any payments that were originally scheduled to be paid following the six (6) months after the Grantee’s separation from service shall continue to be paid in accordance with their predetermined schedule.

i.Agreement with Terms. Receipt of any benefits under this Agreement by the Grantee shall constitute the Grantee’s acceptance of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Agreement, and the Company shall administer this Agreement accordingly.
    - 7 -




THE CLOROX COMPANY
                                
                        By:

    Its: Chief Executive Officer


THE GRANTEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT IS A UNILATERAL CONTRACT AND THAT THE GRANTEE’S RIGHT TO THE SHARES PURSUANT TO THIS AGREEMENT IS ACCEPTED AND EARNED ONLY BY CONTINUING EMPLOYMENT (FOR PURPOSES OF THIS PARAGRAPH, IGNORING ANY ELECTION TO DEFER SETTLEMENT PURSUANT TO SECTION 6) AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OR ACQUIRING SHARES HEREUNDER) AND BY COMPLIANCE WITH THE GRANTEE’S VARIOUS OBLIGATIONS UNDER THIS AGREEMENT. THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE GRANTEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT ADVANCE NOTICE EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW.

The Grantee acknowledges that a copy of the Plan and Plan Information are available for viewing on the Company’s internal HR website at https://clxweb.clorox.com/hr/Pages/HRatClorox/HRContentPages/StockIncentiveProgram.aspx, and the Company’s Annual Report and Proxy Statement (the “Prospectus Information”) are available for viewing on the Company’s Clorox web site at http://CLOROXWEB/hr/stock. The Grantee hereby consents to receive the Prospectus Information electronically, or, in the alternative, to contact the HR Service Center at 1-800-709-7095 to request a paper copy of the Prospectus Information. The Grantee represents that s/he is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Grantee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of this Agreement. The Grantee acknowledges and hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement. The Grantee further agrees to notify the Company upon any change in the residence address indicated below.


Dated:______________________________ Signed:___________________________________
                            Grantee

                Residence Address:

                ___________________________________

                ___________________________________
    - 8 -

 EX-10.4 5 clxq1fy2110qexhibit1041.htm EX-10.4 Document
        


Exhibit 10.4
THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN
PERFORMANCE SHARE AWARD AGREEMENT

NOTICE OF PERFORMANCE SHARE GRANT        
The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this performance share award agreement (the “Agreement”), the following number of Performance Shares on the terms set forth below:

GRANTEE:<<<Participant Name>>>
TARGET AWARD:<<<Target Shares Granted>>>
GRANT ID:<<<Grant ID>>>
PERFORMANCE PERIOD:July 1, 2020 through June 30, 2023
DATE OF GRANT:
  <<<Grant Date - 2>>>
SETTLEMENT DATE:Within 90 days following the last day of the Performance Period, provided the Grantee has remained in the employment or service of the Company or its Subsidiaries through such date (except for a termination of employment or service due to death, Disability or Retirement, as provided below)

AGREEMENT

1.Grant of Performance Shares. The Company hereby grants to the Grantee the Target Award set forth above, payment of which is dependent upon the achievement of certain performance goals more fully described in Section 3 of this Agreement. This Award is subject to the terms, definitions and provisions of the Plan and this Agreement. All terms, provisions, and conditions applicable to the Performance Shares set forth in the Plan and not set forth herein are incorporated by reference. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. All capitalized terms that are used in this Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Plan.

2.Nature and Settlement of Award. The Performance Shares awarded pursuant to this Agreement represent the opportunity to receive Shares of the Company and Dividend Equivalents on such Shares (as described in Section 4 below). The Company shall issue to the Grantee one Share for each vested Performance Share (plus any Dividend Equivalents accrued with respect to such vested Performance Shares), rounded to the nearest whole share, less any Shares withheld in accordance with the provisions of Section 7 of this Agreement. Settlement shall occur on a date chosen by the Committee, which date shall be within ninety (90) days following the last day of the Performance Period (the “Settlement Date”), or any Deferred Settlement Date established pursuant to Section 6 of this Agreement, whichever is later, and except as specifically provided in Section 5 of this Agreement, provided the Grantee has remained in the employment or service of the Company or its Subsidiaries through the Settlement Date; provided, that, in connection with a Change in Control as described in Section 8 of this Agreement, the Settlement Date shall be within sixty (60) days of either the Change in Control or the date of termination of employment without Cause or for “Good Reason” (as defined below), as applicable. Although vested within the meaning of Section 83 of the Internal Revenue Code since no substantial risk of forfeiture exists at the Settlement Date, the Performance Shares (and any associated Dividend Equivalents) will not be earned until the Grantee has fulfilled all of the conditions precedent set forth in this Agreement, including, but not limited to, the obligations set forth in Sections 10(b), 10(c), 10(d), 10(e) and
    - 1 -


Section 11, and the Grantee shall have no right to retain the Shares or the value thereof upon vesting or settlement of the Performance Shares until all such conditions precedent have been satisfied.

3.Determination of Number of Performance Shares Vested. The number of Performance Shares vested, if any, for the Performance Period shall be determined in accordance with the following formula:
# of Performance Shares = Average Payout Percentage x Target Award
The “Average Payout Percentage” is equal to the sum of the Payout Percentage for each of the fiscal years in the Performance Period, divided by three.
“Payout Percentage” for each fiscal year in the Performance Period is based on the growth of annual economic profit (“EP”), calculated as described in the paragraph below, for the applicable fiscal year in the Performance Period as compared to the prior fiscal year (“EP Growth”), expressed as a percentage and calculated based upon EP at the end of each fiscal year of the Performance Period, determined in accordance with the following table:
EP Growth
(for each fiscal year in the Performance Period)
EP Growth Threshold*%
EP Growth Target**%
EP Growth Max***%

* Achievement of the EP Growth Threshold Amount (or below) shall result in a Payout Percentage of 0% for the applicable fiscal year of the Performance Period.

** Achievement of the EP Growth Target Amount shall result in a Payout Percentage of 100% for the applicable fiscal year of the Performance Period

*** Achievement of the EP Growth Max Amount (or above) shall result in a Payout Percentage of 200% for the applicable fiscal year of the Performance Period

Note: Achievement of EP Growth in between the Threshold and Target levels and in between the Target and Max levels shall be determined through linear interpolation. For the avoidance of doubt, if the EP Growth in excess of the Threshold level is not achieved, the Payout Percentage for the applicable fiscal year of the Performance Period shall be 0%.
EP is defined as Earnings Before Interest & Taxes, adjusted for non-cash restructuring charges, times one minus the tax rate, less capital charge.
For avoidance of doubt, while the expectation is that EP for a given fiscal year shall be calculated based upon the Company’s financial statements for such fiscal year that are filed with the SEC, the Committee shall have the authority to include information not reflected in such financial statements for purposes of determining EP for such fiscal year if the Committee determines that the inclusion of such information more accurately reflects the financial performance of the Company for such fiscal year. To the extent that such information used in a prior fiscal year is reflected in the filed financial statements for a subsequent fiscal year, appropriate changes shall be made to relevant information in such filed financial statements for purposes of calculating EP for such subsequent fiscal year to avoid double counting of the same information.
Notwithstanding the above, the applicable EP amount for the corresponding fiscal year that is used as the basis for calculating EP Growth results for such fiscal year shall be adjusted, fairly and appropriately, in accordance with the Plan and, as provided in this Agreement, to reflect accurately the direct and measurable effect of the impact of each of the following events not otherwise reflected in the determination of the initial EP levels (each, an “Event”)
    - 2 -


including, without limitation, the financial statement impact on the Company on account of the occurrence or potential occurrence of an Event: (1) the acquisition or divestiture of a business, (2) a Change in Control, (3) U.S Federal changes in tax statutes or the addition or deletion of taxes to which the Company or any Affiliated Company is subject, (4) force majeure (including events known as “Acts of God”), (5) the adoption of new or revised accounting pronouncements or changes to application of accounting pronouncements, and (6) any extraordinary, unusual or non-recurring item not previously listed. Notwithstanding the foregoing, an event listed in the preceding sentence shall not qualify as an Event, and therefore no adjustment shall be made to the EP levels, unless the impact of the occurrence or potential occurrence of such an event listed in the preceding sentence exceeds $2 million in EP. The purpose of any adjustments on account of the occurrence of an Event is to keep the probability of achieving the EP Growth goals the same as if the Event triggering such adjustment had either not occurred or had not resulted in any financial statement impact. The determination of any adjustments shall be based on the Company’s accounting as set forth in its books and records (including business projections) and/or in the annual budgets and/or long range plans of the Company pursuant to which the EP Growth goals were established. The amount of any such adjustment shall be approved by the Committee in its good faith determination in accordance with the provisions of this paragraph. To the extent applicable, the Committee shall condition the determination of the number of Performance Shares vested under this Section 3 upon the satisfaction of the adjusted EP levels. All Performance Shares that are not vested for the Performance Period shall be forfeited as of the last day of the Performance Period.
4.Dividend Equivalent Rights. No Dividend Equivalents shall be paid to the Grantee prior to the settlement of the award. Rather, such Dividend Equivalent payments will accrue and be notionally credited to the Grantee’s Performance Share account and paid out at the Payout Percentage in the form of additional Shares rounded down to the nearest whole Share (the “Dividend Equivalent Shares”) upon settlement of the award, as described in Section 2 above.

5.Termination of Continuous Service. Except as otherwise provided below, if the Grantee’s employment or service with the Company and its Subsidiaries is terminated for any reason prior to the Settlement Date, all Performance Shares and Dividend Equivalents subject to this Agreement shall be immediately forfeited.

a.Termination due to Death or Disability. If the Grantee’s termination of employment or service is due to death or Disability, all Performance Shares and Dividend Equivalents shall immediately vest and will be paid upon completion of the Performance Period based on the level of performance achieved as of the end of such Performance Period.

b.Termination due to Retirement. If the Grantee’s termination of employment or service is due to Retirement, the Performance Shares shall vest on a pro rata monthly basis, including full credit for partial months elapsed and rounded to the nearest whole Share, and will be paid upon completion of the Performance Period based on the level of performance achieved as of the end of such Performance Period; provided, however, that this provision shall not apply in the event the Grantee’s employment or service is terminated for Cause. The amount of the vested Award may be computed under the following formula: Target Award times (number of full months elapsed in Performance Period (i.e., rounding up for any partial month) divided by number of full months in Performance Period) times percent performance level achieved as of the end of the Performance Period. Dividend Equivalents accrued through the Grantee’s date of termination due to Retirement shall be paid at the same time as the settlement of the vested Performance Shares.

c.Definition of “Retirement.” For purposes of this Agreement, the term “Retirement” shall mean termination of employment or service as an Employee after (1) twenty (20) or more years of “vesting service,” which solely for purposes of this Agreement, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Grantee with respect to the 401(k) Plan (“Vesting Service”), or (2) attaining age fifty-five with ten (10) or more years of Vesting Service.

    - 3 -


d.Definition of “Disability.” For purposes of this Agreement, the Grantee’s employment shall be deemed to have terminated due to the Grantee’s Disability if the Grantee is entitled to long-term disability benefits under the Company’s long-term disability plan or policy, as in effect on the date of termination of the Grantee’s employment.

6.Election to Defer Settlement. Prior to the commencement of the last year of the Performance Period, the Grantee may elect to defer the settlement of the Performance Shares from the last day of the Performance Period until a date at least two years following such date, or until the Grantee’s later termination of employment or service. Such date shall be referred to as the “Deferred Settlement Date”. If the Grantee makes such an election, it will become irrevocable on the date of such election. If the Grantee makes such an election, any Dividend Equivalents awarded with respect to such deferred Performance Shares shall also be deferred under the same terms. If the Grantee makes such an election, but a transaction occurs that subjects the Grantee’s Performance Shares to Section 19 of the Plan prior to the Deferred Settlement Date, the Grantee’s deferral election will terminate and the Grantee’s Performance Shares and Dividend Equivalents will be settled as of the date of that transaction. The Company may terminate any deferral hereunder if a change in law requires such termination.

7.Taxes. Pursuant to Section 16 of the Plan, the Committee shall have the power and the right to deduct or withhold, or require the Grantee to remit to the Company, an amount sufficient to satisfy any applicable tax withholding requirements applicable to this Award. The Committee may condition the issuance of Shares upon the Grantee’s satisfaction of such withholding obligations. The Grantee may elect to satisfy all or part of such withholding requirement by tendering previously-owned Shares or by having the Company withhold Shares having a Fair Market Value equal to the minimum statutory withholding rate that could be imposed on the transaction (or such other rate that will not result in a negative accounting impact) or in such other manner as is acceptable to the Company. Such election shall be irrevocable, made in writing, signed by the Grantee, and shall be subject to any restriction or limitations that the Committee, in its sole discretion, deems appropriate.

8.Change in Control. Upon the occurrence of a Change in Control, unless otherwise specifically prohibited under Applicable Laws or by the rules and regulations of any governing governmental agencies or national securities exchanges, the portion of any and all Performance Shares that remain outstanding following the occurrence of a Change in Control shall be determined by applying actual performance from the beginning of the Performance Period through the date of the Change in Control using the formula set forth above in Section 3 (“Performance Measure Formula”) to determine the amount of the payout or distribution rounded to the nearest whole Share. Notwithstanding the foregoing, if the Change in Control occurs prior to the end of the Performance Period, the Performance Measure Formula shall generally be adjusted to take into account the shorter period of time available to achieve the performance measures set forth above in Section 3 (the “Performance Measures”). If a quantitative Performance Measure Formula for the entire Performance Period has been determined by the Company by adding together one or more goals for Performance Measures (“Performance Measure Goals”) for multiple time periods within the Performance Period (each a “subperiod”), then the adjusted Performance Measure Formula for a given level of performance shall be equal to the sum of (1) the Performance Measure Goals for each completed subperiod for such level of performance and (2) a prorated Performance Measure Goal (determined by the number of days in such subperiod falling on or before the occurrence of the Change in Control divided by the total number of days in such subperiod) for such level of performance for each subperiod not completed on or before the occurrence of the Change in Control. If there are no subperiods, then the quantitative Performance Measure Formula shall be prorated by taking the Performance Measure Goal for each specified level of performance for the entire Performance Period and multiplying it by a fraction, the numerator of which is the number of days in the Performance Period falling on or before the occurrence of the Change in Control and the denominator of which is the total number of days in the Performance Period. In the unlikely event that the Company is unable to substantially adjust the target Performance Measure(s) as set forth above, then the portion of the Performance Shares that shall remain outstanding shall be based on the assumption that the target level of performance for each Performance Measure for the entire Performance Period has been achieved.

    - 4 -


The portion of the Performance Shares that remain outstanding following the occurrence of a Change in Control as determined in the preceding paragraph shall vest in full at the end of the Performance Period so long as the Grantee’s employment with the Company or a Subsidiary does not terminate until the end of the Performance Period. Notwithstanding the foregoing, such portion shall vest in full upon the earliest to occur of the following events: (1) the termination of the Grantee by the Company without Cause, (2) the refusal of the continuing entity to assume, convert, replace or continue the Award, or (3) if applicable, the resignation of the Grantee for “Good Reason” (as defined below).

For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following with respect to the Grantee:

(a) the assignment to the Grantee of any duties inconsistent in any material respect with the Grantee’s position (including offices and reporting requirements), authority, duties or responsibilities, as in effect immediately prior to the occurrence of the Change in Control or the date of the Grantee’s termination of employment, whichever is greater, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(b) any failure by the Company to substantially comply with, or any reduction by the Company in, any of the material provisions of the Grantee’s compensation plans, programs, agreements or arrangements as in effect immediately prior to the Change in Control, including, without limitation, any material reduction in base salary, cash incentive compensation target bonus opportunity, equity compensation opportunity in the aggregate, or employee benefits and perquisites in the aggregate, other than an isolated, insubstantial and inadvertent failure or reduction not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(c) the Company’s requiring the Grantee to be based at any office or location other than that in effect immediately prior to the Change in Control or any office or location not requiring the Grantee’s commute to increase by more than 35 miles from his or her commute immediately prior to the Change in Control;

(d) any purported termination by the Company of the Grantee’s employment other than (A) due to the death or Disability of the Grantee or (B) a termination of the Grantee’s employment by the Company for Cause; or

(e) any material failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume the obligations of the Company under this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.

Any termination by the Grantee for Good Reason shall be communicated by a written notice to the Company within a period not to exceed ninety (90) days of such Grantee’s knowledge of the condition. Such written notice (1) must indicate the specific termination provision in the Good Reason definition relied upon, (2) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Grantee’s employment under the provision so indicated and (3) the Grantee's intended date of termination if the Company does not cure the issue (which date shall be not less than thirty (30) days after the giving of such notice). After receipt by the Company of such written notice, the Company shall have thirty (30) days during which it may remedy the condition and thereby cure the event or circumstance constituting “Good Reason”.

9.Transferability of Performance Shares. Performance Shares shall not be transferable by the Grantee other than by will or by the laws of descent or distribution. For avoidance of doubt, Shares issued to the Grantee in settlement of Performance Shares pursuant to Section 2 of this Agreement shall not be subject to any of the foregoing transferability restrictions.

    - 5 -


10.Protection of Trade Secrets and Limitations on Retention.

i.Definitions.

a.“Affiliated Company” means any organization controlling, controlled by or under common control with the Company.

b.“Confidential Information” means the Company’s technical or business or personnel information not readily available to the public or generally known in the trade, including inventions, developments, trade secrets and other confidential information, knowledge, data and know-how of the Company or any Affiliated Company, whether or not they originated with the Grantee, or information which the Company or any Affiliated Company received from third parties under an obligation of confidentiality.

c.“Conflicting Product” means any product, process, machine, or service of any person or organization, other than the Company or any Affiliated Company, in existence or under development that (1) resembles or competes with a product, process, machine, or service upon or with which the Grantee shall have worked during the two years prior to the Grantee’s termination of employment with the Company or any Affiliated Company or (2) with respect to which during that period of time the Grantee, as a result of his/her job performance and duties, shall have acquired knowledge of Confidential Information, and whose use or marketability could be enhanced by application to it of Confidential Information. For purposes of this section, it shall be conclusively presumed that the Grantee has knowledge of information to which s/he has been directly exposed through actual receipt or review of memorandum or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed.

d.“Conflicting Organization” means any person or organization that is engaged in or about to become engaged in research on or development, production, marketing or selling of a Conflicting Product.

ii.Right to Retain Shares Contingent on Protection of Confidential Information. In partial consideration for the award of these Performance Shares, the Grantee agrees that at all times, both during and after the term of the Grantee’s employment with the Company or any Affiliated Company, to hold in the strictest confidence, and not to use (except for the benefit of the Company at the Company’s direction) or disclose (except for the benefit of the Company at the Company’s direction), regardless of when disclosed to the Grantee, any and all Confidential Information of the Company or any Affiliated Company. The Grantee understands that for purposes of this Section 10(b), Confidential Information further includes, but is not limited to, information pertaining to any aspect of the business of the Company or any Affiliated Company which is either information not known (or known as a result of a wrongful act of the Grantee or of others who were under confidentiality obligations as to the item or items involved) by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company. If, prior to the expiration of the Performance Period or at any time within one (1) year after the Settlement Date, the Grantee discloses or uses, or threatens to disclose or use, any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the Performance Shares, whether vested or not, will be immediately forfeited and cancelled, and the Grantee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares.

iii.No Interference with Customers or Suppliers. In partial consideration for the award of these Performance Shares, in order to forestall the disclosure or use of Confidential Information as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company and to promote fair competition, the Grantee agrees that the Grantee’s right to the Shares upon settlement of the Performance Shares is contingent upon the Grantee refraining, for a period of one (1) year after the Settlement Date of the Performance Shares, for himself/herself or any third party,
    - 6 -


directly or indirectly, from using Confidential Information to (1) divert or attempt to divert from the Company (or any Affiliated Company) any business of any kind in which it is engaged, or (2) intentionally solicit its customers with which it has a contractual relationship as to Conflicting Products, or to interfere with the contractual relationship with any of its suppliers or customers (collectively, “Interfere”). If, during the term of the Performance Period or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Interfere, the Grantee’s right to the Shares upon settlement of the Performance Shares shall not have been earned and the Performance Shares, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares. For avoidance of doubt, the term “Interfere” shall not include any advertisement of Conflicting Products through the use of media intended to reach a broad public audience (such as television, cable or radio broadcasts, generalized online marketing , or newspapers or magazines) or the broad distribution of coupons through the use of direct mail or through independent retail outlets. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE PERFORMANCE SHARES AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS “NO INTERFERENCE WITH CUSTOMERS OR SUPPLIERS” PROVISION DURING THE TERM OF THE PERFORMANCE PERIOD OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

iv.No Solicitation of Employees. In partial consideration for the award of these Performance Shares, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to the Shares upon settlement of the Performance Shares is contingent upon the Grantee refraining, for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from soliciting for employment any person employed by the Company, or by any Affiliated Company, during the period of the solicited person’s employment and for a period of one (1) year after the termination of the solicited person’s employment with the Company or any Affiliated Company (collectively “Solicit”). If, during the term of the Performance Period or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Solicit, the Grantee’s right to the Shares upon settlement of the Performance Shares shall not have been earned and the Performance Shares, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE PERFORMANCE SHARES AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS NON-SOLICITATION OF EMPLOYEES PROVISION DURING THE TERM OF THE PERFORMANCE PERIOD OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

v.Injunctive and Other Available Relief. By acceptance of these Performance Shares, the Grantee acknowledges that, if the Grantee were to breach or threaten to breach his/her obligation hereunder not to Interfere or Solicit or not to disclose or use any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the harm caused to the Company by such breach or threatened breach would be, by its nature, irreparable because, among other things, damages would be significant and the monetary harm that would ensue would not be able to be readily proven, and that the Company would be entitled to injunctive and other appropriate relief to prevent threatened or continued breach and to such other remedies as may be available at law or in equity. To the extent not prohibited by law, any cancellation of the Performance Shares pursuant to any of Sections 10(b) through 10(d) above shall not restrict, abridge or otherwise limit in any fashion the types and scope of injunctive and other available relief to the Company. Notwithstanding any provision of this Agreement to the contrary, nothing under this Agreement shall limit, abridge, modify or otherwise restrict the Company
    - 7 -


(or any Affiliated Company) from pursuing any or all legal, equitable or other appropriate remedies to which the Company may be entitled under any other agreement with the Grantee, any other plan, program, policy or arrangement of the Company (or any Affiliated Company) under which the Grantee is covered or participates, or any applicable law, all to the fullest extent not prohibited under applicable law.

vi.Permitted Reporting and Disclosure. Notwithstanding any language in this Agreement to the contrary, nothing in this Agreement prohibits Grantee from reporting possible violations of federal law or regulation to any governmental agency or governmental entity, or making other disclosures that are protected under federal law or regulation; provided, that, in each case such communications and disclosures are consistent with applicable law. Notwithstanding the foregoing, under no circumstance is Grantee authorized to disclose any information covered by the Company’s attorney-client privilege or attorney work product or the Company’s trade secrets without prior written consent of the Company’s General Counsel. Any reporting or disclosure permitted under this Section 10(f) shall not result in the cancellation of Performance Shares. Grantee is entitled to certain immunities from liability under state and federal law for disclosing trade secrets if the disclosure was made to report or investigate an alleged violation of law, subject to certain conditions. Please see the Company’s Confidential Information Policy for further details.

11.Right to Retain Shares Contingent on Continuing Non-Conflicting Employment. In partial consideration for the award of these Performance Shares, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to the Shares upon settlement of the Performance Shares is contingent upon the Grantee refraining, during the term of the Performance Period and for a period of one (1) year after the Settlement Date, from rendering services, directly or indirectly, as director, officer, employee, agent, consultant or otherwise, to any Conflicting Organization except a Conflicting Organization whose business is diversified and that, as to that part of its business to which the Grantee renders services, is not a Conflicting Organization, provided that the Company shall receive separate written assurances satisfactory to the Company from the Grantee and the Conflicting Organization that the Grantee shall not render services during such period with respect to a Conflicting Product. If, prior to the expiration of the Performance Period or at any time within one (1) year after the Settlement Date, the Grantee shall render services to any Conflicting Organization other than as expressly permitted herein, the Grantee’s right to the Shares upon settlement of the Performance Shares shall not have been earned and the Performance Shares, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE GRANTEE FROM RENDERING SERVICES TO A CONFLICTING ORGANIZATION, BUT PROVIDES FOR THE CANCELLATION OF THE PERFORMANCE SHARES AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO RENDER SUCH SERVICES DURING THE TERM OF THE PERFORMANCE PERIOD OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

12.Repayment Obligation. In the event that (1) the Company issues a restatement of financial results to correct a material error and (2) the Committee determines, in good faith, that the Grantee’s fraud or willful misconduct was a significant contributing factor to the need to issue such restatement and (3) some or all of the Performance Shares that were granted and/or vested prior to such restatement would not have been granted and/or vested, as applicable, based upon the restated financial results, the Grantee shall immediately return to the Company the Performance Shares or any Shares or the pre-tax income derived from any disposition of the Shares previously received in settlement of the Performance Shares that would not have been granted and/or vested based upon the restated financial results (the “Repayment Obligation”). The Company shall be able to enforce the Repayment Obligation by all legal means available, including, without limitation, by withholding such amount from other sums owed by the Company to the Grantee.

13.Miscellaneous Provisions.

    - 8 -


a.Rights as a Stockholder. Neither the Grantee nor the Grantee’s transferee or representative shall have any rights as a stockholder with respect to any Shares subject to this Award until the Performance Shares have been settled and Share certificates have been issued to the Grantee, transferee or representative, as the case may be.

b.Choice of Law, Exclusive Jurisdiction and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of the State of Delaware shall have exclusive jurisdiction over any disputes or other proceedings relating to this Agreement, and venue shall reside with the courts in New Castle County, Delaware, including if jurisdiction shall so permit, the U.S. District Court for the District of Delaware. Accordingly, the Grantee agrees that any claim of any type relating to this Agreement must be brought and maintained in the appropriate court located in New Castle County, Delaware, including if jurisdiction will so permit, in the U.S. District Court for the State of Delaware. The Grantee hereby consents to the jurisdiction over the Grantee of any such courts and waives all objections based on venue or inconvenient forum.

c.Modification or Amendment. This Agreement may be modified or amended by the Board or the Committee at any time; provided, however, no modification or amendment to this Agreement shall be made which would materially and adversely affect the rights of the Grantee, without such Grantee’s written consent.

d.Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of this Agreement, and this Agreement shall be construed and enforced to reflect the intent of the parties to the fullest extent not prohibited by law, and in the event that such provision is not able to be so construed and enforced, then this Agreement shall be construed and enforced as if such illegal or invalid provision had not been included. In amplification of the preceding sentence, in the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall have the power to reduce the time period or scope to the maximum time period or scope permitted by law.

e.References to Plan. All references to the Plan shall be deemed references to the Plan as may be amended.

f.Headings. The captions used in this Agreement are inserted for convenience and shall not be deemed a part of this Agreement for construction or interpretation.

g.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or by the Company forthwith to the Board or the Committee, which shall review such dispute at its next regular meeting. The resolution of such dispute by the Board or the Committee shall be final and binding on all persons. It is the intention of the Company and the Grantee to make the promises contained in this Agreement reasonable and binding only to the extent that it may be lawfully done under existing applicable laws. This Agreement and the Plan constitute the entire and exclusive agreement between the Grantee and the Company, and it supersedes all prior agreements or understandings, whether written or oral, with respect to the grant of Performance Shares set forth in this Agreement.

h.Section 409A Compliance. To the extent applicable, it is intended that the Plan and this Agreement comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision of the Plan or this Agreement that would cause this Award to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

    - 9 -


Notwithstanding any provision of the Plan to the contrary, if the Grantee is a “specified employee” (as defined in Section 1.409A-1(i) of the Treasury Department Regulations) at the time of the Grantee’s “separation from service” (as defined in Section 1.409A-1(h) of the Treasury Department Regulations and including a termination of employment or service on account of Disability that does not satisfy the definition of “disability” under Section 409A-3(i)(4) of the Treasury Department Regulations), and payments to the Grantee hereunder are not exempt from Section 409A as a short-term deferral or otherwise, these payments, to the extent otherwise payable within six (6) months after the Grantee’s separation from service shall be delayed until the earlier of the date which is six (6) months after the date of the Grantee’s separation from service or the date of death of the Grantee. Any payments that were scheduled to be paid during the six (6) month period following the Grantee’s separation from service, but which were delayed pursuant to this Section 13(h), shall be paid without interest on, or as soon as administratively practicable after, the first day following the six (6) month anniversary of the Grantee’s separation from service (or, if earlier, the date of the Grantee’s death). Any payments that were originally scheduled to be paid following the six (6) months after the Grantee’s separation from service shall continue to be paid in accordance with their predetermined schedule.

i.Agreement with Terms. Receipt of any benefits under this Agreement by the Grantee shall constitute the Grantee’s acceptance of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Agreement, and the Company shall administer this Agreement accordingly.



                        THE CLOROX COMPANY
                            
                        By:
    Its: Chief Executive Officer

THE GRANTEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT IS A UNILATERAL CONTRACT AND THAT THE GRANTEE’S RIGHT TO THE SHARES PURSUANT TO THIS AGREEMENT IS ACCEPTED AND EARNED ONLY BY CONTINUING EMPLOYMENT (FOR PURPOSES OF THIS PARAGRAPH, IGNORING ANY ELECTION TO DEFER SETTLEMENT PURSUANT TO SECTION 6) AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OR ACQUIRING SHARES HEREUNDER) AND BY ACHIEVEMENT OF THE PERFORMANCE CRITERIA AND BY COMPLIANCE WITH THE GRANTEE’S VARIOUS OBLIGATIONS UNDER THIS AGREEMENT. THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE GRANTEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT ADVANCE NOTICE EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW.

The Grantee acknowledges that a copy of the Plan and Plan Information are available for viewing on the Company’s internal HR website at https://clxweb.clorox.com/hr/Pages/HRatClorox/HRContentPages/StockIncentiveProgram.aspx, and the Company’s Annual Report and Proxy Statement (the “Prospectus Information”) are available for viewing on the Company’s Clorox website at http://investors.thecloroxcompany.com/sec.cfm. The Grantee hereby consents to receive the Prospectus Information electronically or, in the alternative, to contact the HR Service Center at 1-800-709-7095 to request a paper copy of the Prospectus Information. The Grantee represents that s/he is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Grantee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of the Agreement. The Grantee acknowledges and hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising
    - 10 -


under the Plan or this Agreement. The Grantee further agrees to notify the Company upon any change in the residence address indicated below.



Dated: ____________________________    Signed: _________________________________
                            Grantee


                    Residence Address:
                    __________________________________
                    __________________________________
    - 11 -
 EX-10.5 6 clxq1fy2110qexhibit1051.htm EX-10.5 Document


Exhibit 10.5

THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN
NONQUALIFIED STOCK OPTION AWARD AGREEMENT

NOTICE OF STOCK OPTION GRANT
The Clorox Company, a Delaware company (the “Company”), grants to the Optionee named below an option (the “Option”) to purchase, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this nonqualified stock option agreement (the “Agreement”), the number of shares of Common Stock of the Company (the “Shares”) at the exercise price per share (the “Exercise Price”) set forth as follows:

OPTIONEE:<<<Optionee Name - 1>>>
OPTIONS GRANTED:<<<Total Shares Granted>>>
GRANT ID:<<<Grant ID>>>
EXERCISE PER SHARE:<<<Grant Price - 1>>>
DATE OF GRANT:<<<Grant Date - 2>>>
EXPIRATION DATE:Ten years from Date of Grant
VESTING SCHEDULE:25% on each of the first four anniversaries of the Date of Grant

AGREEMENT

1.Grant of Option. The Company hereby grants to the Optionee the Option to purchase the Shares at the Exercise Price, subject to the terms, definitions and provisions of the Plan and this Agreement. All terms, provisions, and conditions applicable to the Option set forth in the Plan and not set forth herein are incorporated by reference. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. All capitalized terms that are used in this Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Plan.

2.Exercise of Option.

a.Right to Exercise. This Option shall be exercisable prior to the expiration date set forth above (the “Expiration Date”), in accordance with the vesting schedule set forth above (the “Vesting Schedule”) and with the applicable provisions of the Plan and this Agreement. Except as otherwise specifically provided in this Agreement, in no event may this Option be exercised after the Expiration Date. Although vested within the meaning of Section 83 of the Internal Revenue Code since no substantial risk of forfeiture exists once the options become exercisable according to the Vesting Schedule above, the Options will not be earned until the Optionee has fulfilled all of the conditions precedent set forth in this Agreement, including, but not limited to, the obligations set forth in Sections 7(b), 7(c), 7(d), 7(e) and Section 8, and the Optionee shall have no right to retain the Shares or the value thereof upon vesting or exercise of the Options until all conditions precedent have been satisfied.
b.Method of Exercise. This Option shall be exercisable only by delivery of an exercise notice (the “Exercise Notice”), available on the UBS website, the Company’s designee, which shall state the election to exercise the Option, the whole number of vested Shares in respect of which the Option is being exercised and such other provisions as may be required by the Committee. Such Exercise Notice shall be signed by the Optionee and shall be delivered by mail or fax, to the Company’s designee accompanied by payment of the Exercise Price. The Company may require the Optionee to furnish or execute such other documents as the



Company shall reasonably deem necessary (1) to evidence such exercise and (2) to comply with or satisfy the requirements of the Securities Act of 1933, as amended, the Exchange Act, or any Applicable Laws. The Option shall be deemed to be exercised upon receipt by the Company’s designee of such written notice accompanied by the Exercise Price.

No Shares will be issued pursuant to the exercise of the Option unless such issuance and such exercise shall comply with all Applicable Laws. Assuming such compliance, for income tax purposes, the Shares shall be considered transferred to the Optionee on the date on which the Option is exercised with respect to such Shares.

c.Taxes. Pursuant to Section 16 of the Plan, the Committee shall have the power and the right to deduct or withhold, or require the Optionee to remit to the Company, an amount sufficient to satisfy any applicable tax withholding requirements applicable to this Option. The Committee may condition the issuance of Shares upon the Optionee’s satisfaction of such withholding obligations. The Optionee may elect to satisfy all or part of such withholding requirement by tendering previously-owned Shares or by having the Company withhold Shares having a Fair Market Value equal to the minimum statutory tax withholding rate that could be imposed on the transaction (or such other rate that will not result in a negative accounting impact) or in such other manner as is acceptable to the Company. Such election shall be irrevocable, made in writing, signed by the Optionee, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

3.Method of Payment. Pursuant to Section 6(f) of the Plan and subject to such limitations as the Committee may impose (including prohibition of one or more of the following payment methods), payment of the Exercise Price may be made in cash or by check, Shares or a combination thereof.

4.Termination of Employment or Service and Expiration of Exercise Period.

a.Termination of Employment or Service. If the Optionee’s employment or service with the Company and its Subsidiaries is terminated, the Optionee may exercise all or part of this Option prior to the expiration dates set forth in paragraph (b) herein, but only to the extent that the Option had become vested before the Optionee’s employment or service terminated. Notwithstanding the above, if the Optionee’s termination of employment or service is due to (1) Retirement and is more than 6 months from the Date of Grant set forth in this Agreement, then the Option shall continue to vest in accordance with the Vesting Schedule, or (2) death or Disability, the Option shall become 100% vested, and, in each case, shall remain exercisable until the expiration date determined pursuant to paragraph (b) of this Section.

When the Optionee’s employment or service with the Company and its Subsidiaries terminates (except when due to Retirement, death or Disability), this Option shall expire immediately with respect to the number of Shares for which the Option is not yet vested. If the Optionee dies after termination of employment or service, but before the expiration of the Option, all or part of this Option may be exercised (prior to expiration) by the personal representative of the Optionee or by any person who has acquired this Option directly from the Optionee by will, bequest or inheritance, but only to the extent that the Option was vested and exercisable upon termination of the Optionee’s employment or service.

b.Expiration of Exercise Period. Upon termination of the Optionee’s employment or service with the Company and its Subsidiaries, the Option shall expire on the earliest of the following occasions:

i.The Expiration Date;

ii.The date ninety (90) days following the termination of the Optionee’s employment or service for any reason other than Cause, death, Disability, or Retirement;




iii.The date one year following the termination of the Optionee’s employment or service due to death or Disability;

iv.The date five (5) years following the termination of the Optionee’s employment or service due to Retirement, provided the Optionee’s Retirement is more than 6 months from the Date of Grant set forth in this Agreement; or

v.The date of termination of the Optionee’s employment or service for Cause.

c.Definition of “Retirement.” For purposes of this Agreement, the Optionee’s employment or service shall be deemed to have terminated due to “Retirement” if the Optionee terminates employment or service as an Employee for any reason, including Disability (but other than for Cause) after (1) twenty (20) or more years of “vesting service,” which solely for purposes of this Agreement, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Optionee with respect to the 401(k) Plan (“Vesting Service”), or (2) attaining age fifty-five (55) with ten (10) or more years of Vesting Service.

d.Definition of “Disability.” For purposes of this Agreement, the Optionee’s employment shall be deemed to have terminated due to the Optionee’s Disability if the Optionee is entitled to long-term disability benefits under the Company’s long-term disability plan or policy, as in effect on the date of termination of the Optionee’s employment.

5.Change in Control. Upon the occurrence of a Change in Control, unless otherwise specifically prohibited under Applicable Laws or by the rules and regulations of any governing governmental agencies or national securities exchanges, the Option shall become 100% vested and immediately exercisable, unless such Option is assumed, converted or replaced by the continuing entity; provided, however, that in the event the Optionee’s employment is terminated without Cause or by the Optionee for Good Reason upon or within twenty-four (24) months following consummation of a Change in Control, any replacement awards will become immediately exercisable.

For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following with respect to the Optionee:
(a) the assignment to the Optionee of any duties inconsistent in any material respect with the Optionee’s position (including offices and reporting requirements), authority, duties or responsibilities, as in effect immediately prior to the occurrence of the Change in Control or the date of the Optionee’s termination of employment, whichever is greater, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Optionee;
(b) any failure by the Company to substantially comply with, or any reduction by the Company in, any of the material provisions of the Optionee’s compensation plans, programs, agreements or arrangements as in effect immediately prior to the Change in Control, including, without limitation, any material reduction in base salary, cash incentive compensation target bonus opportunity, equity compensation opportunity in the aggregate, or employee benefits and perquisites in the aggregate, other than an isolated, insubstantial and inadvertent failure or reduction not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Optionee;
(c) the Company’s requiring the Optionee to be based at any office or location other than that in effect immediately prior to the Change in Control or any office or location not requiring the Optionee’s commute to increase by more than 35 miles from his or her commute immediately prior to the Change in Control;
(d) any purported termination by the Company of the Optionee’s employment other than (A) due to the death or Disability of the Optionee or (B) a termination of the Optionee’s employment by the Company for Cause; or



(e) any material failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume the obligations of the Company under this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.
Any termination by the Optionee for Good Reason shall be communicated by a written notice to the Company within a period not to exceed ninety (90) days of such Optionee’s knowledge of the condition. Such written notice (1) must indicate the specific termination provision in the Good Reason definition relied upon, (2) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Optionee’s employment under the provision so indicated and (3) the Optionee's intended date of termination if the Company does not cure the issue (which date shall be not less than thirty (30) days after the giving of such notice). After receipt by the Company of such written notice, the Company shall have thirty (30) days during which it may remedy the condition and thereby cure the event or circumstance constituting “Good Reason”.


6.Transferability of Option. This Option shall not be transferable by the Optionee other than by will or the laws of descent and distribution, and the Option shall be exercisable during the Optionee’s lifetime only by the Optionee or on his or her behalf by the Optionee’s guardian or legal representative.

7.Protection of Trade Secrets and Limitations on Exercise.

a.Definitions.

i.“Affiliated Company” means any organization controlling, controlled by or under common control with the Company.

ii.“Confidential Information” means the Company’s technical or business or personnel information not readily available to the public or generally known in the trade, including inventions, developments, trade secrets and other confidential information, knowledge, data and know-how of the Company or any Affiliated Company, whether or not they originated with the Optionee, or information which the Company or any Affiliated Company received from third parties under an obligation of confidentiality.

iii.“Conflicting Product” means any product, process, machine, or service of any person or organization, other than the Company or any Affiliated Company, in existence or under development that (1) resembles or competes with a product, process, machine, or service upon or with which the Optionee shall have worked during the two years prior to the Optionee’s termination of employment with the Company or any Affiliated Company or (2) with respect to which during that period of time the Optionee, as a result of his/her job performance and duties, shall have acquired knowledge of Confidential Information, and whose use or marketability could be enhanced by application to it of Confidential Information. For purposes of this section, it shall be conclusively presumed that the Optionee has knowledge of information to which s/he has been directly exposed through actual receipt or review of memorandum or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed.

iv.“Conflicting Organization” means any person or organization that is engaged in or about to become engaged in research on or development, production, marketing or selling of a Conflicting Product.

b.Right to Retain Shares Contingent on Protection of Confidential Information. In partial consideration for the award of this Option, the Optionee agrees that at all times, both during and after the term of the Optionee’s employment with the Company or any Affiliated Company, to hold in the strictest confidence, and not to use (except for the benefit of the Company at the Company’s direction) or disclose (except for



the benefit of the Company at the Company’s direction), regardless of when disclosed to the Optionee, any and all Confidential Information of the Company or any Affiliated Company. The Optionee understands that for purposes of this Section 7(b), Confidential Information further includes, but is not limited to, information pertaining to any aspect of the business of the Company or any Affiliated Company which is either information not known (or known as a result of a wrongful act of the Optionee or of others who were under confidentiality obligations as to the item or items involved) by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company. If, prior to the expiration of the Option or at any time within one (1) year after the date of exercise of all or any portion of the Option, the Optionee discloses or uses, or threatens to disclose or use, any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the unexercised portion of the Option, whether vested or not, will be immediately forfeited and cancelled, and the Optionee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares.

c.No Interference with Customers or Suppliers. In partial consideration for the award of this Option, in order to forestall the disclosure or use of Confidential Information as well as to avoid the Optionee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Optionee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company and to promote fair competition, the Optionee agrees that the Optionee’s right to exercise this Option is contingent upon the Optionee refraining, prior to the expiration of the Option and for a period of one (1) year after the date of exercise, for himself/herself or any third party, directly or indirectly, from using Confidential Information to (1) divert or attempt to divert from the Company (or any Affiliated Company) any business of any kind in which it is engaged, or (2) intentionally solicit its customers with which it has a contractual relationship as to Conflicting Products, or interfere with the contractual relationship with any of its suppliers or customers (collectively, “Interfere”). If, during the term of the Option or at any time within one (1) year after the date of exercise of all or any portion of the Option, the Optionee breaches his/her obligation not to Interfere, the Optionee’s right to the Shares upon exercise of the Option shall not have been earned and the unexercised portion of the Option, whether vested or not, will be immediately cancelled, and the Optionee shall immediately return to the Company any Shares acquired upon exercise of the Option or the pre-tax income derived from any disposition of such Shares. For avoidance of doubt, the term “Interfere” shall not include any advertisement of Conflicting Products through the use of media intended to reach a broad public audience (such as television, cable or radio broadcasts, generalized online marketing, or newspapers or magazines) or the broad distribution of coupons through the use of direct mail or through independent retail outlets. THE OPTIONEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNEXERCISED PORTION OF THE OPTION AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF SHARES ISSUED UPON AN EXERCISE OF THE OPTION IF THE OPTIONEE SHOULD CHOOSE TO VIOLATE THIS “NO INTERFERENCE WITH CUSTOMERS OR SUPPLIERS” PROVISION PRIOR TO THE EXPIRATION OF THE OPTION OR WITHIN ONE (1) YEAR AFTER EXERCISE.

d.No Solicitation of Employees. In partial consideration for the award of this Option, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Optionee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Optionee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Optionee agrees that the Optionee’s right to exercise this Option is contingent upon the Optionee refraining, prior to the expiration of the Option and for a period of one (1) year after the date of exercise, for himself/herself or any third party, directly or indirectly, from soliciting for employment any person employed by the Company, or by any Affiliated Company, during the period of the solicited person’s employment and for a period of one (1) year after the termination of the solicited person’s employment with the Company or any Affiliated Company (collectively “Solicit”). If, during the term of the Option or at any time within one (1) year after the date of exercise of all or any portion of the Option, the Optionee breaches his/her obligation not to Solicit, the Optionee’s right to the Shares upon exercise of the Option shall not have been earned and the unexercised portion of the Option, whether vested or not, will



be immediately cancelled, and the Optionee shall immediately return to the Company any Shares acquired upon exercise of the Option or the pre-tax income derived from any disposition of such Shares. THE OPTIONEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNEXERCISED PORTION OF THE OPTION AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF SHARES ISSUED UPON AN EXERCISE OF THE OPTION IF THE OPTIONEE SHOULD CHOOSE TO VIOLATE THIS NON-SOLICITATION OF EMPLOYEES PROVISION PRIOR TO THE EXPIRATION OF THE OPTION OR WITHIN ONE (1) YEAR AFTER EXERCISE.

e.Injunctive and Other Available Relief. By acceptance of this Option, the Optionee acknowledges that, if the Optionee were to breach or threaten to breach his/her obligation hereunder not to Interfere or Solicit or not to disclose or use any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the harm caused to the Company by such breach or threatened breach would be, by its nature, irreparable because, among other things, damages would be significant and the monetary harm that would ensue would not be able to be readily proven, and that the Company would be entitled to injunctive and other appropriate relief to prevent threatened or continued breach and to such other remedies as may be available at law or in equity. To the extent not prohibited by law, any cancellation of the Option pursuant to any of Sections 7(b) through 7(d) above shall not restrict, abridge or limit in any fashion the types and scope of injunctive and other available relief to the Company. Notwithstanding any provision of this Agreement to the contrary, nothing under this Agreement shall limit, abridge, modify or otherwise restrict the Company (or any Affiliated Company) from pursuing any or all legal, equitable or other appropriate remedies to which the Company may be entitled under any other agreement with the Optionee, any other plan, program, policy or arrangement of the Company (or any Affiliated Company) under which the Optionee is covered or participates, or any applicable law, all to the fullest extent not prohibited under applicable law.

f.Permitted Reporting and Disclosure. Notwithstanding any language in this Agreement to the contrary, nothing in this Agreement prohibits Optionee from reporting possible violations of federal law or regulation to any governmental agency or governmental entity, or making other disclosures that are protected under federal law or regulation; provided, that, in each case such communications and disclosures are consistent with applicable law. Notwithstanding the foregoing, under no circumstance is Optionee authorized to disclose any information covered by the Company’s attorney-client privilege or attorney work product or the Company’s trade secrets without prior written consent of the Company’s General Counsel. Any reporting or disclosure permitted under this Section 7(f) shall not result in the cancellation of Options. Optionee is entitled to certain immunities from liability under state and federal law for disclosing trade secrets if the disclosure was made to report or investigate an alleged violation of law, subject to certain conditions. Please see the Company’s Confidential Information Policy for further details.

8.Right to Retain Shares Contingent on Continuing Non-Conflicting Employment. In partial consideration for the award of this Option in order to forestall the disclosure or use of Confidential Information, as well as to deter the Optionee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Optionee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Optionee agrees that the Optionee’s right to exercise this Option is contingent upon the Optionee refraining, prior to the expiration of the Option and for a period of one (1) year after the date of exercise, from rendering services, directly or indirectly, as director, officer, employee, agent, consultant or otherwise, to any Conflicting Organization except a Conflicting Organization whose business is diversified and that, as to that part of its business to which the Optionee renders services, is not a Conflicting Organization, provided that the Company shall receive separate written assurances satisfactory to the Company from the Optionee and the Conflicting Organization that the Optionee shall not render services during such period with respect to a Conflicting Product. If, prior to the expiration of the Option or at any time within one (1) year after the date of exercise of all or any portion of the Option, the Optionee shall render services to any Conflicting Organization other than as expressly permitted herein, the Optionee’s right to the



Shares upon exercise of the Option shall not have been earned and the unexercised portion of the Option, whether vested or not, will be immediately cancelled, and the Optionee shall immediately return to the Company any Shares acquired upon exercise of the Option or the pre-tax income derived from any disposition of such Shares. THE OPTIONEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE OPTIONEE FROM RENDERING SERVICES TO A CONFLICTING ORGANIZATION, BUT PROVIDES FOR THE CANCELLATION OF THE UNEXERCISED PORTION OF THE OPTION AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF SHARES ISSUED UPON AN EXERCISE OF THE OPTION IF THE OPTIONEE SHOULD CHOOSE TO RENDER SUCH SERVICES PRIOR TO THE EXPIRATION OF THE OPTION OR WITHIN ONE (1) YEAR AFTER EXERCISE.

9.Repayment Obligation. In the event that (1) the Company issues a significant restatement of financial results and (2) the Committee determines, in good faith, that the Optionee’s fraud or misconduct was a significant contributing factor to such restatement and (3) some or all of the Option that was granted and/or vested prior to such restatement would not have been granted and/or vested, as applicable, based upon the restated financial results, the Optionee shall immediately return to the Company the unexercised portion of the Option and any Shares or the pre-tax income derived from any disposition of the Shares previously received in upon exercise of the Option that would not have been granted and/or vested based upon the restated financial results. Notwithstanding anything herein to the contrary, in no event shall the Repayment Obligation apply to any portion of the Option that vested more than four years prior to the date the applicable restatement is announced. The Company shall be able to enforce the Repayment Obligation by all legal means available, including, without limitation, by withholding such amount from other sums owed by the Company to the Optionee.

10.Miscellaneous Provisions.

a.Rights as a Stockholder. Neither the Optionee nor the Optionee’s transferee or representative shall have any rights as a stockholder with respect to any Shares subject to this Option until the Option has been exercised and Share certificates have been issued to the Optionee, transferee or representative, as the case may be.

b.Choice of Law, Exclusive Jurisdiction and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of the State of Delaware shall have exclusive jurisdiction over any disputes or other proceedings relating to this Agreement, and venue shall reside with the courts in New Castle County, Delaware, including if jurisdiction shall so permit, the U.S. District Court for the District of Delaware. Accordingly, the Optionee agrees that any claim of any type relating to this Agreement must be brought and maintained in the appropriate court located in New Castle County, Delaware, including if jurisdiction will so permit, in the U.S. District Court for the State of Delaware. The Optionee hereby consents to the jurisdiction over the Optionee of any such courts and waives all objections based on venue or inconvenient forum.

c.Modification or Amendment. This Agreement may be modified or amended by the Board or the Committee at any time; provided, however, no modification or amendment to this Agreement shall be made which would materially and adversely affect the rights of the Optionee, without such Optionee’s written consent.

d.Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of this Agreement, and this Agreement shall be construed and enforced to reflect the intent of the parties to the fullest extent not prohibited by law, and in the event that such provision is not able to be so construed and enforced, then this Agreement shall be construed and enforced as if such illegal or invalid provision had not been included. In amplification of the preceding sentence, in the event that the time period or scope of any provision is declared by a court or



arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall have the power to reduce the time period or scope to the maximum time period or scope permitted by law.

e.References to Plan. All references to the Plan shall be deemed references to the Plan as may be amended.

f.Headings. The captions used in this Agreement are inserted for convenience and shall not be deemed a part of this Option for construction or interpretation.

g.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Optionee or by the Company forthwith to the Board or the Committee, which shall review such dispute at its next regular meeting. The resolution of such dispute by the Board or the Committee shall be final and binding on all persons. It is the intention of the Company and the Optionee to make the promises contained in this Agreement reasonable and binding only to the extent that it may be lawfully done under existing applicable laws. This Agreement and the Plan constitute the entire and exclusive agreement between the Optionee and the Company, and it supersedes all prior agreements or understandings, whether written or oral, with respect to the grant of Options set forth in this Agreement.

h.Section 409A Compliance. To the extent applicable, it is intended that the Plan and this Agreement comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision of the Plan or this Agreement that would cause this Award to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

i.Agreement with Terms. Receipt of any benefits under this Agreement by the Optionee shall constitute the Optionee’s acceptance of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Agreement, and the Company shall administer this Agreement accordingly.





THE CLOROX COMPANY
                                
                            By:

    Its: Chief Executive Officer


THE OPTIONEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT IS A UNILATERAL CONTRACT AND THAT THE OPTIONEE’S RIGHT TO THE SHARES PURSUANT TO THE OPTION HEREOF IS ACCEPTED AND EARNED ONLY BY CONTINUING EMPLOYMENT AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER) AND BY COMPLIANCE WITH THE OPTIONEE’S VARIOUS OBLIGATIONS UNDER THIS AGREEMENT. THE OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, SHALL CONFER UPON THE OPTIONEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE OPTIONEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE OPTIONEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON,



WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT ADVANCE NOTICE EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW.


The Optionee acknowledges that a copy of the Plan and Plan Information are available for viewing on the Company’s internal HR website at https://clxweb.clorox.com/hr/Pages/HRatClorox/HRContentPages/StockIncentiveProgram.aspx, and the Company’s Annual Report and Proxy Statement (the “Prospectus Information”) are available for viewing on the Company’s Clorox website at http://investors.thecloroxcompany.com/sec.cfm. The Optionee hereby consents to receive the Prospectus Information electronically or, in the alternative, to contact the HR Service Center at 1-800-709-7095 to request a paper copy of the Prospectus Information. The Optionee represents that s/he is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Optionee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of this Agreement. The Optionee acknowledges and hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement. The Optionee further agrees to notify the Company upon any change in the residence address indicated below.

Dated:______________________________ Signed:___________________________________
                            Optionee


                Residence Address:

                ___________________________________

                ___________________________________

 EX-31.1 7 clxq1fy21exhibit311.htm EX-31.1 Document
Exhibit 31.1
CERTIFICATION
I, Linda Rendle, certify that:
1.I have reviewed this quarterly report on Form 10-Q of The Clorox Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 2, 2020
 
 
/s/ Linda Rendle
Linda Rendle
Chief Executive Officer


 EX-31.2 8 clxq1fy21exhibit312.htm EX-31.2 Document
Exhibit 31.2
CERTIFICATION
I, Kevin B. Jacobsen, certify that:
1.I have reviewed this quarterly report on Form 10-Q of The Clorox Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 2, 2020
 
 
/s/ Kevin B. Jacobsen
Kevin B. Jacobsen
Executive Vice President - Chief Financial Officer


 EX-32 9 clxq1fy21exhibit32.htm EX-32 Document
Exhibit 32
CERTIFICATION

In connection with the periodic report of The Clorox Company (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (the “Report”), we, Linda Rendle, Chief Executive Officer of the Company, and Kevin B. Jacobsen, Executive Vice President - Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to our knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: November 2, 2020

/s/ Linda Rendle
Linda Rendle
Chief Executive Officer
 
 
/s/ Kevin B. Jacobsen
Kevin B. Jacobsen
Executive Vice President - Chief Financial Officer


 EX-101.SCH 10 clx-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - BUSINESS ACQUIRED link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - BUSINESS ACQUIRED (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - BUSINESS ACQUIRED (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - BUSINESS ACQUIRED (Fair Value Of Assets Acquired and Liabilities Assumed) (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - INVENTORIES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - INCOME TAXES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2118106 - Disclosure - NET EARNINGS PER SHARE (EPS) link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) link:presentationLink link:calculationLink link:definitionLink 2121107 - Disclosure - COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 2322305 - Disclosure - COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 2423410 - Disclosure - COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2124108 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2325306 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2426411 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) link:presentationLink link:calculationLink link:definitionLink 2427412 - Disclosure - STOCKHOLDERS' EQUITY (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2428413 - Disclosure - STOCKHOLDERS' EQUITY (Share Repurchase Programs) (Details) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 2130109 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 2331307 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) link:presentationLink link:calculationLink link:definitionLink 2433416 - Disclosure - EMPLOYEE BENEFIT PLANS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2134110 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES link:presentationLink link:calculationLink link:definitionLink 2435417 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES (Details) link:presentationLink link:calculationLink link:definitionLink 2136111 - Disclosure - SEGMENT RESULTS link:presentationLink link:calculationLink link:definitionLink 2337308 - Disclosure - SEGMENT RESULTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2438418 - Disclosure - SEGMENT RESULTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2439419 - Disclosure - SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 clx-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 clx-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 clx-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Treasury Stock [Member] Treasury Stock [Member] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred income taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Segments [Axis] Segments [Axis] EMPLOYEE BENEFIT PLANS Retirement Benefits [Text Block] Schedule of Changes in Accumulated Other Comprehensive Net (Losses) Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Other Current Assets [Member] Other Current Assets [Member] Derivative assets Derivative Asset $2 Billion Open-Market Purchase Program [Member] $2 Billion Open-Market Purchase Program [Member] $2 Billion Open-Market Purchase Program [Member] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Dividends to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Deferred income taxes Deferred Income Tax Liabilities, Net Loss on settlement Business Combination, Settlement Of Pre-Existing Net Liabilities Business Combination, Settlement Of Pre-Existing Net Liabilities Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Total current liabilities Liabilities, Current Commodity Purchase Derivative Contracts [Axis] Commodity Purchase Derivative Contracts [Axis] Commodity Purchase Derivative Contracts [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Commitments and contingencies Commitments and Contingencies Business combinations including purchase accounting adjustments Noncontrolling Interest, Increase from Business Combination Treasury stock purchased Payments for Repurchase of Common Stock ASSETS Assets [Abstract] Investment, Name [Axis] Investment, Name [Axis] Cash acquired Cash Acquired from Acquisition Accounting Policies [Abstract] Accounting Policies [Abstract] Evergreen Program [Member] Evergreen Program [Member] Evergreen Program [Member] Entity Shell Company Entity Shell Company Cover page. Cover [Abstract] Document Type Document Type COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Operating lease right-of-use assets Operating Lease, Right-of-Use Asset The weighted-average estimated useful life of intangible assets subject to amortization Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Product Concentration Risk [Member] Product Concentration Risk [Member] Treasury stock purchased (in shares) Shares repurchased (in shares) Treasury Stock, Shares, Acquired Other employee stock plan activities (in shares) Other Employee Stock Plan Activities, Shares Number of shares issued during the period as a result of exercises of employee stock options or the vesting of other share-based awards. Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Customer [Axis] Customer [Axis] Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding Preferred Stock, Value, Issued Long-Term Inter-Company Loans [Member] Long-Term Inter-Company Loans [Member] Long-term inter-company loans included in foreign currency adjustments. Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Quarterly Report Document Quarterly Report Raw materials and packaging Inventory, Raw Materials and Supplies, Net of Reserves Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other liabilities Other Liabilities, Noncurrent Other Payments for (Proceeds from) Other Investing Activities AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Professional Products [Member] Professional Products [Member] Professional Products [Member] Domestic Plan [Member] Domestic Plan [Member] Work in process Inventory, Work in Process, Net of Reserves Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Inventories, net Total Inventory, Net Net sales Revenue from Contract with Customer, Excluding Assessed Tax Advertising costs Advertising Expense Concentration percentage Concentration Risk, Percentage Entity File Number Entity File Number Business Acquisition [Axis] Business Acquisition [Axis] Household [Member] Household [Member] Household [Member] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Cash, cash equivalents, and restricted cash: Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Letter of credit Letter of credit Borrowing capacity under the letter of credit without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding. Document Fiscal Period Focus Document Fiscal Period Focus Noncurrent liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities Interest cost Defined Benefit Plan, Interest Cost Current maturities of long-term debt and Long-term debt Debt Instrument, Fair Value Disclosure Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares Schedule of Weighted Average Number of Shares [Table Text Block] Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Total Commodity Purchase Derivative Contracts [Member] Total Commodity Purchase Derivative Contracts [Member] Total Commodity Purchase Derivative Contracts [Member] Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Business Combinations [Abstract] Business Combinations [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Alameda County, California Matter [Member] Alameda County, California Matter [Member] Alameda County, California Matter [Member] Bags and Wraps [Member] Bags, Wraps, And Containers [Member] Bags, Wraps, And Containers [Member] Income taxes payable / prepaid Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Weighted average shares outstanding (in thousands) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Schedule of Share Repurchases Under Authorized Programs Class of Treasury Stock [Table Text Block] Joint venture net sales Business Acquisition Revenue Reported By Acquired Entity For Current Period Business Acquisition Revenue Reported By Acquired Entity For Current Period Amendment Flag Amendment Flag Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Net cash provided by operations Net Cash Provided by (Used in) Operating Activities Transaction Type [Axis] Transaction Type [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Schedule of Assets and Liabilities for Fair Value Disclosure Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Local Phone Number Local Phone Number Intercompany Foreign Currency Balance by Description [Axis] Intercompany Foreign Currency Balance by Description [Axis] Segments [Domain] Segments [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] OTHER CONTINGENCIES AND GUARANTEES [Abstract] OTHER CONTINGENCIES AND GUARANTEES [Abstract] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Selling and administrative expenses Selling, General and Administrative Expense Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Notional amount Derivative, Notional Amount Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] OTHER CONTINGENCIES AND GUARANTEES OTHER CONTINGENCIES AND GUARANTEES [Text Block] This item represents the complete disclosure regarding the entity's exposure to loss pertaining to environmental matters, litigation and potential losses not disclosed in other notes and guarantees. Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] SEGMENT RESULTS Segment Reporting Disclosure [Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Concentration Risk [Table] Concentration Risk [Table] Total other liabilities in the fair value hierarchy Financial Liabilities Fair Value Disclosure Total assets Assets Revenue from Contract with Customer [Member] Revenue from Contract with Customer Benchmark [Member] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Purchases of Inventory [Member] Purchases of Inventory [Member] Purchases of Inventory [Member] Income taxes payable Accrued Income Taxes, Current Entity Small Business Entity Small Business Interest expense Interest Expense Depreciation and amortization Depreciation, Depletion and Amortization Entity Filer Category Entity Filer Category Dickinson County, Michigan Matter [Member] Dickinson County, Michigan Matter [Member] Dickinson County, Michigan Matter [Member] Total liabilities Liabilities Entity Address, City or Town Entity Address, City or Town Investment Type [Axis] Investment Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Business Combination, Separately Recognized Transactions [Line Items] Business Combination, Separately Recognized Transactions [Line Items] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Gains (losses) recognized in Other comprehensive (loss) income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Inventories, net Increase (Decrease) in Inventories Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Document Fiscal Year Focus Document Fiscal Year Focus Maximum duration, commodity contracts Maximum Length of Time Hedged in Cash Flow Hedge Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Operating Segments [Member] Operating Segments [Member] Class of Stock [Line Items] Class of Stock [Line Items] Treasury stock purchased Value of shares repurchased Treasury Stock, Value, Acquired, Cost Method Commodity Purchase Derivative Contracts [Domain] Commodity Purchase Derivative Contracts [Domain] Commodity Purchase Derivative Contracts [Domain] Balance, beginning (in shares) Balance, ending (in shares) Shares, Issued Derivative liabilities Derivative Liability Adjustments to reconcile net earnings to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accounts Payable and Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Equity method investments Equity Method Investments Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Earnings before income taxes Earnings (losses) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Research and development costs Research and Development Expense FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract] FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract] Financial Instruments and Fair Value Measurements [Abstract] Letter of credit, amount outstanding Letters of Credit Outstanding, Amount Maximum undiscounted costs Maximum Exposure, Undiscounted Cost Maximum potential amount of future payments (undiscounted) that the Company could incur over an estimated remediation period. Businesses acquired, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Common stock, shares authorized (in shares) Common Stock, Shares Authorized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Dilutive effect of stock options and other (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Selected Financial Information Relating to the Company's Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Estimate of Fair Value Measurement [Member] Estimate of Fair Value Measurement [Member] Income Statement [Abstract] Income Statement [Abstract] Accumulated other comprehensive net (loss) income [Member] AOCI Attributable to Parent [Member] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Reacquired rights (included in Other intangible assets, net) Customer relationships (included in Other intangible assets, net) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Current assets Assets, Current [Abstract] Goodwill deductible for tax purposes Business Acquisition, Goodwill, Expected Tax Deductible Amount Trust assets for nonqualified deferred compensation plans Investments, Fair Value Disclosure Dividends Dividends Subsegments [Domain] Subsegments [Domain] Total comprehensive income attributable to Clorox Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Capital expenditures Payments to Acquire Property, Plant, and Equipment Consolidation Items [Domain] Consolidation Items [Domain] Entity Tax Identification Number Entity Tax Identification Number Less: Fair value of previously held equity interest Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Soybean Oil Futures [Member] Soybean Oil Futures [Member] Soybean Oil Futures [Member] Other intangible assets, net Other Intangible Assets, Net Net earnings Net earnings Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Trading Symbol Trading Symbol Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, before Tax Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Notes and loans payable, net Proceeds from (Repayments of) Short-term Debt Derivative instruments subject to contractually defined counterparty liability position limits Derivative Instruments Subject To Contractually Defined Counterparty Liability Position Limits Derivative instruments subject to contractually defined counterparty liability position limits. Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Business Combination, Separately Recognized Transactions [Table] Business Combination, Separately Recognized Transactions [Table] Current maturities of long-term debt and Long-term debt Long-term Debt Service cost Defined Benefit Plan, Service Cost City Area Code City Area Code Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Customer Relationships [Member] Customer Relationships [Member] Cost of products sold Cost of Goods and Services Sold Equity Components [Axis] Equity Components [Axis] Title of 12(b) Security Title of 12(b) Security Finished goods Inventory, Finished Goods, Net of Reserves Balance Sheet Location [Domain] Balance Sheet Location [Domain] Current operating lease liabilities Operating Lease, Liability, Current Contractual Rights [Member] Contractual Rights [Member] Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Amortization of unrecognized items Defined Benefit Plan, Amortization of Gain (Loss) Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] UNITED STATES UNITED STATES Total Net periodic benefit Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Remediation period Remediation period Estimated time frame of disbursements over which remediation efforts are estimated to occur for an individual site. STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Cleaning [Member] Cleaning [Member] Cleaning [Member] Commodity Contract [Member] Commodity Contract [Member] Customer [Domain] Customer [Domain] Cumulative Effect of Accounting Changes, Net of Tax [Member] Cumulative Effect, Period of Adoption, Adjustment [Member] Lifestyle [Member] Lifestyle [Member] Lifestyle [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Derivative [Table] Derivative [Table] Concentration Risk [Line Items] Concentration Risk [Line Items] Non-recurring, non-cash gain Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net Number of reportable segments Number of Reportable Segments Joint Venture In Kingdom Of Saudi Arabia [Member] Joint Venture In Kingdom Of Saudi Arabia [Member] Joint Venture In Kingdom Of Saudi Arabia Retirement Plan Type [Domain] Retirement Plan Type [Domain] Vitamins, Minerals and Supplements [Member] Vitamins, Minerals and Supplements [Member] Vitamins, Minerals and Supplements Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Consolidation Items [Axis] Consolidation Items [Axis] Goodwill impairment Goodwill, Impairment Loss Receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Noncontrolling interest, ownership percentage by parent Noncontrolling Interest, Ownership Percentage by Parent Grilling [Member] Grilling [Member] Grilling [Member] Schedule of Comprehensive Income Comprehensive Income (Loss) [Table Text Block] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Goodwill Goodwill Goodwill Total other comprehensive (loss) income, net of tax Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Number of repurchase programs Number Of Repurchase Programs Number of Repurchase Programs Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] LIFO allowances Inventory, LIFO Reserve Trademarks, net Trademarks, net Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite or finite period of benefit. Equity [Abstract] Equity [Abstract] Total other assets in the fair value hierarchy Assets, Fair Value Disclosure Receivables, net Increase (Decrease) in Receivables Entity Central Index Key Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Customer Concentration Risk [Member] Customer Concentration Risk [Member] Derivative Contract [Domain] Derivative Contract [Domain] Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Basic net earnings per share (in dollars per share) Earnings Per Share, Basic Net cash used for financing activities Net Cash Provided by (Used in) Financing Activities Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock: $1.00 par value; 750,000,000 shares authorized; 158,741,461 shares issued as of September 30, 2020 and June 30, 2020; and 126,037,019 and 126,198,606 shares outstanding as of September 30, 2020 and June 30, 2020, respectively Common Stock, Value, Issued Long-term Debt [Member] Long-term Debt [Member] Retirement Income Plans [Member] Retirement Income Plans [Member] Retirement Income [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Trust assets for nonqualified deferred compensation plans Deferred Compensation Plan Assets Current maturities of long-term debt and Long-term debt [Member] CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember Current Maturities of Long-term Debt and Long-term Debt [Member] Retirement Benefits [Abstract] Comprehensive income Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Total fair value of net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Cash margin balances amount Margin Deposit Assets Maximum duration, interest rate contracts Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Jet Fuel Swaps [Member] Jet Fuel Swaps [Member] Jet Fuel Swaps [Member] Intercompany Foreign Currency Balance, Name [Domain] Intercompany Foreign Currency Balance, Name [Domain] Foreign Exchange Forward Contract [Member] Foreign Exchange Forward [Member] Authorization limit Stock Repurchase Program, Authorization Limit Stock Repurchase Program, Authorization Limit Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Long-term debt Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Total Clorox stockholders’ equity Balance, beginning Balance, ending Stockholders' Equity Attributable to Parent Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total purchase consideration Business Combination, Consideration Transferred Total liabilities and stockholders’ equity Liabilities and Equity Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accumulated other comprehensive net (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax INCOME TAXES Income Tax Disclosure [Text Block] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Time deposits [Member] Bank Time Deposits [Member] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Total purchase consideration Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other Assets [Member] Other Assets [Member] Operating lease right-of-use assets and liabilities, net Operating Lease, Right-of-Use Asset And Liability, Net Operating Lease, Right-of-Use Asset And Liability, Net Antidilutive stock options and other (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Trust Assets for nonqualified deferred compensation plans [Member] Trust Assets for nonqualified deferred compensation plans [Member] Trust Assets For Nonqualified Deferred Compensation Plans [Member] Other Other Noncash Income (Expense) Equity Component [Domain] Equity Component [Domain] Effects of Derivative Instruments Designated as Hedging Instruments on OCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Cash dividends paid Payments of Dividends Entity Address, Address Line One Entity Address, Address Line One Gross profit Gross Profit Property, plant and equipment, net of accumulated depreciation and amortization of $2,270 and $2,224, respectively Property, Plant and Equipment, Net Transaction [Domain] Transaction [Domain] Interest Rate Contract [Member] Interest Rate Contract [Member] Net earnings attributable to Clorox Net Income (Loss) Attributable to Parent Entity Address, State or Province Entity Address, State or Province Percentage of liability for aggregate remediation and associated costs, other than legal fees Percentage of liability for aggregate remediation and associated costs, other than legal fees The percentage of costs that the entity has agreed to under cost-sharing arrangements with other potentially responsible parties for an individual site. Changes in: Increase (Decrease) in Operating Capital [Abstract] International [Member] International [Member] International [Member] Net current period other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax INVENTORIES, NET Inventory Disclosure [Text Block] Investment, Name [Domain] Investment, Name [Domain] Maximum duration, foreign exchange contracts Maximum Length of Time, Foreign Currency Cash Flow Hedge Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Less: Total comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Net earnings per share attributable to Clorox Earnings Per Share [Abstract] Food Products [Member] Food Products [Member] Food Products [Member] Pension and postretirement benefit adjustments [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Working capital, net (includes cash acquired of $26) Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Working Capital, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Working Capital, Net Less: Fair value of noncontrolling interests Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Pension and postretirement benefit adjustments Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Discretionary contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Text Block] The entire disclosure for financial instruments and fair value measurements. Common Stock [Member] Common Stock [Member] Foreign currency translation adjustments [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Net unrealized gains (losses) on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Income tax benefit (expense) Other Comprehensive Income (Loss), Tax Investments, including money market funds [Member] Money Market Funds [Member] Property, plant and equipment, accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect BUSINESS ACQUIRED Business Combination Disclosure [Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Other employee stock plan activities Other Employee Stock Plan Activities, Amount Amount includes the value of stock granted during the period as a result of exercises of employee stock options or vesting of other share-based awards. Ownership [Axis] Ownership [Axis] Other (income) expense, net Other Expense (Income), Net The net amount of other income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines. Treasury stock, shares (in shares) Treasury Stock, Shares Cash and Cash Equivalents [Member] Cash and Cash Equivalents [Member] Water Filtration [Member] Water Filtration [Member] Water Filtration [Member] Loss Contingencies [Table] Loss Contingencies [Table] Ownership [Domain] Ownership [Domain] Reported Value Measurement [Member] Reported Value Measurement [Member] Weighted average long-term expected rate or return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Plan Name [Domain] Plan Name [Domain] Natural Personal Care [Member] Natural Personal Care [Member] Natural Personal Care [Member] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Total stockholders’ equity Balance, beginning Cumulative effect of accounting changes, net of tax Balance, ending Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Share Repurchase Programs [Table] Share Repurchase Programs [Table] Disclosure of information about share repurchase programs and shares repurchased. Income taxes Income Tax Expense (Benefit) Beginning of period End of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Diluted net earnings per share (in dollars per share) Earnings Per Share, Diluted Share Repurchase Programs [Line Items] Share Repurchase Programs [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Amounts reclassified from accumulated other comprehensive net (loss) income Amounts reclassified from Accumulated other comprehensive net (loss) income Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Cash paid Payments to Acquire Businesses, Gross Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Derivative [Line Items] Derivative [Line Items] Liability for aggregate future remediation costs Accrual for Environmental Loss Contingencies Health and Wellness [Member] Health and Wellness [Member] Health and Wellness Net unrealized gains (losses) on derivatives [Member] Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Deferred income taxes Deferred Income Tax Expense (Benefit) Security Exchange Name Security Exchange Name Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Noncontrolling Interest [Member] Noncontrolling Interest [Member] Retained Earnings [Member] Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Measurement Basis [Axis] Measurement Basis [Axis] Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Effective tax rate on earnings from continuing operations Effective Income Tax Rate Reconciliation, Percent Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities Issuance of common stock for employee stock plans and other Issuance Of Common Stock For Employee Stock Plans And Other The cash inflow associated with the amount received from holders exercising their stock options. Also includes the net cash inflow (outflow) from other financing activities. Investments [Domain] Investments [Domain] Document Transition Report Document Transition Report Cat Litter [Member] Cat Litter [Member] Cat Litter [Member] Other Postretirement Benefits Plan [Member] Other Postretirement Benefits Plan [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Walmart Stores, Inc. [Member] Walmart Stores, Inc. [Member] Walmart Stores, Inc. and its affiliates [Member] Treasury shares, at cost: 32,704,442 and 32,542,855 shares as of September 30, 2020 and June 30, 2020, respectively Treasury Stock, Value NET EARNINGS PER SHARE (EPS) Earnings Per Share [Text Block] Current liabilities Liabilities, Current [Abstract] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Segment Results Segment Reporting, Policy [Policy Text Block] Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Subsegments [Axis] Subsegments [Axis] EX-101.PRE 14 clx-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 15 clx-20200930_htm.xml IDEA: XBRL DOCUMENT 0000021076 2020-07-01 2020-09-30 0000021076 2020-10-19 0000021076 2019-07-01 2019-09-30 0000021076 2020-09-30 0000021076 2020-06-30 0000021076 2019-06-30 0000021076 2019-09-30 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 2020-07-09 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember us-gaap:ContractualRightsMember 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember us-gaap:CustomerRelationshipsMember 2020-07-09 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2020-07-01 2020-09-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2020-09-30 0000021076 clx:SoybeanOilFuturesMember 2020-09-30 0000021076 clx:JetFuelSwapsMember 2020-09-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2020-06-30 0000021076 clx:SoybeanOilFuturesMember 2020-06-30 0000021076 clx:JetFuelSwapsMember 2020-06-30 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2020-09-30 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2020-06-30 0000021076 us-gaap:InterestRateContractMember 2020-07-01 2020-09-30 0000021076 us-gaap:InterestRateContractMember 2020-09-30 0000021076 us-gaap:InterestRateContractMember 2020-06-30 0000021076 us-gaap:CommodityContractMember 2020-07-01 2020-09-30 0000021076 us-gaap:CommodityContractMember 2019-07-01 2019-09-30 0000021076 us-gaap:ForeignExchangeContractMember 2020-07-01 2020-09-30 0000021076 us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000021076 us-gaap:InterestRateContractMember 2019-07-01 2019-09-30 0000021076 us-gaap:CommodityContractMember clx:SoybeanOilFuturesMember 2020-09-30 0000021076 us-gaap:CommodityContractMember clx:SoybeanOilFuturesMember 2020-06-30 0000021076 us-gaap:OtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:OtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:OtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:OtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2020-09-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2020-09-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2020-06-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2020-06-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LongTermDebtMember 2020-09-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LongTermDebtMember 2020-09-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LongTermDebtMember 2020-06-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LongTermDebtMember 2020-06-30 0000021076 us-gaap:CommonStockMember 2019-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000021076 us-gaap:RetainedEarningsMember 2019-06-30 0000021076 us-gaap:TreasuryStockMember 2019-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2019-06-30 0000021076 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-06-30 0000021076 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-06-30 0000021076 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000021076 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000021076 us-gaap:CommonStockMember 2019-09-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000021076 us-gaap:RetainedEarningsMember 2019-09-30 0000021076 us-gaap:TreasuryStockMember 2019-09-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000021076 us-gaap:NoncontrollingInterestMember 2019-09-30 0000021076 us-gaap:CommonStockMember 2020-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000021076 us-gaap:RetainedEarningsMember 2020-06-30 0000021076 us-gaap:TreasuryStockMember 2020-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2020-06-30 0000021076 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000021076 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000021076 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000021076 us-gaap:CommonStockMember 2020-09-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000021076 us-gaap:RetainedEarningsMember 2020-09-30 0000021076 us-gaap:TreasuryStockMember 2020-09-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000021076 us-gaap:NoncontrollingInterestMember 2020-09-30 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2020-09-30 0000021076 clx:EvergreenProgramMember 2020-09-30 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2020-07-01 2020-09-30 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2019-07-01 2019-09-30 0000021076 clx:EvergreenProgramMember 2020-07-01 2020-09-30 0000021076 clx:EvergreenProgramMember 2019-07-01 2019-09-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2019-09-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-07-01 2019-09-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2019-09-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-09-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-07-01 2020-09-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-09-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000021076 clx:LongTermInterCompanyLoansMember 2020-07-01 2020-09-30 0000021076 clx:LongTermInterCompanyLoansMember 2019-07-01 2019-09-30 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000021076 clx:RetirementIncomeMember country:US 2020-07-01 2020-09-30 0000021076 clx:RetirementIncomeMember country:US 2019-07-01 2019-09-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2020-06-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2020-09-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2020-07-01 2020-09-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2017-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2020-09-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2020-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2020-07-01 2020-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2020-07-01 2020-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2019-07-01 2019-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2020-07-01 2020-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2019-07-01 2019-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2020-07-01 2020-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2019-07-01 2019-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2020-07-01 2020-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2019-07-01 2019-09-30 0000021076 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000021076 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CleaningMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CleaningMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:VitaminsMineralsAndSupplementsMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:VitaminsMineralsAndSupplementsMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:BagsWrapsAndContainersMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:BagsWrapsAndContainersMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CatLitterMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CatLitterMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:GrillingMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:GrillingMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:FoodProductsMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:FoodProductsMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:NaturalPersonalCareMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:NaturalPersonalCareMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:WaterFiltrationMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:WaterFiltrationMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2019-07-01 2019-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 shares iso4217:USD iso4217:USD shares pure clx:repurchase_program clx:reportable_segment 0000021076 false --06-30 Q1 2021 10-Q true 2020-09-30 false 1-07151 THE CLOROX COMPANY DE 31-0595760 1221 Broadway Oakland CA 94612-1888 510 271-7000 Common Stock - $1.00 par value CLX NYSE Yes Yes Large Accelerated Filer false false false 126049929 1916000000 1506000000 996000000 843000000 920000000 663000000 238000000 211000000 179000000 137000000 32000000 30000000 25000000 25000000 -80000000 2000000 526000000 258000000 109000000 55000000 417000000 203000000 2000000 0 415000000 203000000 3.28 1.61 3.22 1.59 126346000 125823000 128729000 127465000 434000000 190000000 2000000 0 432000000 190000000 860000000 871000000 685000000 648000000 534000000 454000000 65000000 47000000 2144000000 2020000000 2270000000 2224000000 1176000000 1103000000 281000000 291000000 1793000000 1577000000 786000000 785000000 265000000 109000000 332000000 328000000 6777000000 6213000000 64000000 64000000 1395000000 1329000000 57000000 25000000 1516000000 1418000000 2781000000 2780000000 268000000 278000000 797000000 767000000 104000000 62000000 5466000000 5305000000 1.00 1.00 5000000 5000000 0 0 0 0 0 0 1.00 1.00 750000000 750000000 158741461 158741461 126037019 126198606 159000000 159000000 1146000000 1137000000 3840000000 3567000000 32704442 32542855 3407000000 3315000000 -623000000 -640000000 1115000000 908000000 196000000 0 1311000000 908000000 6777000000 6213000000 417000000 203000000 51000000 44000000 13000000 6000000 20000000 7000000 71000000 -19000000 8000000 -73000000 70000000 -6000000 18000000 10000000 20000000 -82000000 -1000000 1000000 30000000 4000000 383000000 271000000 69000000 54000000 85000000 0 -3000000 -12000000 -151000000 -42000000 0 51000000 100000000 110000000 140000000 133000000 -7000000 9000000 -247000000 -183000000 3000000 -2000000 -12000000 44000000 879000000 113000000 867000000 157000000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2020 and 2019, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2020, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which improves consistency in the application of accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and by clarifying and amending existing guidance. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The amendments that are related to changes in ownership of foreign equity method investments or foreign subsidiaries are to be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The amendments that are related to franchise taxes that are partially based on income are to be applied on either a retrospective basis for all periods presented or a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. All other amendments under this ASU are to be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div>In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The Company adopted this guidance as of July 1, 2020 on a prospective basis, and the adoption did not have a material impact on the Company’s consolidated financial statements, as the Company had no goodwill impairments during the first quarter of fiscal year 2021. The future impact of this new standard will depend on the specific facts and circumstances of future impairments that may occur, if any. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2020 and 2019, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2020, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which improves consistency in the application of accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and by clarifying and amending existing guidance. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The amendments that are related to changes in ownership of foreign equity method investments or foreign subsidiaries are to be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The amendments that are related to franchise taxes that are partially based on income are to be applied on either a retrospective basis for all periods presented or a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. All other amendments under this ASU are to be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div>In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The Company adopted this guidance as of July 1, 2020 on a prospective basis, and the adoption did not have a material impact on the Company’s consolidated financial statements, as the Company had no goodwill impairments during the first quarter of fiscal year 2021. The future impact of this new standard will depend on the specific facts and circumstances of future impairments that may occur, if any. 0 BUSINESS ACQUIRED<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Saudi Joint Venture Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture). The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. The Company had previously accounted for its 30 percent investment of $27 as of June 30, 2020, under the equity method of accounting. Subsequent to the closing of this transaction, the Company’s total ownership interest in each of the entities increased to 51 percent. The Company has consolidated this joint venture into the Company's consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total purchase consideration of $111 consisted of $100 cash paid, which was sourced from operations, and $11 on the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date using generally accepted accounting principles for business combinations. The excess of the purchase price over the fair value of the net identifiable assets acquired has been allocated to goodwill in the International reportable segment in the amount of $212. The goodwill is primarily attributable to the synergies expected to arise after the acquisition and reflects the value of further growth anticipated in the Gulf region. None of the goodwill is deductible for tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, non-cash gain recorded in Other (income) expense, net in the consolidated statement of earnings and adjusted in Other operating activities in the consolidated statement of cash flows for the first quarter of fiscal year 2021. The fair values of the noncontrolling interests and previously held equity interest were determined using a discounted cash flow (DCF) method under the income approach. Under this approach, the Company estimates future cash flows and discounts these cash flows at a rate of return that reflects the entities’ relative risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the estimated fair value of the joint ventures’ assets acquired and liabilities assumed and the related deferred income taxes as of the acquisition date. Due to the timing of the acquisition, the fair values of the assets acquired and liabilities assumed were based on a preliminary valuation and the Company’s estimates and assumptions are subject to change within the measurement period. The primary areas of the purchase price that are not yet finalized are related to goodwill and income taxes. The definite-lived intangibles acquired primarily represent the Company reacquiring previously licensed trademarks and customer relationships. The weighted-average estimated useful life of intangible assets subject to amortization is 9 years.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Venture</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reacquired rights (included in Other intangible assets, net)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships (included in Other intangible assets, net)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital, net (includes cash acquired of $26)</span></div></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Fair value of noncontrolling interests</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Fair value of previously held equity interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Included in the Company’s results for the first quarter of fiscal year 2021 was $23 of net sales from the joint venture. Pro forma results reflecting this transaction were not presented because it is not significant to the Company's consolidated financial results.</span></div> 0.30 27000000 0.51 111000000 100000000 11000000 212000000 0 85000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the estimated fair value of the joint ventures’ assets acquired and liabilities assumed and the related deferred income taxes as of the acquisition date. Due to the timing of the acquisition, the fair values of the assets acquired and liabilities assumed were based on a preliminary valuation and the Company’s estimates and assumptions are subject to change within the measurement period. The primary areas of the purchase price that are not yet finalized are related to goodwill and income taxes. The definite-lived intangibles acquired primarily represent the Company reacquiring previously licensed trademarks and customer relationships. The weighted-average estimated useful life of intangible assets subject to amortization is 9 years.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Venture</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reacquired rights (included in Other intangible assets, net)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships (included in Other intangible assets, net)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital, net (includes cash acquired of $26)</span></div></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Fair value of noncontrolling interests</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Fair value of previously held equity interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P9Y 212000000 138000000 46000000 10000000 26000000 31000000 5000000 20000000 412000000 198000000 103000000 111000000 23000000 INVENTORIES, NET<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, consisted of the following as of:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6/30/2020</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and packaging</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO allowances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, consisted of the following as of:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6/30/2020</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and packaging</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO allowances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 396000000 340000000 161000000 140000000 9000000 7000000 32000000 33000000 534000000 454000000 FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Risk Management and Derivative Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the notional amount of commodity derivatives was $22, of which $11 related to soybean oil futures used for the Food products business and $11 related to jet fuel swaps used for the Grilling business. As of June 30, 2020, the notional amount of commodity derivatives was $27, of which $14 related to soybean oil futures and $13 related to jet fuel swaps.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk Management</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $58 and $70, respectively, as of September 30, 2020 and June 30, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into over-the-counter interest rate forward or swap contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt or to manage the Company’s level of fixed and floating rate debt. These interest rate forward or swap contracts historically have had durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by U.S. government bond and interest rate derivative dealers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notional amounts of outstanding interest rate contracts used by the Company were $300 and $225, respectively, as of September 30, 2020 and June 30, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These contracts represent forward starting interest rate swap contracts with a maturity date of September 2022 to manage the exposure to interest rate volatility associated with future interest payments on a forecasted debt issuance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commodity, Foreign Exchange and Interest Rate Derivatives </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate forward contracts for forecasted interest payments as cash flow hedges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains (losses) recognized in Other comprehensive (loss) income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of September 30, 2020, that is expected to be reclassified into Net earnings within the next twelve months is $(10). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterparty Risk Management and Derivative Contract Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of September 30, 2020 and June 30, 2020, $2 and $3, respectively, contained such terms. As of September 30, 2020 and June 30, 2020, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard &amp; Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both September 30, 2020 and June 30, 2020, the Company and each of its counterparties had been assigned investment grade ratings by both Standard &amp; Poor’s and Moody’s.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of September 30, 2020 and June 30, 2020, the Company maintained cash margin balances related to exchange-traded futures contracts of $1 and $2, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trust Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has held interests in mutual funds and cash equivalents as part of the trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which to invest their compensation deferrals in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and June 30, 2020, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase futures contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate forward contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase futures contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase swaps contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contract</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:24.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.506%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, including money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust assets for nonqualified deferred compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and Long-term debt</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">term debt and Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,051 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,051 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.</span></div> P2Y 22000000 11000000 11000000 27000000 14000000 13000000 P2Y 58000000 70000000 P3Y 300000000 225000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains (losses) recognized in Other comprehensive (loss) income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000 0 -1000000 1000000 3000000 0 3000000 1000000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -1000000 0 0 0 -2000000 -2000000 -3000000 -2000000 -10000000 2000000 3000000 1000000 2000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and June 30, 2020, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.</span></div> The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase futures contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate forward contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase futures contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase swaps contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contract</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:24.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.506%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, including money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust assets for nonqualified deferred compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and Long-term debt</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">term debt and Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,051 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,051 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.</span></div> 1000000 1000000 0 0 4000000 4000000 1000000 1000000 5000000 5000000 1000000 1000000 0 0 1000000 1000000 3000000 3000000 3000000 3000000 1000000 1000000 1000000 1000000 4000000 4000000 5000000 5000000 379000000 379000000 584000000 584000000 318000000 318000000 165000000 165000000 114000000 114000000 100000000 100000000 811000000 811000000 849000000 849000000 2781000000 3049000000 2780000000 3051000000 2781000000 3049000000 2780000000 3051000000 INCOME TAXESIn determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 20.7% and 21.5% for the three months ended September 30, 2020 and 2019, respectively. The decrease in the effective tax rate on earnings for the current three-month period was primarily due to the non-taxability of a portion of the remeasurement gain recognized on the Company’s previously held investment in the Saudi joint venture, partially offset by a lower rate benefit from excess tax benefits. 0.207 0.215 NET EARNINGS PER SHARE (EPS)<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,346</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,823</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,383</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,729</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,465</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive stock options and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,346</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,823</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,383</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,729</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,465</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive stock options and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 126346000 125823000 2383000 1642000 128729000 127465000 441000 0 COMPREHENSIVE INCOME<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of Comprehensive income for the periods indicated:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.946%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Total comprehensive income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income attributable to Clorox</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of Comprehensive income for the periods indicated:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.946%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Total comprehensive income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income attributable to Clorox</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 417000000 203000000 10000000 -16000000 5000000 2000000 -2000000 -1000000 17000000 -13000000 434000000 190000000 2000000 0 432000000 190000000 STOCKHOLDERS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EQUITY</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the components of Stockholders’ equity were as follows for the periods indicated: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:103%">(Dollars in millions except per share data; shares in thousands)</span></div></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Net (Loss) Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2019</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,150 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,194)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33,055)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting changes, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to Clorox stockholders ($1.06 per share declared)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other employee stock plan activities</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock purchased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2019</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,241 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,278)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33,246)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,315)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,543)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to Clorox stockholders ($1.11 per share declared)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to noncontrolling interests</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business combinations including purchase accounting adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other employee stock plan activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock purchased</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,840 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,407)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,704)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Open-market purchase program</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evergreen Program</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized gains (losses) on derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and postretirement benefit adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated other comprehensive net (loss) income</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2019</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense), and other</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in foreign currency translation adjustments are re-measurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.</span></div> <div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the components of Stockholders’ equity were as follows for the periods indicated: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:103%">(Dollars in millions except per share data; shares in thousands)</span></div></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Net (Loss) Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2019</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,150 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,194)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33,055)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting changes, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to Clorox stockholders ($1.06 per share declared)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other employee stock plan activities</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock purchased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2019</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,241 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,278)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33,246)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,315)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,543)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to Clorox stockholders ($1.11 per share declared)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to noncontrolling interests</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business combinations including purchase accounting adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other employee stock plan activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock purchased</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,840 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,407)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,704)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings. 159000000 158741000 1046000000 3150000000 -3194000000 33055000 -602000000 0 559000000 22000000 22000000 203000000 203000000 -13000000 -13000000 1.06 134000000 134000000 6000000 6000000 -9000000 0 20000000 472000 11000000 104000000 663000 104000000 159000000 158741000 1043000000 3241000000 -3278000000 33246000 -615000000 0 550000000 159000000 158741000 1137000000 3567000000 -3315000000 32543000 -640000000 0 908000000 415000000 2000000 417000000 17000000 17000000 1.11 141000000 141000000 4000000 4000000 198000000 198000000 13000000 13000000 -4000000 -1000000 8000000 283000 3000000 100000000 444000 100000000 159000000 158741000 1146000000 3840000000 -3407000000 32704000 -623000000 196000000 1311000000 2 2 2000000000 0 <div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Open-market purchase program</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evergreen Program</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 2 0 0 0 0 100000000 444000 104000000 663000 100000000 444000 104000000 663000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized gains (losses) on derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and postretirement benefit adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated other comprehensive net (loss) income</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2019</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense), and other</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -414000000 -23000000 -165000000 -602000000 -15000000 1000000 0 -14000000 0 -2000000 -2000000 -4000000 1000000 1000000 1000000 3000000 -16000000 2000000 1000000 -13000000 -430000000 -21000000 -164000000 -615000000 -450000000 -18000000 -172000000 -640000000 9000000 3000000 0 12000000 0 -3000000 -2000000 -5000000 -1000000 1000000 0 0 10000000 5000000 2000000 17000000 -440000000 -13000000 -170000000 -623000000 0 0 0 0 EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized items</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2021 net periodic benefit cost is 3.1%.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020 and 2019, the Company made $2 in contributions to its domestic retirement income plans. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs are reflected in Other (income) expense, net.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized items</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2021 net periodic benefit cost is 3.1%.</span></div> 0 0 4000000 5000000 4000000 4000000 -3000000 -2000000 3000000 3000000 0.031 0 0 2000000 2000000 OTHER CONTINGENCIES AND GUARANTEES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of September 30, 2020 and June 30, 2020, for its share of aggregate future remediation costs related to these matters. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One matter, which accounted for $14 of the recorded liability as of September 30, 2020 and June 30, 2020, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30-year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $14, which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $28 over an estimated 30-year period, or require the Company to take other actions and incur costs not included in the study. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability, as of September 30, 2020 and June 30, 2020. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements, and the future availability of alternative clean-up technologies.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had not recorded any material liabilities on the aforementioned guarantees as of September 30, 2020 and June 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company was party to a letter of credit of $11, related to one of its insurance carriers, of which $0 had been drawn upon.</span></div> 28000000 28000000 14000000 14000000 P30Y 14000000 28000000 P30Y 10000000 10000000 0.243 P30Y 11000000 0 SEGMENT RESULTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates through strategic business units (SBUs) that are aggregated into four reportable segments based on the economics and nature of the products sold: Health and Wellness, Household, Lifestyle and International. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate. </span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (losses) before income taxes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 25% and 26% for the three months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleaning</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitamins, Minerals and Supplements</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bags and Wraps</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat Litter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grilling</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food Products</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natural Personal Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Water Filtration</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates through strategic business units (SBUs) that are aggregated into four reportable segments based on the economics and nature of the products sold: Health and Wellness, Household, Lifestyle and International. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.</span></div> 4 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate. </span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (losses) before income taxes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2019</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleaning</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitamins, Minerals and Supplements</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bags and Wraps</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat Litter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grilling</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food Products</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natural Personal Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Water Filtration</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div> 813000000 633000000 500000000 361000000 318000000 271000000 285000000 241000000 0 0 1916000000 1506000000 251000000 170000000 109000000 32000000 102000000 71000000 124000000 39000000 -60000000 -54000000 526000000 258000000 0.25 0.26 0.29 0.32 0.09 0.06 0.04 0.04 0.42 0.42 0.11 0.12 0.06 0.08 0.09 0.04 0.26 0.24 0.09 0.09 0.04 0.05 0.04 0.04 0.17 0.18 0.15 0.16 1 1 XML 16 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
 3 Months Ended
Sep. 30, 2020
Oct. 19, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 1-07151  
Entity Registrant Name THE CLOROX COMPANY  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 31-0595760  
Entity Address, Address Line One 1221 Broadway  
Entity Address, City or Town Oakland  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94612-1888  
City Area Code 510  
Local Phone Number 271-7000  
Title of 12(b) Security Common Stock - $1.00 par value  
Trading Symbol CLX  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   126,049,929
Entity Central Index Key 0000021076  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2021  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]    
Net sales $ 1,916 $ 1,506
Cost of products sold 996 843
Gross profit 920 663
Selling and administrative expenses 238 211
Advertising costs 179 137
Research and development costs 32 30
Interest expense 25 25
Other (income) expense, net (80) 2
Earnings before income taxes 526 258
Income taxes 109 55
Net earnings 417 203
Less: Net earnings attributable to noncontrolling interests 2 0
Net earnings attributable to Clorox $ 415 $ 203
Net earnings per share attributable to Clorox    
Basic net earnings per share (in dollars per share) $ 3.28 $ 1.61
Diluted net earnings per share (in dollars per share) $ 3.22 $ 1.59
Weighted average shares outstanding (in thousands)    
Basic (in shares) 126,346 125,823
Diluted (in shares) 128,729 127,465
Comprehensive income $ 434 $ 190
Less: Total comprehensive income attributable to noncontrolling interests 2 0
Total comprehensive income attributable to Clorox $ 432 $ 190
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2020
Jun. 30, 2020
Current assets    
Cash and cash equivalents $ 860 $ 871
Receivables, net 685 648
Inventories, net 534 454
Prepaid expenses and other current assets 65 47
Total current assets 2,144 2,020
Property, plant and equipment, net of accumulated depreciation and amortization of $2,270 and $2,224, respectively 1,176 1,103
Operating lease right-of-use assets 281 291
Goodwill 1,793 1,577
Trademarks, net 786 785
Other intangible assets, net 265 109
Other assets 332 328
Total assets 6,777 6,213
Current liabilities    
Current operating lease liabilities 64 64
Accounts payable and accrued liabilities 1,395 1,329
Income taxes payable 57 25
Total current liabilities 1,516 1,418
Long-term debt 2,781 2,780
Long-term operating lease liabilities 268 278
Other liabilities 797 767
Deferred income taxes 104 62
Total liabilities 5,466 5,305
Commitments and contingencies
Stockholders’ equity    
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding 0 0
Common stock: $1.00 par value; 750,000,000 shares authorized; 158,741,461 shares issued as of September 30, 2020 and June 30, 2020; and 126,037,019 and 126,198,606 shares outstanding as of September 30, 2020 and June 30, 2020, respectively 159 159
Additional paid-in capital 1,146 1,137
Retained earnings 3,840 3,567
Treasury shares, at cost: 32,704,442 and 32,542,855 shares as of September 30, 2020 and June 30, 2020, respectively (3,407) (3,315)
Accumulated other comprehensive net (loss) income (623) (640)
Total Clorox stockholders’ equity 1,115 908
Noncontrolling interests 196 0
Total stockholders’ equity 1,311 908
Total liabilities and stockholders’ equity $ 6,777 $ 6,213
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2020
Jun. 30, 2020
Statement of Financial Position [Abstract]    
Property, plant and equipment, accumulated depreciation and amortization $ 2,270 $ 2,224
Preferred stock, par value (in dollars per share) $ 1.00 $ 1.00
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 158,741,461 158,741,461
Common stock, shares outstanding (in shares) 126,037,019 126,198,606
Treasury stock, shares (in shares) 32,704,442 32,542,855
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Operating activities:    
Net earnings $ 417 $ 203
Adjustments to reconcile net earnings to net cash provided by operations:    
Depreciation and amortization 51 44
Stock-based compensation 13 6
Deferred income taxes 20 7
Other (71) 19
Changes in:    
Receivables, net (8) 73
Inventories, net (70) 6
Prepaid expenses and other current assets (18) (10)
Accounts payable and accrued liabilities 20 (82)
Operating lease right-of-use assets and liabilities, net (1) 1
Income taxes payable / prepaid 30 4
Net cash provided by operations 383 271
Investing activities:    
Capital expenditures (69) (54)
Businesses acquired, net of cash acquired (85) 0
Other 3 12
Net cash used for investing activities (151) (42)
Financing activities:    
Notes and loans payable, net 0 51
Treasury stock purchased (100) (110)
Cash dividends paid (140) (133)
Issuance of common stock for employee stock plans and other (7) 9
Net cash used for financing activities (247) (183)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 3 (2)
Net increase (decrease) in cash, cash equivalents, and restricted cash (12) 44
Cash, cash equivalents, and restricted cash:    
Beginning of period 879 113
End of period $ 867 $ 157
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2020 and 2019, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2020, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

Recently Issued Accounting Standards

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which improves consistency in the application of accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and by clarifying and amending existing guidance. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The amendments that are related to changes in ownership of foreign equity method investments or foreign subsidiaries are to be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The amendments that are related to franchise taxes that are partially based on income are to be applied on either a retrospective basis for all periods presented or a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. All other amendments under this ASU are to be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

Recently Adopted Accounting Standards
In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The Company adopted this guidance as of July 1, 2020 on a prospective basis, and the adoption did not have a material impact on the Company’s consolidated financial statements, as the Company had no goodwill impairments during the first quarter of fiscal year 2021. The future impact of this new standard will depend on the specific facts and circumstances of future impairments that may occur, if any.
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS ACQUIRED
 3 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
BUSINESS ACQUIRED BUSINESS ACQUIRED
Saudi Joint Venture Acquisition

On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture). The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. The Company had previously accounted for its 30 percent investment of $27 as of June 30, 2020, under the equity method of accounting. Subsequent to the closing of this transaction, the Company’s total ownership interest in each of the entities increased to 51 percent. The Company has consolidated this joint venture into the Company's consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests.

The total purchase consideration of $111 consisted of $100 cash paid, which was sourced from operations, and $11 on the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date using generally accepted accounting principles for business combinations. The excess of the purchase price over the fair value of the net identifiable assets acquired has been allocated to goodwill in the International reportable segment in the amount of $212. The goodwill is primarily attributable to the synergies expected to arise after the acquisition and reflects the value of further growth anticipated in the Gulf region. None of the goodwill is deductible for tax purposes.

As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, non-cash gain recorded in Other (income) expense, net in the consolidated statement of earnings and adjusted in Other operating activities in the consolidated statement of cash flows for the first quarter of fiscal year 2021. The fair values of the noncontrolling interests and previously held equity interest were determined using a discounted cash flow (DCF) method under the income approach. Under this approach, the Company estimates future cash flows and discounts these cash flows at a rate of return that reflects the entities’ relative risk.
 
The following table summarizes the estimated fair value of the joint ventures’ assets acquired and liabilities assumed and the related deferred income taxes as of the acquisition date. Due to the timing of the acquisition, the fair values of the assets acquired and liabilities assumed were based on a preliminary valuation and the Company’s estimates and assumptions are subject to change within the measurement period. The primary areas of the purchase price that are not yet finalized are related to goodwill and income taxes. The definite-lived intangibles acquired primarily represent the Company reacquiring previously licensed trademarks and customer relationships. The weighted-average estimated useful life of intangible assets subject to amortization is 9 years.

Joint Venture
Goodwill$212 
Reacquired rights (included in Other intangible assets, net)138 
Property, plant and equipment46 
Customer relationships (included in Other intangible assets, net)10 
Working capital, net (includes cash acquired of $26)
31 
Noncurrent liabilities, net(5)
Deferred income taxes(20)
Total fair value of net assets412 
Less: Fair value of noncontrolling interests(198)
Less: Fair value of previously held equity interest(103)
Total purchase consideration$111 

Included in the Company’s results for the first quarter of fiscal year 2021 was $23 of net sales from the joint venture. Pro forma results reflecting this transaction were not presented because it is not significant to the Company's consolidated financial results.
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES, NET
 3 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
INVENTORIES, NET INVENTORIES, NET
Inventories, net, consisted of the following as of:
9/30/20206/30/2020
Finished goods$396 $340 
Raw materials and packaging161 140 
Work in process9 7 
LIFO allowances(32)(33)
Total$534 $454 
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.20.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
 3 Months Ended
Sep. 30, 2020
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments

The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.

Commodity Price Risk Management

The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.

As of September 30, 2020, the notional amount of commodity derivatives was $22, of which $11 related to soybean oil futures used for the Food products business and $11 related to jet fuel swaps used for the Grilling business. As of June 30, 2020, the notional amount of commodity derivatives was $27, of which $14 related to soybean oil futures and $13 related to jet fuel swaps.

Foreign Currency Risk Management

The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.

The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $58 and $70, respectively, as of September 30, 2020 and June 30, 2020.

Interest Rate Risk Management

The Company may enter into over-the-counter interest rate forward or swap contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt or to manage the Company’s level of fixed and floating rate debt. These interest rate forward or swap contracts historically have had durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by U.S. government bond and interest rate derivative dealers.

The notional amounts of outstanding interest rate contracts used by the Company were $300 and $225, respectively, as of September 30, 2020 and June 30, 2020. These contracts represent forward starting interest rate swap contracts with a maturity date of September 2022 to manage the exposure to interest rate volatility associated with future interest payments on a forecasted debt issuance.
Commodity, Foreign Exchange and Interest Rate Derivatives

The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate forward contracts for forecasted interest payments as cash flow hedges.

The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:

Gains (losses) recognized in Other comprehensive (loss) income
Three Months Ended
9/30/20209/30/2019
Commodity purchase derivative contracts$1 $— 
Foreign exchange derivative contracts(1)1 
Interest rate derivative contracts3 — 
Total$3 $1 

Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months Ended
9/30/20209/30/2019
Commodity purchase derivative contractsCost of products sold$(1)$— 
Foreign exchange derivative contractsCost of products sold— — 
Interest rate derivative contractsInterest expense(2)(2)
Total$(3)$(2)

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of September 30, 2020, that is expected to be reclassified into Net earnings within the next twelve months is $(10).
Counterparty Risk Management and Derivative Contract Requirements

The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of September 30, 2020 and June 30, 2020, $2 and $3, respectively, contained such terms. As of September 30, 2020 and June 30, 2020, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.

Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both September 30, 2020 and June 30, 2020, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.

Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of September 30, 2020 and June 30, 2020, the Company maintained cash margin balances related to exchange-traded futures contracts of $1 and $2, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.

Trust Assets

The Company has held interests in mutual funds and cash equivalents as part of the trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which to invest their compensation deferrals in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.

Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of September 30, 2020 and June 30, 2020, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 9/30/20206/30/2020
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contractsOther current assets1$1 $1 $— $— 
Interest rate forward contractsOther assets24 4 1 1 
 $5 $5 $1 $1 
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$— $— $1 $1 
Commodity purchase swaps contractsAccounts payable and accrued liabilities23 3 3 3 
Foreign exchange forward contractAccounts payable and accrued liabilities21 1 1 1 
$4 $4 $5 $5 

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 9/30/20206/30/2020
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Investments, including money market funds
Cash and cash
equivalents (a)
1$379 $379 $584 $584 
Time deposits
Cash and cash
equivalents (a)
2318 318 165 165 
Trust assets for nonqualified deferred compensation plansOther assets1114 114 100 100 
 $811 $811 $849 $849 
Liabilities
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (b)
22,781 3,049 2,780 3,051 
$2,781 $3,049 $2,780 $3,051 

____________________

(a)Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(b)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES
 3 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXESIn determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 20.7% and 21.5% for the three months ended September 30, 2020 and 2019, respectively. The decrease in the effective tax rate on earnings for the current three-month period was primarily due to the non-taxability of a portion of the remeasurement gain recognized on the Company’s previously held investment in the Saudi joint venture, partially offset by a lower rate benefit from excess tax benefits.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.20.2
NET EARNINGS PER SHARE (EPS)
 3 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
NET EARNINGS PER SHARE (EPS) NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months Ended
9/30/20209/30/2019
Basic126,346125,823
Dilutive effect of stock options and other2,3831,642
Diluted128,729127,465
Antidilutive stock options and other441 — 

Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.20.2
COMPREHENSIVE INCOME
 3 Months Ended
Sep. 30, 2020
Stockholders' Equity Note [Abstract]  
COMPREHENSIVE INCOME COMPREHENSIVE INCOME
The following table provides a summary of Comprehensive income for the periods indicated:
Three Months Ended
9/30/20209/30/2019
Net earnings$417 $203 
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments10 (16)
Net unrealized gains (losses) on derivatives5 2 
Pension and postretirement benefit adjustments2 1 
Total other comprehensive (loss) income, net of tax17 (13)
Comprehensive income434 190 
Less: Total comprehensive income attributable to noncontrolling interests2 — 
Total comprehensive income attributable to Clorox$432 $190 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS' EQUITY
 3 Months Ended
Sep. 30, 2020
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended September 30
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income		Non-controlling interests
Total Stockholders’ Equity
AmountSharesAmountShares
Balance as of June 30, 2019$159 158,741 $1,046 $3,150 $(3,194)(33,055)$(602)$— $559 
Cumulative effect of accounting changes, net of tax (1)
22 22 
Net earnings203 203 
Other comprehensive (loss) income(13)(13)
Dividends to Clorox stockholders ($1.06 per share declared)
(134)(134)
Stock-based compensation6 6 
Other employee stock plan activities(9)— 20 472 11 
Treasury stock purchased(104)(663)(104)
Balance as of September 30, 2019$159 158,741 $1,043 $3,241 $(3,278)(33,246)$(615)$— $550 
Balance as of June 30, 2020$159 158,741 $1,137 $3,567 $(3,315)(32,543)$(640)$— $908 
Net earnings415 2 417 
Other comprehensive (loss) income17 17 
Dividends to Clorox stockholders ($1.11 per share declared)
(141)(141)
Dividends to noncontrolling interests(4)(4)
Business combinations including purchase accounting adjustments198 198 
Stock-based compensation13 13 
Other employee stock plan activities(4)(1)8 283 3 
Treasury stock purchased(100)(444)(100)
Balance as of September 30, 2020$159 158,741 $1,146 $3,840 $(3,407)(32,704)$(623)$196 $1,311 

(1) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings.

The Company has two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.

Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:
Three Months Ended
9/30/20209/30/2019
AmountShares
(in thousands)		AmountShares
(in thousands)
Open-market purchase program$— — $— — 
Evergreen Program100 444 104 663 
Total stock repurchases$100 444 $104 663 
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three Months Ended September 30
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of June 30, 2019$(414)$(23)$(165)$(602)
Other comprehensive (loss) income before reclassifications(15)1 — (14)
Amounts reclassified from Accumulated other comprehensive net (loss) income— 2 2 4 
Income tax benefit (expense)(1)(1)(1)(3)
Net current period other comprehensive (loss) income(16)2 1 (13)
Balance as of September 30, 2019$(430)$(21)$(164)$(615)
Balance as of June 30, 2020$(450)$(18)$(172)$(640)
Other comprehensive (loss) income before reclassifications9 3 — 12 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 3 2 5 
Income tax benefit (expense), and other1 (1)— — 
Net current period other comprehensive (loss) income10 5 2 17 
Balance as of September 30, 2020$(440)$(13)$(170)$(623)

Included in foreign currency translation adjustments are re-measurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.20.2
EMPLOYEE BENEFIT PLANS
 3 Months Ended
Sep. 30, 2020
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months Ended
9/30/20209/30/2019
Service cost$— $— 
Interest cost4 5 
Expected return on plan assets (1)
(4)(4)
Amortization of unrecognized items3 2 
Total$3 $3 
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2021 net periodic benefit cost is 3.1%.
The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended September 30, 2020 and 2019.
During the three months ended September 30, 2020 and 2019, the Company made $2 in contributions to its domestic retirement income plans.
Net periodic benefit costs are reflected in Other (income) expense, net.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.20.2
OTHER CONTINGENCIES AND GUARANTEES
 3 Months Ended
Sep. 30, 2020
OTHER CONTINGENCIES AND GUARANTEES [Abstract]  
OTHER CONTINGENCIES AND GUARANTEES OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of September 30, 2020 and June 30, 2020, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $14 of the recorded liability as of September 30, 2020 and June 30, 2020, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30-year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $14, which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $28 over an estimated 30-year period, or require the Company to take other actions and incur costs not included in the study.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability, as of September 30, 2020 and June 30, 2020. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements, and the future availability of alternative clean-up technologies.
The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of September 30, 2020 and June 30, 2020.
As of September 30, 2020, the Company was party to a letter of credit of $11, related to one of its insurance carriers, of which $0 had been drawn upon.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT RESULTS
 3 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
SEGMENT RESULTS SEGMENT RESULTS
The Company operates through strategic business units (SBUs) that are aggregated into four reportable segments based on the economics and nature of the products sold: Health and Wellness, Household, Lifestyle and International. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months Ended
9/30/20209/30/2019
Health and Wellness$813 $633 
Household500 361 
Lifestyle318 271 
International285 241 
Corporate— — 
Total$1,916 $1,506 
Earnings (losses) before income taxes
Three Months Ended
9/30/20209/30/2019
Health and Wellness$251 $170 
Household109 32 
Lifestyle102 71 
International124 39 
Corporate(60)(54)
Total$526 $258 

All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 25% and 26% for the three months ended September 30, 2020 and 2019, respectively.
The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:
Net sales
Three Months Ended
9/30/20209/30/2019
Cleaning29 %32 %
Professional Products9 %6 %
Vitamins, Minerals and Supplements4 %4 %
Health and Wellness42 %42 %
Bags and Wraps11 %12 %
Cat Litter6 %8 %
Grilling9 %4 %
Household26 %24 %
Food Products9 %9 %
Natural Personal Care4 %5 %
Water Filtration4 %4 %
Lifestyle17 %18 %
International15 %16 %
Total100 %100 %
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2020 and 2019, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2020, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Issued Accounting Standards
Recently Issued Accounting Standards

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which improves consistency in the application of accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and by clarifying and amending existing guidance. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The amendments that are related to changes in ownership of foreign equity method investments or foreign subsidiaries are to be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The amendments that are related to franchise taxes that are partially based on income are to be applied on either a retrospective basis for all periods presented or a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. All other amendments under this ASU are to be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

Recently Adopted Accounting Standards
In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The Company adopted this guidance as of July 1, 2020 on a prospective basis, and the adoption did not have a material impact on the Company’s consolidated financial statements, as the Company had no goodwill impairments during the first quarter of fiscal year 2021. The future impact of this new standard will depend on the specific facts and circumstances of future impairments that may occur, if any.
Fair Value Measurement
Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of September 30, 2020 and June 30, 2020, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
Segment Results
The Company operates through strategic business units (SBUs) that are aggregated into four reportable segments based on the economics and nature of the products sold: Health and Wellness, Household, Lifestyle and International. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS ACQUIRED (Tables)
 3 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the estimated fair value of the joint ventures’ assets acquired and liabilities assumed and the related deferred income taxes as of the acquisition date. Due to the timing of the acquisition, the fair values of the assets acquired and liabilities assumed were based on a preliminary valuation and the Company’s estimates and assumptions are subject to change within the measurement period. The primary areas of the purchase price that are not yet finalized are related to goodwill and income taxes. The definite-lived intangibles acquired primarily represent the Company reacquiring previously licensed trademarks and customer relationships. The weighted-average estimated useful life of intangible assets subject to amortization is 9 years.

Joint Venture
Goodwill$212 
Reacquired rights (included in Other intangible assets, net)138 
Property, plant and equipment46 
Customer relationships (included in Other intangible assets, net)10 
Working capital, net (includes cash acquired of $26)
31 
Noncurrent liabilities, net(5)
Deferred income taxes(20)
Total fair value of net assets412 
Less: Fair value of noncontrolling interests(198)
Less: Fair value of previously held equity interest(103)
Total purchase consideration$111 
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES, NET (Tables)
 3 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
Inventories, net, consisted of the following as of:
9/30/20206/30/2020
Finished goods$396 $340 
Raw materials and packaging161 140 
Work in process9 7 
LIFO allowances(32)(33)
Total$534 $454 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.20.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Sep. 30, 2020
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
Effects of Derivative Instruments Designated as Hedging Instruments on OCI
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:

Gains (losses) recognized in Other comprehensive (loss) income
Three Months Ended
9/30/20209/30/2019
Commodity purchase derivative contracts$1 $— 
Foreign exchange derivative contracts(1)1 
Interest rate derivative contracts3 — 
Total$3 $1 
Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings
Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months Ended
9/30/20209/30/2019
Commodity purchase derivative contractsCost of products sold$(1)$— 
Foreign exchange derivative contractsCost of products sold— — 
Interest rate derivative contractsInterest expense(2)(2)
Total$(3)$(2)
Schedule of Assets and Liabilities for Fair Value Disclosure The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 9/30/20206/30/2020
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contractsOther current assets1$1 $1 $— $— 
Interest rate forward contractsOther assets24 4 1 1 
 $5 $5 $1 $1 
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$— $— $1 $1 
Commodity purchase swaps contractsAccounts payable and accrued liabilities23 3 3 3 
Foreign exchange forward contractAccounts payable and accrued liabilities21 1 1 1 
$4 $4 $5 $5 

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 9/30/20206/30/2020
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Investments, including money market funds
Cash and cash
equivalents (a)
1$379 $379 $584 $584 
Time deposits
Cash and cash
equivalents (a)
2318 318 165 165 
Trust assets for nonqualified deferred compensation plansOther assets1114 114 100 100 
 $811 $811 $849 $849 
Liabilities
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (b)
22,781 3,049 2,780 3,051 
$2,781 $3,049 $2,780 $3,051 

____________________

(a)Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(b)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.20.2
NET EARNINGS PER SHARE (EPS) (Tables)
 3 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months Ended
9/30/20209/30/2019
Basic126,346125,823
Dilutive effect of stock options and other2,3831,642
Diluted128,729127,465
Antidilutive stock options and other441 — 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.20.2
COMPREHENSIVE INCOME (Tables)
 3 Months Ended
Sep. 30, 2020
Stockholders' Equity Note [Abstract]  
Schedule of Comprehensive Income
The following table provides a summary of Comprehensive income for the periods indicated:
Three Months Ended
9/30/20209/30/2019
Net earnings$417 $203 
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments10 (16)
Net unrealized gains (losses) on derivatives5 2 
Pension and postretirement benefit adjustments2 1 
Total other comprehensive (loss) income, net of tax17 (13)
Comprehensive income434 190 
Less: Total comprehensive income attributable to noncontrolling interests2 — 
Total comprehensive income attributable to Clorox$432 $190 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Schedule of Stockholders Equity
Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended September 30
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income		Non-controlling interests
Total Stockholders’ Equity
AmountSharesAmountShares
Balance as of June 30, 2019$159 158,741 $1,046 $3,150 $(3,194)(33,055)$(602)$— $559 
Cumulative effect of accounting changes, net of tax (1)
22 22 
Net earnings203 203 
Other comprehensive (loss) income(13)(13)
Dividends to Clorox stockholders ($1.06 per share declared)
(134)(134)
Stock-based compensation6 6 
Other employee stock plan activities(9)— 20 472 11 
Treasury stock purchased(104)(663)(104)
Balance as of September 30, 2019$159 158,741 $1,043 $3,241 $(3,278)(33,246)$(615)$— $550 
Balance as of June 30, 2020$159 158,741 $1,137 $3,567 $(3,315)(32,543)$(640)$— $908 
Net earnings415 2 417 
Other comprehensive (loss) income17 17 
Dividends to Clorox stockholders ($1.11 per share declared)
(141)(141)
Dividends to noncontrolling interests(4)(4)
Business combinations including purchase accounting adjustments198 198 
Stock-based compensation13 13 
Other employee stock plan activities(4)(1)8 283 3 
Treasury stock purchased(100)(444)(100)
Balance as of September 30, 2020$159 158,741 $1,146 $3,840 $(3,407)(32,704)$(623)$196 $1,311 
(1) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings.
Schedule of Share Repurchases Under Authorized Programs
Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:
Three Months Ended
9/30/20209/30/2019
AmountShares
(in thousands)		AmountShares
(in thousands)
Open-market purchase program$— — $— — 
Evergreen Program100 444 104 663 
Total stock repurchases$100 444 $104 663 
Schedule of Changes in Accumulated Other Comprehensive Net (Losses) Income
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three Months Ended September 30
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of June 30, 2019$(414)$(23)$(165)$(602)
Other comprehensive (loss) income before reclassifications(15)1 — (14)
Amounts reclassified from Accumulated other comprehensive net (loss) income— 2 2 4 
Income tax benefit (expense)(1)(1)(1)(3)
Net current period other comprehensive (loss) income(16)2 1 (13)
Balance as of September 30, 2019$(430)$(21)$(164)$(615)
Balance as of June 30, 2020$(450)$(18)$(172)$(640)
Other comprehensive (loss) income before reclassifications9 3 — 12 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 3 2 5 
Income tax benefit (expense), and other1 (1)— — 
Net current period other comprehensive (loss) income10 5 2 17 
Balance as of September 30, 2020$(440)$(13)$(170)$(623)
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.20.2
EMPLOYEE BENEFIT PLANS (Tables)
 3 Months Ended
Sep. 30, 2020
Retirement Benefits [Abstract]  
Schedule of Components of Net Periodic Benefit Cost
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months Ended
9/30/20209/30/2019
Service cost$— $— 
Interest cost4 5 
Expected return on plan assets (1)
(4)(4)
Amortization of unrecognized items3 2 
Total$3 $3 
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2021 net periodic benefit cost is 3.1%.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT RESULTS (Tables)
 3 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Selected Financial Information Relating to the Company's Segments
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months Ended
9/30/20209/30/2019
Health and Wellness$813 $633 
Household500 361 
Lifestyle318 271 
International285 241 
Corporate— — 
Total$1,916 $1,506 
Earnings (losses) before income taxes
Three Months Ended
9/30/20209/30/2019
Health and Wellness$251 $170 
Household109 32 
Lifestyle102 71 
International124 39 
Corporate(60)(54)
Total$526 $258 
The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:
Net sales
Three Months Ended
9/30/20209/30/2019
Cleaning29 %32 %
Professional Products9 %6 %
Vitamins, Minerals and Supplements4 %4 %
Health and Wellness42 %42 %
Bags and Wraps11 %12 %
Cat Litter6 %8 %
Grilling9 %4 %
Household26 %24 %
Food Products9 %9 %
Natural Personal Care4 %5 %
Water Filtration4 %4 %
Lifestyle17 %18 %
International15 %16 %
Total100 %100 %
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)
 3 Months Ended
Sep. 30, 2020
USD ($)
Accounting Policies [Abstract]  
Goodwill impairment $ 0
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS ACQUIRED (Narrative) (Details) - USD ($)
 3 Months Ended
Jul. 09, 2020
Sep. 30, 2020
Jun. 30, 2020
Business Combination, Separately Recognized Transactions [Line Items]      
Total purchase consideration $ 111,000,000    
Cash paid 100,000,000    
Loss on settlement 11,000,000    
Goodwill   $ 1,793,000,000 $ 1,577,000,000
Non-recurring, non-cash gain   85,000,000  
Joint venture net sales   $ 23,000,000  
Joint Venture In Kingdom Of Saudi Arabia [Member]      
Business Combination, Separately Recognized Transactions [Line Items]      
Goodwill 212,000,000    
Goodwill deductible for tax purposes $ 0    
The weighted-average estimated useful life of intangible assets subject to amortization 9 years    
Joint Venture In Kingdom Of Saudi Arabia [Member]      
Business Combination, Separately Recognized Transactions [Line Items]      
Noncontrolling interest, ownership percentage by parent 51.00%    
Joint Venture In Kingdom Of Saudi Arabia [Member]      
Business Combination, Separately Recognized Transactions [Line Items]      
Equity method investment, ownership percentage 30.00%    
Equity method investments $ 27,000,000    
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS ACQUIRED (Fair Value Of Assets Acquired and Liabilities Assumed) (Details) - USD ($)
$ in Millions
Jul. 09, 2020
Sep. 30, 2020
Jun. 30, 2020
Business Combination, Separately Recognized Transactions [Line Items]      
Goodwill   $ 1,793 $ 1,577
Joint Venture In Kingdom Of Saudi Arabia [Member]      
Business Combination, Separately Recognized Transactions [Line Items]      
Goodwill $ 212    
Property, plant and equipment 46    
Working capital, net (includes cash acquired of $26) 31    
Noncurrent liabilities, net (5)    
Deferred income taxes (20)    
Total fair value of net assets 412    
Less: Fair value of noncontrolling interests (198)    
Less: Fair value of previously held equity interest (103)    
Total purchase consideration 111    
Cash acquired 26    
Contractual Rights [Member] | Joint Venture In Kingdom Of Saudi Arabia [Member]      
Business Combination, Separately Recognized Transactions [Line Items]      
Reacquired rights (included in Other intangible assets, net) 138    
Customer relationships (included in Other intangible assets, net) 138    
Customer Relationships [Member] | Joint Venture In Kingdom Of Saudi Arabia [Member]      
Business Combination, Separately Recognized Transactions [Line Items]      
Reacquired rights (included in Other intangible assets, net) 10    
Customer relationships (included in Other intangible assets, net) $ 10    
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES, NET (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Jun. 30, 2020
Inventory Disclosure [Abstract]    
Finished goods $ 396 $ 340
Raw materials and packaging 161 140
Work in process 9 7
LIFO allowances (32) (33)
Total $ 534 $ 454
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.20.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($)
 3 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Derivative [Line Items]    
Maximum duration, foreign exchange contracts 2 years  
Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months $ (10,000,000)  
Derivative instruments subject to contractually defined counterparty liability position limits 2,000,000 $ 3,000,000
Interest Rate Contract [Member]    
Derivative [Line Items]    
Notional amount $ 300,000,000 225,000,000
Maximum duration, interest rate contracts 3 years  
Purchases of Inventory [Member] | Foreign Exchange Contract [Member]    
Derivative [Line Items]    
Notional amount $ 58,000,000 70,000,000
Total Commodity Purchase Derivative Contracts [Member]    
Derivative [Line Items]    
Maximum duration, commodity contracts 2 years  
Notional amount $ 22,000,000 27,000,000
Jet Fuel Swaps [Member]    
Derivative [Line Items]    
Notional amount 11,000,000 13,000,000
Soybean Oil Futures [Member]    
Derivative [Line Items]    
Notional amount 11,000,000 14,000,000
Soybean Oil Futures [Member] | Commodity Contract [Member]    
Derivative [Line Items]    
Cash margin balances amount $ 1,000,000 $ 2,000,000
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.20.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) recognized in Other comprehensive (loss) income $ 3 $ 1
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings (3) (2)
Commodity Contract [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) recognized in Other comprehensive (loss) income 1 0
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings (1) 0
Foreign Exchange Contract [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) recognized in Other comprehensive (loss) income (1) 1
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 0 0
Interest Rate Contract [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) recognized in Other comprehensive (loss) income 3 0
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings $ (2) $ (2)
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.20.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Jun. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 860 $ 871
Total assets 6,777 6,213
Total liabilities 5,466 5,305
Reported Value Measurement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 5 1
Derivative liabilities 4 5
Total assets 811 849
Total liabilities 2,781 2,780
Estimate of Fair Value Measurement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 5 1
Derivative liabilities 4 5
Total other assets in the fair value hierarchy 811 849
Total other liabilities in the fair value hierarchy 3,049 3,051
Other Current Assets [Member] | Fair Value, Inputs, Level 1 [Member] | Reported Value Measurement [Member] | Commodity Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 1 0
Other Current Assets [Member] | Fair Value, Inputs, Level 1 [Member] | Estimate of Fair Value Measurement [Member] | Commodity Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 1 0
Other Assets [Member] | Fair Value, Inputs, Level 2 [Member] | Reported Value Measurement [Member] | Interest Rate Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 4 1
Other Assets [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | Interest Rate Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 4 1
Other Assets [Member] | Trust Assets for nonqualified deferred compensation plans [Member] | Fair Value, Inputs, Level 1 [Member] | Reported Value Measurement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Trust assets for nonqualified deferred compensation plans 114 100
Other Assets [Member] | Trust Assets for nonqualified deferred compensation plans [Member] | Fair Value, Inputs, Level 1 [Member] | Estimate of Fair Value Measurement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Trust assets for nonqualified deferred compensation plans 114 100
Accounts Payable and Accrued Liabilities [Member] | Fair Value, Inputs, Level 1 [Member] | Reported Value Measurement [Member] | Commodity Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 0 1
Accounts Payable and Accrued Liabilities [Member] | Fair Value, Inputs, Level 1 [Member] | Estimate of Fair Value Measurement [Member] | Commodity Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 0 1
Accounts Payable and Accrued Liabilities [Member] | Fair Value, Inputs, Level 2 [Member] | Reported Value Measurement [Member] | Commodity Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 3 3
Accounts Payable and Accrued Liabilities [Member] | Fair Value, Inputs, Level 2 [Member] | Reported Value Measurement [Member] | Foreign Exchange Forward Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 1 1
Accounts Payable and Accrued Liabilities [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | Commodity Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 3 3
Accounts Payable and Accrued Liabilities [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | Foreign Exchange Forward Contract [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 1 1
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] | Reported Value Measurement [Member] | Investments, including money market funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 379 584
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] | Estimate of Fair Value Measurement [Member] | Investments, including money market funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 379 584
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] | Reported Value Measurement [Member] | Time deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 318 165
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | Time deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 318 165
Current maturities of long-term debt and Long-term debt [Member] | Fair Value, Inputs, Level 2 [Member] | Reported Value Measurement [Member] | Long-term Debt [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current maturities of long-term debt and Long-term debt 2,781 2,780
Current maturities of long-term debt and Long-term debt [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | Long-term Debt [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current maturities of long-term debt and Long-term debt $ 3,049 $ 3,051
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES (Narrative) (Details)
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Income Tax Disclosure [Abstract]    
Effective tax rate on earnings from continuing operations 20.70% 21.50%
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.20.2
NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) - shares
shares in Thousands
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Earnings Per Share [Abstract]    
Basic (in shares) 126,346 125,823
Dilutive effect of stock options and other (in shares) 2,383 1,642
Diluted (in shares) 128,729 127,465
Antidilutive stock options and other (in shares) 441 0
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.20.2
COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Stockholders' Equity Note [Abstract]    
Net earnings $ 417 $ 203
Other comprehensive (loss) income, net of tax:    
Foreign currency translation adjustments 10 (16)
Net unrealized gains (losses) on derivatives 5 2
Pension and postretirement benefit adjustments 2 1
Total other comprehensive (loss) income, net of tax 17 (13)
Comprehensive income 434 190
Less: Total comprehensive income attributable to noncontrolling interests 2 0
Total comprehensive income attributable to Clorox $ 432 $ 190
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Class of Stock [Line Items]    
Dividends declared per share (in dollars per share) $ 1.11 $ 1.06
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ 908 $ 559
Cumulative effect of accounting changes, net of tax 1,311 550
Net earnings 417 203
Other comprehensive (loss) income 17 (13)
Dividends (141) (134)
Dividends to noncontrolling interests 4  
Business combinations including purchase accounting adjustments 198  
Stock-based compensation 13 6
Other employee stock plan activities 3 11
Treasury stock purchased $ (100) $ (104)
Treasury stock purchased (in shares) (444) (663)
Balance, ending $ 1,311 $ 550
Cumulative Effect of Accounting Changes, Net of Tax [Member]    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning   22
Cumulative effect of accounting changes, net of tax   22
Common Stock [Member]    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ 159 $ 159
Balance, beginning (in shares) 158,741 158,741
Cumulative effect of accounting changes, net of tax $ 159 $ 159
Balance, ending $ 159 $ 159
Balance, ending (in shares) 158,741 158,741
Additional Paid-in Capital [Member]    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ 1,137 $ 1,046
Cumulative effect of accounting changes, net of tax 1,146 1,043
Stock-based compensation 13 6
Other employee stock plan activities (4) (9)
Balance, ending 1,146 1,043
Retained Earnings [Member]    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning 3,567 3,150
Cumulative effect of accounting changes, net of tax 3,840 3,241
Net earnings 415 203
Dividends (141) (134)
Other employee stock plan activities (1) 0
Balance, ending 3,840 3,241
Retained Earnings [Member] | Cumulative Effect of Accounting Changes, Net of Tax [Member]    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning   22
Cumulative effect of accounting changes, net of tax   22
Treasury Stock [Member]    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ (3,315) $ (3,194)
Balance, beginning (in shares) 32,543 33,055
Cumulative effect of accounting changes, net of tax $ (3,407) $ (3,278)
Other employee stock plan activities $ 8 $ 20
Other employee stock plan activities (in shares) 283 472
Treasury stock purchased $ (100) $ (104)
Treasury stock purchased (in shares) (444) (663)
Balance, ending $ (3,407) $ (3,278)
Balance, ending (in shares) 32,704 33,246
Accumulated other comprehensive net (loss) income [Member]    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ (640) $ (602)
Cumulative effect of accounting changes, net of tax (623) (615)
Other comprehensive (loss) income 17 (13)
Balance, ending (623) (615)
Noncontrolling Interest [Member]    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning 0 0
Cumulative effect of accounting changes, net of tax 196 0
Net earnings 2  
Dividends to noncontrolling interests 4  
Business combinations including purchase accounting adjustments 198  
Balance, ending $ 196 $ 0
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS' EQUITY (Narrative) (Details)
 3 Months Ended
Sep. 30, 2020
USD ($)
repurchase_program
Sep. 30, 2019
USD ($)
repurchase_program
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Number of repurchase programs | repurchase_program 2 2
Long-Term Inter-Company Loans [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Amounts reclassified from accumulated other comprehensive net (loss) income $ 0 $ 0
$2 Billion Open-Market Purchase Program [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Stock repurchase program, authorized amount 2,000,000,000  
Evergreen Program [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Authorization limit $ 0  
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS' EQUITY (Share Repurchase Programs) (Details) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Share Repurchase Programs [Line Items]    
Value of shares repurchased $ 100 $ 104
Shares repurchased (in shares) 444 663
$2 Billion Open-Market Purchase Program [Member]    
Share Repurchase Programs [Line Items]    
Value of shares repurchased $ 0 $ 0
Shares repurchased (in shares) 0 0
Evergreen Program [Member]    
Share Repurchase Programs [Line Items]    
Value of shares repurchased $ 100 $ 104
Shares repurchased (in shares) 444 663
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning $ 908  
Balance, ending 1,115  
Foreign currency translation adjustments [Member]    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning (450) $ (414)
Other comprehensive (loss) income before reclassifications 9 (15)
Amounts reclassified from Accumulated other comprehensive net (loss) income 0 0
Income tax benefit (expense) 1 (1)
Net current period other comprehensive (loss) income 10 (16)
Balance, ending (440) (430)
Net unrealized gains (losses) on derivatives [Member]    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning (18) (23)
Other comprehensive (loss) income before reclassifications 3 1
Amounts reclassified from Accumulated other comprehensive net (loss) income 3 2
Income tax benefit (expense) (1) (1)
Net current period other comprehensive (loss) income 5 2
Balance, ending (13) (21)
Pension and postretirement benefit adjustments [Member]    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning (172) (165)
Other comprehensive (loss) income before reclassifications 0 0
Amounts reclassified from Accumulated other comprehensive net (loss) income 2 2
Income tax benefit (expense) 0 (1)
Net current period other comprehensive (loss) income 2 1
Balance, ending (170) (164)
Accumulated other comprehensive net (loss) income [Member]    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning (640) (602)
Other comprehensive (loss) income before reclassifications 12 (14)
Amounts reclassified from Accumulated other comprehensive net (loss) income 5 4
Income tax benefit (expense) 0 (3)
Net current period other comprehensive (loss) income 17 (13)
Balance, ending $ (623) $ (615)
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.20.2
EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Defined Benefit Plan Disclosure [Line Items]    
Total $ 0 $ 0
Weighted average long-term expected rate or return on plan assets 3.10%  
Other Postretirement Benefits Plan [Member] | Retirement Income Plans [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Service cost $ 0 0
Interest cost 4 5
Expected return on plan assets (4) (4)
Amortization of unrecognized items 3 2
Total $ 3 $ 3
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.20.2
EMPLOYEE BENEFIT PLANS (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Defined Benefit Plan Disclosure [Line Items]    
Net periodic benefit $ 0 $ 0
Other Postretirement Benefits Plan [Member] | Retirement Income Plans [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Net periodic benefit (3) (3)
UNITED STATES | Retirement Income Plans [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Discretionary contributions $ 2 $ 2
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.20.2
OTHER CONTINGENCIES AND GUARANTEES (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Jun. 30, 2017
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 28 $ 28  
Letter of credit 11    
Letter of credit, amount outstanding 0    
Alameda County, California Matter [Member]      
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 14 14 $ 14
Remediation period 30 years    
Maximum undiscounted costs $ 28    
Dickinson County, Michigan Matter [Member]      
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 10 $ 10  
Remediation period 30 years    
Percentage of liability for aggregate remediation and associated costs, other than legal fees 24.30%    
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT RESULTS (Narrative) (Details) - reportable_segment
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Concentration Risk [Line Items]    
Number of reportable segments 4  
Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Walmart Stores, Inc. [Member]    
Concentration Risk [Line Items]    
Concentration percentage 25.00% 26.00%
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Segment Reporting Information [Line Items]    
Net sales $ 1,916 $ 1,506
Earnings (losses) before income taxes $ 526 $ 258
Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 100.00% 100.00%
Health and Wellness [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 42.00% 42.00%
Health and Wellness [Member] | Cleaning [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 29.00% 32.00%
Health and Wellness [Member] | Professional Products [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 9.00% 6.00%
Health and Wellness [Member] | Vitamins, Minerals and Supplements [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 4.00% 4.00%
Health and Wellness [Member] | Bags and Wraps [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 11.00% 12.00%
Health and Wellness [Member] | Cat Litter [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 6.00% 8.00%
Health and Wellness [Member] | Grilling [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 9.00% 4.00%
Household [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 26.00% 24.00%
Household [Member] | Food Products [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 9.00% 9.00%
Household [Member] | Natural Personal Care [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 4.00% 5.00%
Household [Member] | Water Filtration [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 4.00% 4.00%
Lifestyle [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 17.00% 18.00%
International [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]    
Segment Reporting Information [Line Items]    
Concentration percentage 15.00% 16.00%
Operating Segments [Member] | Health and Wellness [Member]    
Segment Reporting Information [Line Items]    
Net sales $ 813 $ 633
Earnings (losses) before income taxes 251 170
Operating Segments [Member] | Household [Member]    
Segment Reporting Information [Line Items]    
Net sales 500 361
Earnings (losses) before income taxes 109 32
Operating Segments [Member] | Lifestyle [Member]    
Segment Reporting Information [Line Items]    
Net sales 318 271
Earnings (losses) before income taxes 102 71
Operating Segments [Member] | International [Member]    
Segment Reporting Information [Line Items]    
Net sales 285 241
Earnings (losses) before income taxes 124 39
Corporate, Non-Segment [Member]    
Segment Reporting Information [Line Items]    
Net sales 0 0
Earnings (losses) before income taxes $ (60) $ (54)
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 185 289 1 false 63 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.clorox.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) Sheet http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 6 false false R7.htm 2104102 - Disclosure - BUSINESS ACQUIRED Sheet http://www.clorox.com/role/BUSINESSACQUIRED BUSINESS ACQUIRED Notes 7 false false R8.htm 2108103 - Disclosure - INVENTORIES, NET Sheet http://www.clorox.com/role/INVENTORIESNET INVENTORIES, NET Notes 8 false false R9.htm 2111104 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 2116105 - Disclosure - INCOME TAXES Sheet http://www.clorox.com/role/INCOMETAXES INCOME TAXES Notes 10 false false R11.htm 2118106 - Disclosure - NET EARNINGS PER SHARE (EPS) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPS NET EARNINGS PER SHARE (EPS) Notes 11 false false R12.htm 2121107 - Disclosure - COMPREHENSIVE INCOME Sheet http://www.clorox.com/role/COMPREHENSIVEINCOME COMPREHENSIVE INCOME Notes 12 false false R13.htm 2124108 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 2130109 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANS EMPLOYEE BENEFIT PLANS Notes 14 false false R15.htm 2134110 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES Sheet http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEES OTHER CONTINGENCIES AND GUARANTEES Notes 15 false false R16.htm 2136111 - Disclosure - SEGMENT RESULTS Sheet http://www.clorox.com/role/SEGMENTRESULTS SEGMENT RESULTS Notes 16 false false R17.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 2305301 - Disclosure - BUSINESS ACQUIRED (Tables) Sheet http://www.clorox.com/role/BUSINESSACQUIREDTables BUSINESS ACQUIRED (Tables) Tables http://www.clorox.com/role/BUSINESSACQUIRED 18 false false R19.htm 2309302 - Disclosure - INVENTORIES, NET (Tables) Sheet http://www.clorox.com/role/INVENTORIESNETTables INVENTORIES, NET (Tables) Tables http://www.clorox.com/role/INVENTORIESNET 19 false false R20.htm 2312303 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS 20 false false R21.htm 2319304 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables NET EARNINGS PER SHARE (EPS) (Tables) Tables http://www.clorox.com/role/NETEARNINGSPERSHAREEPS 21 false false R22.htm 2322305 - Disclosure - COMPREHENSIVE INCOME (Tables) Sheet http://www.clorox.com/role/COMPREHENSIVEINCOMETables COMPREHENSIVE INCOME (Tables) Tables http://www.clorox.com/role/COMPREHENSIVEINCOME 22 false false R23.htm 2325306 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.clorox.com/role/STOCKHOLDERSEQUITY 23 false false R24.htm 2331307 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables EMPLOYEE BENEFIT PLANS (Tables) Tables http://www.clorox.com/role/EMPLOYEEBENEFITPLANS 24 false false R25.htm 2337308 - Disclosure - SEGMENT RESULTS (Tables) Sheet http://www.clorox.com/role/SEGMENTRESULTSTables SEGMENT RESULTS (Tables) Tables http://www.clorox.com/role/SEGMENTRESULTS 25 false false R26.htm 2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Details http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies 26 false false R27.htm 2406402 - Disclosure - BUSINESS ACQUIRED (Narrative) (Details) Sheet http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails BUSINESS ACQUIRED (Narrative) (Details) Details http://www.clorox.com/role/BUSINESSACQUIREDTables 27 false false R28.htm 2407403 - Disclosure - BUSINESS ACQUIRED (Fair Value Of Assets Acquired and Liabilities Assumed) (Details) Sheet http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails BUSINESS ACQUIRED (Fair Value Of Assets Acquired and Liabilities Assumed) (Details) Details http://www.clorox.com/role/BUSINESSACQUIREDTables 28 false false R29.htm 2410404 - Disclosure - INVENTORIES, NET (Details) Sheet http://www.clorox.com/role/INVENTORIESNETDetails INVENTORIES, NET (Details) Details http://www.clorox.com/role/INVENTORIESNETTables 29 false false R30.htm 2413405 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) Details http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 30 false false R31.htm 2414406 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) Details http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 31 false false R32.htm 2415407 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) Details http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 32 false false R33.htm 2417408 - Disclosure - INCOME TAXES (Narrative) (Details) Sheet http://www.clorox.com/role/INCOMETAXESNarrativeDetails INCOME TAXES (Narrative) (Details) Details http://www.clorox.com/role/INCOMETAXES 33 false false R34.htm 2420409 - Disclosure - NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) Details http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables 34 false false R35.htm 2423410 - Disclosure - COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details) Sheet http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details) Details http://www.clorox.com/role/COMPREHENSIVEINCOMETables 35 false false R36.htm 2426411 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) Details http://www.clorox.com/role/STOCKHOLDERSEQUITYTables 36 false false R37.htm 2427412 - Disclosure - STOCKHOLDERS' EQUITY (Narrative) (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY (Narrative) (Details) Details http://www.clorox.com/role/STOCKHOLDERSEQUITYTables 37 false false R38.htm 2428413 - Disclosure - STOCKHOLDERS' EQUITY (Share Repurchase Programs) (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails STOCKHOLDERS' EQUITY (Share Repurchase Programs) (Details) Details http://www.clorox.com/role/STOCKHOLDERSEQUITYTables 38 false false R39.htm 2429414 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) Details http://www.clorox.com/role/STOCKHOLDERSEQUITYTables 39 false false R40.htm 2432415 - Disclosure - EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) Details http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables 40 false false R41.htm 2433416 - Disclosure - EMPLOYEE BENEFIT PLANS (Narrative) (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails EMPLOYEE BENEFIT PLANS (Narrative) (Details) Details http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables 41 false false R42.htm 2435417 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES (Details) Sheet http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails OTHER CONTINGENCIES AND GUARANTEES (Details) Details http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEES 42 false false R43.htm 2438418 - Disclosure - SEGMENT RESULTS (Narrative) (Details) Sheet http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails SEGMENT RESULTS (Narrative) (Details) Details http://www.clorox.com/role/SEGMENTRESULTSTables 43 false false R44.htm 2439419 - Disclosure - SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) Sheet http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) Details http://www.clorox.com/role/SEGMENTRESULTSTables 44 false false All Reports Book All Reports clx-20200930.htm clx-20200930.xsd clx-20200930_cal.xml clx-20200930_def.xml clx-20200930_lab.xml clx-20200930_pre.xml clxq1fy2110qexhibit1011.htm clxq1fy2110qexhibit1021.htm clxq1fy2110qexhibit1031.htm clxq1fy2110qexhibit1041.htm clxq1fy2110qexhibit1051.htm clxq1fy21exhibit311.htm clxq1fy21exhibit312.htm clxq1fy21exhibit32.htm http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "clx-20200930.htm": { "axisCustom": 1, "axisStandard": 26, "contextCount": 185, "dts": { "calculationLink": { "local": [ "clx-20200930_cal.xml" ] }, "definitionLink": { "local": [ "clx-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "clx-20200930.htm" ] }, "labelLink": { "local": [ "clx-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "clx-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "clx-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 392, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 5 }, "keyCustom": 18, "keyStandard": 271, "memberCustom": 27, "memberStandard": 34, "nsprefix": "clx", "nsuri": "http://www.clorox.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.clorox.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - INCOME TAXES", "role": "http://www.clorox.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118106 - Disclosure - NET EARNINGS PER SHARE (EPS)", "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPS", "shortName": "NET EARNINGS PER SHARE (EPS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121107 - Disclosure - COMPREHENSIVE INCOME", "role": "http://www.clorox.com/role/COMPREHENSIVEINCOME", "shortName": "COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124108 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130109 - Disclosure - EMPLOYEE BENEFIT PLANS", "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANS", "shortName": "EMPLOYEE BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "clx:OTHERCONTINGENCIESANDGUARANTEESTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134110 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES", "role": "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEES", "shortName": "OTHER CONTINGENCIES AND GUARANTEES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "clx:OTHERCONTINGENCIESANDGUARANTEESTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136111 - Disclosure - SEGMENT RESULTS", "role": "http://www.clorox.com/role/SEGMENTRESULTS", "shortName": "SEGMENT RESULTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - BUSINESS ACQUIRED (Tables)", "role": "http://www.clorox.com/role/BUSINESSACQUIREDTables", "shortName": "BUSINESS ACQUIRED (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - INVENTORIES, NET (Tables)", "role": "http://www.clorox.com/role/INVENTORIESNETTables", "shortName": "INVENTORIES, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)", "role": "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables)", "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables", "shortName": "NET EARNINGS PER SHARE (EPS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - COMPREHENSIVE INCOME (Tables)", "role": "http://www.clorox.com/role/COMPREHENSIVEINCOMETables", "shortName": "COMPREHENSIVE INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325306 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)", "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables", "shortName": "EMPLOYEE BENEFIT PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337308 - Disclosure - SEGMENT RESULTS (Tables)", "role": "http://www.clorox.com/role/SEGMENTRESULTSTables", "shortName": "SEGMENT RESULTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i11bb6ab0c30e4373ab86a1a04af2ddd6_D20200709-20200709", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - BUSINESS ACQUIRED (Narrative) (Details)", "role": "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails", "shortName": "BUSINESS ACQUIRED (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i11bb6ab0c30e4373ab86a1a04af2ddd6_D20200709-20200709", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - BUSINESS ACQUIRED (Fair Value Of Assets Acquired and Liabilities Assumed) (Details)", "role": "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "BUSINESS ACQUIRED (Fair Value Of Assets Acquired and Liabilities Assumed) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "if492820757ea48fe9a7ab4447c036d32_I20200709", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - INVENTORIES, NET (Details)", "role": "http://www.clorox.com/role/INVENTORIESNETDetails", "shortName": "INVENTORIES, NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details)", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details)", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "if1c795e10ed44759b6d38cf8b5b0f884_I20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - INCOME TAXES (Narrative) (Details)", "role": "http://www.clorox.com/role/INCOMETAXESNarrativeDetails", "shortName": "INCOME TAXES (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details)", "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails", "shortName": "NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423410 - Disclosure - COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details)", "role": "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "shortName": "COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426411 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Equity) (Details)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails", "shortName": "STOCKHOLDERS' EQUITY (Schedule of Equity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "clx:NumberOfRepurchasePrograms", "reportCount": 1, "unique": true, "unitRef": "repurchase_program", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427412 - Disclosure - STOCKHOLDERS' EQUITY (Narrative) (Details)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "shortName": "STOCKHOLDERS' EQUITY (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "clx:NumberOfRepurchasePrograms", "reportCount": 1, "unique": true, "unitRef": "repurchase_program", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428413 - Disclosure - STOCKHOLDERS' EQUITY (Share Repurchase Programs) (Details)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails", "shortName": "STOCKHOLDERS' EQUITY (Share Repurchase Programs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "iafa81fc54b784f4f83cd46aa65a637dc_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i53ca0bdb9d914a408194faf757b303b3_I20200630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails", "shortName": "STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "idb8a2b2739024826b6259aae64af114b_I20200630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details)", "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "shortName": "EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - EMPLOYEE BENEFIT PLANS (Narrative) (Details)", "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "shortName": "EMPLOYEE BENEFIT PLANS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i5e38dbcffa5043cab4f24143587d3f2c_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:AccrualForEnvironmentalLossContingencies", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccrualForEnvironmentalLossContingencies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435417 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES (Details)", "role": "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails", "shortName": "OTHER CONTINGENCIES AND GUARANTEES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AccrualForEnvironmentalLossContingencies", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i224d4a5f297a4a799b781954664f3f06_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccrualForEnvironmentalLossContingencies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "reportable_segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438418 - Disclosure - SEGMENT RESULTS (Narrative) (Details)", "role": "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "shortName": "SEGMENT RESULTS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "reportable_segment", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439419 - Disclosure - SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details)", "role": "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails", "shortName": "SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "iec23cf7d4f21465e93369a0fab4e09b3_D20200701-20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - BUSINESS ACQUIRED", "role": "http://www.clorox.com/role/BUSINESSACQUIRED", "shortName": "BUSINESS ACQUIRED", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - INVENTORIES, NET", "role": "http://www.clorox.com/role/INVENTORIESNET", "shortName": "INVENTORIES, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "clx:FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20200930.htm", "contextRef": "i460a622654264d1a8089b9dee9993e50_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "clx:FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "clx_A2BillionOpenMarketPurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "$2 Billion Open-Market Purchase Program [Member]", "label": "$2 Billion Open-Market Purchase Program [Member]", "terseLabel": "$2 Billion Open-Market Purchase Program [Member]" } } }, "localname": "A2BillionOpenMarketPurchaseProgramMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails" ], "xbrltype": "domainItemType" }, "clx_AlamedaCountyCaliforniaMatterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alameda County, California Matter [Member]", "label": "Alameda County, California Matter [Member]", "terseLabel": "Alameda County, California Matter [Member]" } } }, "localname": "AlamedaCountyCaliforniaMatterMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "domainItemType" }, "clx_BagsWrapsAndContainersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bags, Wraps, And Containers [Member]", "label": "Bags, Wraps, And Containers [Member]", "terseLabel": "Bags and Wraps [Member]" } } }, "localname": "BagsWrapsAndContainersMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_BusinessAcquisitionRevenueReportedByAcquiredEntityForCurrentPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Acquisition Revenue Reported By Acquired Entity For Current Period", "label": "Business Acquisition Revenue Reported By Acquired Entity For Current Period", "terseLabel": "Joint venture net sales" } } }, "localname": "BusinessAcquisitionRevenueReportedByAcquiredEntityForCurrentPeriod", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "clx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapitalNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Working Capital, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Working Capital, Net", "terseLabel": "Working capital, net (includes cash acquired of $26)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapitalNet", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "clx_BusinessCombinationSettlementOfPreExistingNetLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Settlement Of Pre-Existing Net Liabilities", "label": "Business Combination, Settlement Of Pre-Existing Net Liabilities", "terseLabel": "Loss on settlement" } } }, "localname": "BusinessCombinationSettlementOfPreExistingNetLiabilities", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "clx_CatLitterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cat Litter [Member]", "label": "Cat Litter [Member]", "terseLabel": "Cat Litter [Member]" } } }, "localname": "CatLitterMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_CleaningMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cleaning [Member]", "label": "Cleaning [Member]", "terseLabel": "Cleaning [Member]" } } }, "localname": "CleaningMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_CommodityPurchaseDerivativeContractsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commodity Purchase Derivative Contracts [Axis]", "label": "Commodity Purchase Derivative Contracts [Axis]", "terseLabel": "Commodity Purchase Derivative Contracts [Axis]" } } }, "localname": "CommodityPurchaseDerivativeContractsAxis", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "clx_CommodityPurchaseDerivativeContractsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commodity Purchase Derivative Contracts [Domain]", "label": "Commodity Purchase Derivative Contracts [Domain]", "terseLabel": "Commodity Purchase Derivative Contracts [Domain]" } } }, "localname": "CommodityPurchaseDerivativeContractsDomain", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Current Maturities of Long-term Debt and Long-term Debt [Member]", "label": "CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember", "verboseLabel": "Current maturities of long-term debt and Long-term debt [Member]" } } }, "localname": "CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "clx_DerivativeInstrumentsSubjectToContractuallyDefinedCounterpartyLiabilityPositionLimits": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative instruments subject to contractually defined counterparty liability position limits.", "label": "Derivative Instruments Subject To Contractually Defined Counterparty Liability Position Limits", "terseLabel": "Derivative instruments subject to contractually defined counterparty liability position limits" } } }, "localname": "DerivativeInstrumentsSubjectToContractuallyDefinedCounterpartyLiabilityPositionLimits", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "clx_DickinsonCountyMichiganMatterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dickinson County, Michigan Matter [Member]", "label": "Dickinson County, Michigan Matter [Member]", "terseLabel": "Dickinson County, Michigan Matter [Member]" } } }, "localname": "DickinsonCountyMichiganMatterMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "domainItemType" }, "clx_EvergreenProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Evergreen Program [Member]", "label": "Evergreen Program [Member]", "terseLabel": "Evergreen Program [Member]" } } }, "localname": "EvergreenProgramMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails" ], "xbrltype": "domainItemType" }, "clx_FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments and fair value measurements.", "label": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS" } } }, "localname": "FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTextBlock", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "clx_FinancialInstrumentsAndFairValueMeasurementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial Instruments and Fair Value Measurements [Abstract]", "label": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]", "terseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]" } } }, "localname": "FinancialInstrumentsAndFairValueMeasurementsAbstract", "nsuri": "http://www.clorox.com/20200930", "xbrltype": "stringItemType" }, "clx_FoodProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Food Products [Member]", "label": "Food Products [Member]", "terseLabel": "Food Products [Member]" } } }, "localname": "FoodProductsMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_GrillingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Grilling [Member]", "label": "Grilling [Member]", "terseLabel": "Grilling [Member]" } } }, "localname": "GrillingMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_HealthAndWellnessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health and Wellness", "label": "Health and Wellness [Member]", "terseLabel": "Health and Wellness [Member]" } } }, "localname": "HealthAndWellnessMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_HouseholdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Household [Member]", "label": "Household [Member]", "terseLabel": "Household [Member]" } } }, "localname": "HouseholdMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_InternationalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "International [Member]" } } }, "localname": "InternationalMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_IssuanceOfCommonStockForEmployeeStockPlansAndOther": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock options. Also includes the net cash inflow (outflow) from other financing activities.", "label": "Issuance Of Common Stock For Employee Stock Plans And Other", "terseLabel": "Issuance of common stock for employee stock plans and other" } } }, "localname": "IssuanceOfCommonStockForEmployeeStockPlansAndOther", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "clx_JetFuelSwapsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Jet Fuel Swaps [Member]", "label": "Jet Fuel Swaps [Member]", "terseLabel": "Jet Fuel Swaps [Member]" } } }, "localname": "JetFuelSwapsMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_JointVentureInKingdomOfSaudiArabiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Joint Venture In Kingdom Of Saudi Arabia", "label": "Joint Venture In Kingdom Of Saudi Arabia [Member]", "terseLabel": "Joint Venture In Kingdom Of Saudi Arabia [Member]" } } }, "localname": "JointVentureInKingdomOfSaudiArabiaMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_LetterOfCreditBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Borrowing capacity under the letter of credit without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding.", "label": "Letter of credit", "terseLabel": "Letter of credit" } } }, "localname": "LetterOfCreditBorrowingCapacity", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "clx_LifestyleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lifestyle [Member]", "label": "Lifestyle [Member]", "terseLabel": "Lifestyle [Member]" } } }, "localname": "LifestyleMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_LongTermInterCompanyLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term inter-company loans included in foreign currency adjustments.", "label": "Long-Term Inter-Company Loans [Member]", "terseLabel": "Long-Term Inter-Company Loans [Member]" } } }, "localname": "LongTermInterCompanyLoansMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_MaximumExposureUndiscountedCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum potential amount of future payments (undiscounted) that the Company could incur over an estimated remediation period.", "label": "Maximum Exposure, Undiscounted Cost", "terseLabel": "Maximum undiscounted costs" } } }, "localname": "MaximumExposureUndiscountedCost", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "clx_NaturalPersonalCareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Natural Personal Care [Member]", "label": "Natural Personal Care [Member]", "terseLabel": "Natural Personal Care [Member]" } } }, "localname": "NaturalPersonalCareMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_NumberOfRepurchasePrograms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Repurchase Programs", "label": "Number Of Repurchase Programs", "terseLabel": "Number of repurchase programs" } } }, "localname": "NumberOfRepurchasePrograms", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "integerItemType" }, "clx_OTHERCONTINGENCIESANDGUARANTEESTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item represents the complete disclosure regarding the entity's exposure to loss pertaining to environmental matters, litigation and potential losses not disclosed in other notes and guarantees.", "label": "OTHER CONTINGENCIES AND GUARANTEES [Text Block]", "terseLabel": "OTHER CONTINGENCIES AND GUARANTEES" } } }, "localname": "OTHERCONTINGENCIESANDGUARANTEESTextBlock", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEES" ], "xbrltype": "textBlockItemType" }, "clx_OperatingLeaseRightofUseAssetAndLiabilityNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease, Right-of-Use Asset And Liability, Net", "label": "Operating Lease, Right-of-Use Asset And Liability, Net", "terseLabel": "Operating lease right-of-use assets and liabilities, net" } } }, "localname": "OperatingLeaseRightofUseAssetAndLiabilityNet", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "clx_OtherContingenciesAndGuaranteesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "OTHER CONTINGENCIES AND GUARANTEES [Abstract]", "terseLabel": "OTHER CONTINGENCIES AND GUARANTEES [Abstract]" } } }, "localname": "OtherContingenciesAndGuaranteesAbstract", "nsuri": "http://www.clorox.com/20200930", "xbrltype": "stringItemType" }, "clx_OtherEmployeeStockPlanActivitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount includes the value of stock granted during the period as a result of exercises of employee stock options or vesting of other share-based awards.", "label": "Other Employee Stock Plan Activities, Amount", "terseLabel": "Other employee stock plan activities" } } }, "localname": "OtherEmployeeStockPlanActivitiesAmount", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "clx_OtherEmployeeStockPlanActivitiesShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of exercises of employee stock options or the vesting of other share-based awards.", "label": "Other Employee Stock Plan Activities, Shares", "terseLabel": "Other employee stock plan activities (in shares)" } } }, "localname": "OtherEmployeeStockPlanActivitiesShares", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "sharesItemType" }, "clx_OtherExpenseIncomeNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net amount of other income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines.", "label": "Other Expense (Income), Net", "terseLabel": "Other (income) expense, net" } } }, "localname": "OtherExpenseIncomeNet", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "clx_ProfessionalProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Professional Products [Member]", "label": "Professional Products [Member]", "terseLabel": "Professional Products [Member]" } } }, "localname": "ProfessionalProductsMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_PurchasesofInventoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchases of Inventory [Member]", "label": "Purchases of Inventory [Member]", "terseLabel": "Purchases of Inventory [Member]" } } }, "localname": "PurchasesofInventoryMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_RemediationPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimated time frame of disbursements over which remediation efforts are estimated to occur for an individual site.", "label": "Remediation period", "terseLabel": "Remediation period" } } }, "localname": "RemediationPeriod", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "durationItemType" }, "clx_RetirementIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Retirement Income [Member]", "label": "Retirement Income Plans [Member]", "terseLabel": "Retirement Income Plans [Member]" } } }, "localname": "RetirementIncomeMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_ShareRepurchaseProgramsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Repurchase Programs [Line Items]", "terseLabel": "Share Repurchase Programs [Line Items]" } } }, "localname": "ShareRepurchaseProgramsLineItems", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails" ], "xbrltype": "stringItemType" }, "clx_ShareRepurchaseProgramsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share repurchase programs and shares repurchased.", "label": "Share Repurchase Programs [Table]", "terseLabel": "Share Repurchase Programs [Table]" } } }, "localname": "ShareRepurchaseProgramsTable", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails" ], "xbrltype": "stringItemType" }, "clx_SiteContingencyAgreedPercentageOfCostSharing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of costs that the entity has agreed to under cost-sharing arrangements with other potentially responsible parties for an individual site.", "label": "Percentage of liability for aggregate remediation and associated costs, other than legal fees", "terseLabel": "Percentage of liability for aggregate remediation and associated costs, other than legal fees" } } }, "localname": "SiteContingencyAgreedPercentageOfCostSharing", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "percentItemType" }, "clx_SoybeanOilFuturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Soybean Oil Futures [Member]", "label": "Soybean Oil Futures [Member]", "terseLabel": "Soybean Oil Futures [Member]" } } }, "localname": "SoybeanOilFuturesMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_StockRepurchaseProgramAuthorizationLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Repurchase Program, Authorization Limit", "label": "Stock Repurchase Program, Authorization Limit", "terseLabel": "Authorization limit" } } }, "localname": "StockRepurchaseProgramAuthorizationLimit", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "clx_TotalCommodityPurchaseDerivativeContractsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Commodity Purchase Derivative Contracts [Member]", "label": "Total Commodity Purchase Derivative Contracts [Member]", "terseLabel": "Total Commodity Purchase Derivative Contracts [Member]" } } }, "localname": "TotalCommodityPurchaseDerivativeContractsMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_TrademarksNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite or finite period of benefit.", "label": "Trademarks, net", "terseLabel": "Trademarks, net" } } }, "localname": "TrademarksNet", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "clx_TrustAssetsForNonqualifiedDeferredCompensationPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trust Assets For Nonqualified Deferred Compensation Plans [Member]", "label": "Trust Assets for nonqualified deferred compensation plans [Member]", "terseLabel": "Trust Assets for nonqualified deferred compensation plans [Member]" } } }, "localname": "TrustAssetsForNonqualifiedDeferredCompensationPlansMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "clx_VitaminsMineralsAndSupplementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vitamins, Minerals and Supplements", "label": "Vitamins, Minerals and Supplements [Member]", "terseLabel": "Vitamins, Minerals and Supplements [Member]" } } }, "localname": "VitaminsMineralsAndSupplementsMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_WalmartStoresIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Walmart Stores, Inc. and its affiliates [Member]", "label": "Walmart Stores, Inc. [Member]", "terseLabel": "Walmart Stores, Inc. [Member]" } } }, "localname": "WalmartStoresIncMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_WaterFiltrationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Water Filtration [Member]", "label": "Water Filtration [Member]", "terseLabel": "Water Filtration [Member]" } } }, "localname": "WaterFiltrationMember", "nsuri": "http://www.clorox.com/20200930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r524" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r525" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r526" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r526" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r526" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r527" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r526" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r526" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r526" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r526" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r522" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r523" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r147", "r166", "r167", "r168", "r169", "r171", "r173", "r177" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r147", "r166", "r167", "r168", "r169", "r171", "r173", "r177" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r105", "r110", "r191", "r337", "r338", "r339", "r353", "r354" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect of Accounting Changes, Net of Tax [Member]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r105", "r110", "r191", "r337", "r338", "r339", "r353", "r354" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r105", "r110", "r191", "r337", "r338", "r339", "r353", "r354" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r183", "r242", "r243", "r498" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r183", "r242", "r243", "r498" ], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r14", "r185", "r186" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "auth_ref": [ "r209", "r212", "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.", "label": "Accrual for Environmental Loss Contingencies", "terseLabel": "Liability for aggregate future remediation costs" } } }, "localname": "AccrualForEnvironmentalLossContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r10", "r464", "r481" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r53", "r59", "r61", "r396" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension and postretirement benefit adjustments [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment, accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r52", "r59", "r61", "r395" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "Net unrealized gains (losses) on derivatives [Member]" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r56", "r58", "r59", "r483", "r503", "r504" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive net (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r444", "r445", "r446", "r447", "r448", "r450" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r59", "r61", "r102", "r103", "r104", "r396", "r499", "r500" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive net (loss) income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r51", "r59", "r61", "r396", "r445", "r446", "r447", "r448", "r450" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "The weighted-average estimated useful life of intangible assets subject to amortization" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r102", "r103", "r104", "r337", "r338", "r339" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r333", "r334", "r341", "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r343" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive stock options and other (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r98", "r155", "r168", "r175", "r190", "r389", "r397", "r442", "r463", "r480" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r47", "r98", "r190", "r389", "r397", "r442" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r430" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total other assets in the fair value hierarchy" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r408", "r413" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r324", "r328" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r324", "r328", "r370", "r371" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill deductible for tax purposes" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "negatedTerseLabel": "Less: Fair value of noncontrolling interests" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r378", "r379", "r380" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS ACQUIRED" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIRED" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r373" ], "calculation": { "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred income taxes" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r372", "r373" ], "calculation": { "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Customer relationships (included in Other intangible assets, net)", "verboseLabel": "Reacquired rights (included in Other intangible assets, net)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r372", "r373" ], "calculation": { "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total fair value of net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities": { "auth_ref": [ "r373" ], "calculation": { "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities", "negatedTerseLabel": "Noncurrent liabilities, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r372", "r373" ], "calculation": { "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Total purchase consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Combination, Separately Recognized Transactions [Line Items]", "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.", "label": "Business Combination, Separately Recognized Transactions [Table]", "terseLabel": "Business Combination, Separately Recognized Transactions [Table]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "negatedLabel": "Less: Fair value of previously held equity interest" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of net gain (loss) recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net", "terseLabel": "Non-recurring, non-cash gain" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r437", "r438" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Reported Value Measurement [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash acquired" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r30", "r93" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Member]" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]", "terseLabel": "Cash, cash equivalents, and restricted cash:" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r88", "r93", "r94" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r88", "r443" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r428" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r39", "r213", "r468", "r488" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommodityContractMember": { "auth_ref": [ "r270", "r420" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to commodity prices.", "label": "Commodity Contract [Member]", "terseLabel": "Commodity Contract [Member]" } } }, "localname": "CommodityContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r102", "r103" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r227" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock: $1.00 par value; 750,000,000 shares authorized; 158,741,461 shares issued as of September 30, 2020 and June 30, 2020; and 126,037,019 and 126,198,606 shares outstanding as of September 30, 2020 and June 30, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r66", "r67", "r75", "r474", "r493" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income attributable to Clorox" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r66", "r74", "r387", "r388", "r401", "r473", "r492" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Total comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r66", "r73", "r386", "r401", "r472", "r491" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r72", "r80", "r471", "r490" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOME" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r139", "r140", "r183", "r439", "r440" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r139", "r140", "r183", "r439", "r440", "r505" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r139", "r140", "r183", "r439", "r440", "r505" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r139", "r140", "r183", "r439", "r440" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r136", "r139", "r140", "r141", "r439", "r441" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r139", "r140", "r183", "r439", "r440" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualRightsMember": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).", "label": "Contractual Rights [Member]", "terseLabel": "Contractual Rights [Member]" } } }, "localname": "ContractualRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r171", "r177", "r179" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r78", "r458" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r137", "r183" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r436" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Current maturities of long-term debt and Long-term debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r33" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Trust assets for nonqualified deferred compensation plans" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r99", "r352", "r357", "r358", "r359" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r345", "r346" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r247", "r285", "r312", "r318", "r319" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Amortization of unrecognized items" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r293", "r317" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Weighted average long-term expected rate or return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r262", "r270", "r272", "r316", "r318", "r319" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Discretionary contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r247", "r284", "r311", "r318", "r319" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r247", "r251", "r283", "r310", "r318", "r319" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r281", "r308", "r318", "r319" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "negatedLabel": "Net periodic benefit", "totalLabel": "Total" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r249", "r282", "r309", "r318", "r319" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r91", "r150" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r48", "r49", "r436" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative assets" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r409", "r412", "r417", "r421" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r406", "r409", "r417", "r421", "r422", "r425", "r427" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r48", "r49", "r436" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r403", "r405" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r402", "r404", "r405", "r406", "r407", "r414", "r417", "r423", "r424", "r427" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r234", "r479" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r323", "r327", "r331" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan [Member]" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net earnings per share attributable to Clorox" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r76", "r108", "r109", "r110", "r111", "r112", "r116", "r118", "r123", "r124", "r125", "r130", "r131", "r475", "r494" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r76", "r108", "r109", "r110", "r111", "r112", "r118", "r123", "r124", "r125", "r130", "r131", "r475", "r494" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r126", "r128", "r129", "r132" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET EARNINGS PER SHARE (EPS)" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPS" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r443" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate on earnings from continuing operations" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r102", "r103", "r104", "r107", "r113", "r115", "r133", "r191", "r227", "r234", "r337", "r338", "r339", "r353", "r354", "r444", "r445", "r446", "r447", "r448", "r450", "r499", "r500", "r501" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r31", "r156", "r188" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value Measurement [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r430", "r431", "r432", "r433" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r430", "r437" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities for Fair Value Disclosure" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r318", "r431", "r455", "r456", "r457" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r430", "r434" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r270", "r272", "r277", "r318", "r431", "r455" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r270", "r272", "r277", "r318", "r431", "r456" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r318", "r455", "r456", "r457" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total other liabilities in the fair value hierarchy" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r200", "r202", "r204", "r205", "r459", "r460" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r200", "r203" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r270", "r419" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward Contract [Member]" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r194", "r196", "r462" ], "calculation": { "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDFairValueOfAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails", "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r91", "r195", "r197", "r199" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r77", "r98", "r155", "r167", "r171", "r174", "r177", "r190", "r442" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r155", "r167", "r171", "r174", "r177", "r461", "r469", "r478", "r495" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Earnings (losses) before income taxes", "totalLabel": "Earnings before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r349", "r350", "r351", "r355", "r360", "r364", "r365", "r366" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r114", "r115", "r153", "r347", "r356", "r362", "r496" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r90" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": { "auth_ref": [ "r90" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.", "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable", "verboseLabel": "Income taxes payable / prepaid" } } }, "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r90" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r90" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r90" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables, net" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r119", "r120", "r121", "r125" ], "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of stock options and other (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of the entity to which the long-term intercompany foreign balances of the entity relate.", "label": "Intercompany Foreign Currency Balance by Description [Axis]", "terseLabel": "Intercompany Foreign Currency Balance by Description [Axis]" } } }, "localname": "IntercompanyForeignCurrencyBalanceByDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntercompanyForeignCurrencyBalanceNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name or description of the foreign entity or investment that is of a long-term nature.", "label": "Intercompany Foreign Currency Balance, Name [Domain]", "terseLabel": "Intercompany Foreign Currency Balance, Name [Domain]" } } }, "localname": "IntercompanyForeignCurrencyBalanceNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r69", "r149", "r451", "r452", "r476" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r270", "r418" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract [Member]" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES, NET" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNET" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r21", "r192" ], "calculation": { "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r45" ], "calculation": { "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedLabel": "LIFO allowances" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r44" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "auth_ref": [ "r23", "r24", "r192" ], "calculation": { "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "terseLabel": "Raw materials and packaging" } } }, "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r22", "r192" ], "calculation": { "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r430" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "verboseLabel": "Trust assets for nonqualified deferred compensation plans" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letter of credit, amount outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r98", "r169", "r190", "r390", "r397", "r398", "r442" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r98", "r190", "r442", "r467", "r486" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r36", "r98", "r190", "r390", "r397", "r398", "r442" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r11", "r223", "r465", "r482" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Current maturities of long-term debt and Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]", "terseLabel": "Long-term Debt [Member]" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r37", "r222" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarginDepositAssets": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash or securities placed with a broker or counterparty as security for a trading or derivatives securities position which was partially obtained with funds provided by the broker dealer.", "label": "Margin Deposit Assets", "terseLabel": "Cash margin balances amount" } } }, "localname": "MarginDepositAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.", "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge", "terseLabel": "Maximum duration, foreign exchange contracts" } } }, "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "terseLabel": "Maximum duration, commodity contracts" } } }, "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MaximumLengthOfTimeHedgedInInterestRateCashFlowHedge1": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "Maximum period the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge", "terseLabel": "Maximum duration, interest rate contracts" } } }, "localname": "MaximumLengthOfTimeHedgedInInterestRateCashFlowHedge1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r43", "r98", "r190", "r442", "r466", "r485" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "terseLabel": "Dividends to noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Investments, including money market funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r88" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used for financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r88" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used for investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r88", "r89", "r92" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r62", "r65", "r71", "r92", "r98", "r106", "r108", "r109", "r110", "r111", "r114", "r115", "r122", "r155", "r167", "r171", "r174", "r177", "r190", "r442", "r470", "r489" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net earnings attributable to Clorox" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r62", "r65", "r114", "r115", "r392", "r400" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "auth_ref": [ "r235", "r374", "r394" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from a business combination.", "label": "Noncontrolling Interest, Increase from Business Combination", "terseLabel": "Business combinations including purchase accounting adjustments" } } }, "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r102", "r103", "r104", "r234", "r384" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r454" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r454" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r453" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r171", "r177" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r408", "r425" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets [Member]" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r54", "r56", "r386", "r395" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Pension and postretirement benefit adjustments" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r386", "r387", "r395" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r59", "r444", "r446", "r450" ], "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other comprehensive (loss) income before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r56" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net unrealized gains (losses) on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r52", "r56", "r410", "r415", "r426" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gains (losses) recognized in Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r56", "r60", "r416" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r63", "r66", "r68", "r72", "r227", "r444", "r449", "r450", "r471", "r490" ], "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Net current period other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r63", "r66", "r386", "r387", "r395" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive (loss) income", "totalLabel": "Total other comprehensive (loss) income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r57", "r72", "r347", "r361", "r363", "r444", "r447", "r450", "r471", "r490" ], "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedLabel": "Income tax benefit (expense)" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r408", "r425" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Other intangible assets, net" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r92" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r299", "r303", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r322", "r323", "r324", "r325", "r326", "r327" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits Plan [Member]" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r82", "r85", "r100" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r86" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Treasury stock purchased" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r86" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Cash dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r83", "r381" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r83" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Businesses acquired, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r84" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r269", "r271", "r277", "r295", "r297", "r298", "r299", "r300", "r301", "r318", "r320", "r321", "r322", "r332" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r335", "r336" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r28", "r29" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [ "r100" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Notes and loans payable, net" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk [Member]" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r62", "r65", "r87", "r98", "r106", "r114", "r115", "r155", "r167", "r171", "r174", "r177", "r190", "r386", "r391", "r393", "r400", "r401", "r442", "r478" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings", "totalLabel": "Net earnings", "verboseLabel": "Net earnings" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r9", "r207", "r487" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net of accumulated depreciation and amortization of $2,270 and $2,224, respectively" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r59", "r61", "r444", "r448", "r450" ], "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "negatedLabel": "Amounts reclassified from Accumulated other comprehensive net (loss) income", "terseLabel": "Amounts reclassified from accumulated other comprehensive net (loss) income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r344", "r521" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r234", "r340", "r484", "r502", "r504" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r102", "r103", "r104", "r107", "r113", "r115", "r191", "r337", "r338", "r339", "r353", "r354", "r499", "r501" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r299", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r323", "r327", "r331" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r299", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r323", "r327", "r331" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r299", "r303", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r299", "r303", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r146", "r147", "r166", "r172", "r173", "r180", "r181", "r183", "r241", "r242", "r458" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r139", "r183" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r59", "r449", "r450" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Net (Losses) Income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Effects of Derivative Instruments Designated as Hedging Instruments on OCI" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.", "label": "Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Comprehensive Income" } } }, "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r302", "r303", "r306", "r307", "r318" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r25", "r26", "r27" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories, Net" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Components of Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r155", "r158", "r170", "r198" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r155", "r158", "r170", "r198" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Selected Financial Information Relating to the Company's Segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r40", "r96", "r134", "r135", "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Stockholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r236", "r237", "r238", "r239" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Schedule of Share Repurchases Under Authorized Programs" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r142", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r177", "r183", "r497" ], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r142", "r144", "r145", "r155", "r159", "r171", "r175", "r176", "r177", "r178", "r180", "r182", "r183", "r184" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT RESULTS" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r95", "r160", "r161", "r162", "r163", "r164", "r165", "r181" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Results" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, ending (in shares)", "periodStartLabel": "Balance, beginning (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r142", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r177", "r183", "r198", "r208", "r210", "r211", "r497" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r42", "r102", "r103", "r104", "r107", "r113", "r115", "r133", "r191", "r227", "r234", "r337", "r338", "r339", "r353", "r354", "r444", "r445", "r446", "r447", "r448", "r450", "r499", "r500", "r501" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r18", "r19", "r98", "r187", "r190", "r442" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning", "totalLabel": "Total Clorox stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r98", "r102", "r103", "r104", "r107", "r113", "r190", "r191", "r234", "r337", "r338", "r339", "r353", "r354", "r384", "r385", "r399", "r442", "r444", "r445", "r450", "r500", "r501" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning", "totalLabel": "Total stockholders\u2019 equity", "verboseLabel": "Cumulative effect of accounting changes, net of tax" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r97", "r234", "r240" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction [Domain]" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r41", "r236" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r41", "r236" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r13", "r227", "r234" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Treasury stock purchased (in shares)", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r41", "r236", "r239" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury shares, at cost: 32,704,442 and 32,542,855 shares as of September 30, 2020 and June 30, 2020, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r227", "r234", "r236" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Treasury stock purchased", "terseLabel": "Value of shares repurchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYShareRepurchaseProgramsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r117", "r125" ], "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding (in thousands)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r116", "r125" ], "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=6395460&loc=d3e13647-108346" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e526-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r522": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r523": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r524": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r525": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r526": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r527": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 66 0000021076-20-000021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000021076-20-000021-xbrl.zip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end

%RARY2N,XQ74M -2;P"!5BP,"T*%B-QN2EV7$5&=:'GCU334*]K//5M$[N26I&N0\) MFXY&(5< T20F$:EMFK!O@0A #9H<5<*9IA_);.%8/.GQ@M'0'N"+L5Y4DY1& M2>I6 J"ZQ1GYDTIHB[5+IB'$:J-Y0W?W3/.?-SE8RPMN\E9CYAZG#SU0ZP>T M9S);?EQ^A/DCLODN$H5(N-F2I[@*)"WX_Q5L;$'NY]C6VW1)FF2ULB2!+;>@ M)-63@^65HN3J^05>Y)NZQW+0]_SP &1H -K4]^DB+U;YW8!)\Q^+EOH S&Q,E?%NZR%&1 MJ01.(P.DJH)U+@:]0N)=;^2JNC/X%D6)M0XVH88?QR7!"J/ %)'*^R!UH\N! MO2BD]("J<>V%*+I!*/A,XQ+